Formulations and their use

Abstract

The present invention provides preparations and formulations that can cross and be incorporated into the membranes of cells, organelles, or exosomes. [Solution] A formulation is provided comprising (i) a basic composition comprising a mixture of oils selected from the group consisting of emu oil, coconut oil, macadamia nut oil, high oleic acid sunflower seed oil, olive oil, and a mixture of two, three, four, or five of the aforementioned oils, wherein the oil comprises a mixture of fatty acids including myristic acid, palmitic acid, stearic acid, linoleic acid, oleic acid, and elaidic acid, and (ii) one or more additional components dispersed in the basic composition, selected from the group consisting of essential oils, wherein the fatty acid composition of the basic composition is the same as the fatty acid composition of the cell membrane of human cells, and the mixture of oils accounts for 30% to 99% by volume of the formulation.

Description

Technical Field

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 982,918, filed Feb. 28, 2020, which is incorporated herein by reference.

Background Art

[0002] Healthy cell membranes function as barriers to the extracellular environment. They also act as hubs that filter and interpret signals from the surrounding cells and convert external signals into cellular responses by modulating gene expression changes. Healthy cell membranes can also send signals to other cells, receive signals from other cells, and integrate signals to elicit responses in cells near or even on the opposite side of the body.

[0003] Modern Western diets filled with processed foods rich in ω6 rather than ω3 fats (in combination with other factors of modern life such as the widespread use of plastics, pesticides, synthetic food additives, etc.) can alter membrane composition, leading to changes in many physical parameters of cell membranes such as membrane fluidity and permeability, and can interfere with the ability of interacting membrane proteins and structures (Phillips R., Membranes by the Numbers arxiv.org 6 Mar 2017). These changes can contribute to the development of many chronic diseases, especially in patients with a genetic predisposition to specific diseases.

[0004] Many disease states are driven by imbalances in lipids and phospholipids in cell membranes, as well as deficiencies in cell membrane composition and function. Disruptions in cell membrane function can lead to abnormal regulation of growth and proliferation. ​(Among others, it can lead to diseases such as cancer, keloids, or psoriasis; a part of the skin barrier As a result of (for example, eczema or wounds that do not heal); for example, diabetes, dyslipidemia , and as hormonal dysregulation in metabolic syndrome, etc.; insufficient immune function As a function; or, for example, in neuronal signals in multiple sclerosis and Alzheimer's disease, etc. This can manifest as a disruption in communication.

[0005] One possible manifestation of a deficiency in cell membrane function is a reduced tolerance to pain and inflammation. It is an increase in predisposition to pain. Pain is a perception associated with potential or actual damage to body tissues. It is defined as (PMID 25722692). Pain is caused by damage to a structure or tissue. The physical responses (inflammation, swelling, increased muscle tone, and physical sensitization), as well as pain itself. It is accompanied by both secondary emotional responses (anger, frustration, anxiety, insomnia, and emotional sensitization). It is a multifaceted experience for the patient. It should be noted that insomnia further reduces overall pain tolerance. It reduces, worsens inflammation, increases abnormal muscle tension, pain, and swelling, and therefore pain. This perpetuates a negative feedforward cycle.

[0006] Current oral and topical solutions for pain treatment are, for the most part, only temporary. This treatment addresses some aspects of pain, but not all aspects, and does not address the underlying cause. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase. This inhibits prostaglandin synthesis, leading to a reduction in inflammation and swelling, while Central pain processing remains unaddressed. Similarly, opioids, mu, delta, Alternatively, they bind to kappaopioid receptors and transmit pain signals to the central nervous system (CNS). This reduces neuronal excitability in neurons, leading to less perceived pain (PMI). D 9202932) does not address inflammation, local swelling, or muscle tension. In fact, currently the city None of the pain relievers on the market address the root cause of all the multiple components of pain. They don't address that either.

[0007] In addition, current oral pain medications have significant safety concerns. For example, opioids, It is highly addictive, requiring higher doses over time to achieve the same effect, and is toxic to the body. Hyperalgesia occurs through multiple molecular mechanisms in both the central and peripheral pain systems. Creating a state (Zhizhong Z. Pan, Mechanisms of Opioid Tolerance, Molecular Pain) (pp. 413-422). This class of medicines is prone to addiction, leading to over-administration by self-medication. There is a high risk of accidental death from overdose. NSAIDs are toxic to the kidneys, ears, and liver. There is a significant risk of systemic bleeding and peptic ulcer formation. NSAIDs are complex. It can also lead to a state of hyperalgesia through the proposed mechanism (PMID 2572). 2692). Acetaminophen, the third major oral pain medication, affects the liver and kidneys. It is toxic and potentially increases the risk of hemorrhagic and peptic ulcers.

[0008] Current topical pain relievers also have limitations. For example, NSAID creams do not promote tissue healing. In addition to inhibiting bleeding, it also increases the risk of bleeding, heart attack, hypertension, stroke, peptic ulcers, and bowel perforation. It has the potential to significantly increase the risk. Menthol-based creams are used in cold climates. It is not practical for use by patients with or damaged skin. Capsaicin and Arnica cream has a lower risk of bleeding, heart attack, high blood pressure, and stroke than NSAID cream, but still has the potential to cause skin irritation. In addition, none of the current topical pain medications penetrate deeper than the outermost layer of the epidermis, providing pain relief only for the surface structures and leaving the pain of the underlying structures untreated. Furthermore, the effects of current topical pain medications typically wear off after a few hours and require repeated application. The diseases listed above are just some examples of the most common chronic diseases that afflict modern people. In fact, almost all diseases can be affected to some extent by imbalances in cell membrane composition and / or function. There is a need for formulations that can safely and effectively address multiple aspects of pain, including those that can address disruptions in cell membrane composition and function. For topical formulations, it would be necessary to penetrate the diseased tissue and deliver the active ingredient to the injured area. Ideally, it would have a rapid onset of efficacy, a long duration of efficacy, and would accelerate the healing of the diseased tissue so that the pain or other pathological process improves. There is also a need for formulations that can improve the absorption of substances applied to the skin. The application of such formulations before applying commercial products is ideally thought to facilitate, restore, and / or improve delivery to the skin and to promote the incorporation of components into the cell membrane or intracellular space depending on size, charge, or other properties.

[0009] SUMMARY OF THE INVENTION

[0010]

[0011]

[0012] ​​​​​​​​​​​​The objective of this invention is to provide a formulation that can correct imbalances in cell membrane composition.

[0013] A further objective of the present invention is to provide a formulation that can correct the disruption of cell membrane function.

[0014] Providing a formulation that can improve the absorption of a substance applied to the skin is an additional aspect of the present invention. That is the objective.

[0015] A formulation that treats disease by modulating cell membrane composition and / or function Providing such a product is also an objective of this invention.

[0016] Another objective of the present invention is to provide a topical formulation that can induce the production of pluripotent stem cells.

[0017] To provide a topical formulation that can reprogram differentiated skin cells into a pluripotent stem cell state. This is an additional objective of the present invention.

[0018] Providing a topical formulation that can alter gene expression without the use of a viral vector is the purpose of this This is a further objective of the invention.

[0019] A locality that can penetrate and deliver the active ingredient to the injured area beyond the outermost layer of the epidermis. Providing a suitable formulation is also an objective of the present invention.

[0020] To intentionally induce a delayed response, the outermost layer of the epidermis is extended distal to the site of injury. Alternatively, we can provide a topical formulation that can penetrate and deliver the active ingredient distal to the target tissue. This is the objective of the present invention.

[0021] For the purposes described above and other enhancements, the present invention can be incorporated into existing cell membranes, To provide a formulation that can restore vesicular membrane composition and / or function and modulate therapeutic effects. The formulations affect the function of the membranes of cells, organelles, or exosomes, and / or or it may transcend the function of cells and / or organelles and / or exosomes. specific, which can be incorporated, modulated, regulated, or restored. The formulation contains a mixture of fatty acids in a specific ratio. The formulation contains components that correct defects in cell membrane composition, for example. It can be supplied. The formulation reduces the transmission of intracellular and intercellular signals, for example. It can also be formulated to reduce signaling pathways related to pain, inflammation, excessive oxidation, etc. The formulation increases the healthy stem cell response to injury, while simultaneously suppressing abnormal cell proliferation and division. The formulation may also be formulated to limit and / or other abnormal responses. It interferes with the function of the cell membranes of viruses, fungi, insects, and parasites, thereby controlling microorganisms. Destruction or inactivation of viruses, fungi, insects, and parasites, or microorganisms, viruses The loss of the ability of insects, fungi, insects, and parasites to infect or inhabit their hosts. It can also be formulated to produce oil and / or fat. Fatty acids in formulations produce oil and / or fat. They can be used as a source or incorporated individually into a mixture. In addition to fatty acids, the formulation may include, for example, the following: It may include other components as described in detail. The ratio of fatty acids in the mixture and the formulation itself. The ratio (i.e., the individual components of the formulation and their quantities) is determined to address a specific disease. to and / or the cell membrane, as well as various organelles within a cell (e.g., a mammalian cell) To eliminate defects in the membrane and / or to restore its composition, and / or To restore and / or improve cellular function, for example, as detailed below. It can be customized. The formulation can be, for example, 1) for direct therapeutic use in tissues and cells. For the delivery of materials, and / or 2) for reconstructing tissue within intercellular and intracellular spaces, To reconstruct tissue and / or the function of the cell membrane or the membrane of intracellular organelles Raw materials needed for recovery (e.g., protein, minerals, vitamins, medications, etc.) This can enable the delivery of the drug. In certain embodiments, the incorporation of the formulation into the cell membrane can cause pain. Pain-transmembrane tangents that need to cluster together to send pain signals Lipid rafts containing protein clusters can be directly fragmented.

[0022] Formulations according to the present invention generally consist of (i) a basic composition and a formulation in which cells, organelles or have a fatty acid composition that is substantially the same as that of the exosome membrane, The composition contains one or more additional components dispersed within it. The fatty acid composition of the formulation is such that the formulation is The following: transcending the membrane function and / or function of cells, organelles, or exosomes. To do, to be incorporated, to modulate, to adjust, or to restore Or it can be made to have multiple capabilities. The basic composition may contain lipids. Lipids are, for example, oils. It may be a mixed oil or another substance containing fatty acids. Therefore, lipids are, for example, essential oils or It may be a mixture of essential oils. The basic composition makes up about 40% to about 99% by volume of the formulation. Obtain. In some embodiments, the basic composition comprises one or more oils. One or more types of oils include, for example, emu oil, coconut oil, macadamia nut oil, and high-oleic acid oil. Sunflower seed oil, olive oil, and two, three, or four of the aforementioned oils, or The group may be selected from a mixture containing five types. In some embodiments, the basic composition may be selected from a group consisting of a mixture of five types. , comprising a mixture of emu oil, coconut oil, and macadamia nut oil. Some embodiments In this product, the basic composition consists of high-oleic sunflower seed oil, coconut oil, and macadamia oil. Contains a mixture of nut oils. Emu oil, for example, makes up 0% to about 99% by volume of the basic composition. It can constitute. Coconut oil may, for example, contain medium-chain triglycerides derived from coconut oil. It can constitute 0% to 95% by volume of the basic composition. High oleic sunflower seed oil is an example. For example, it can constitute 0% to about 90% by volume of the basic composition. Macadamia nut oil is, for example It can constitute 0% to about 25% by volume of the basic composition. Olive oil, for example, is part of the basic composition. It can consist of approximately 0% to approximately 80% by volume. In some embodiments, the basic composition is coco It consists of medium-chain triglycerides derived from nut oil. However, other oils and lipids also... These are fatty acids that are substantially similar to those found in the membranes of cells, organelles, or exosomes. Composition (or, in a particular embodiment, the membrane of a cell, organelle, or exosome) Having a fatty acid composition containing more oleic acid than other substances, and the formulation is used with cells and / or cross-sectional, combined membrane function and / or function of organelles and / or exosomes. To provide a basic composition that has the ability to mix, modulate, adjust, or restore. Insofar as it is combined in sufficient quantities, it can be used in the formulation of the present invention. The formulation is by Biosilicate (for example, food-grade diatomaceous earth) Earth (FDGE) biosilicate or multiple biosilicates (for example, multiple It may further include FDGE biosilicate. The biosilicate is, for example, in the formulation. The duration of the desired effect can be extended. The formulation is similar to conventional drugs (i.e., the effect on disease in humans). Even if it does not contain substances approved by regulatory authorities (e.g., the US FDA) for treatment Good. The formulation does not need to contain preservatives.

[0023] One or more additional components of the formulation include phospholipids, ceramides, cholesterol, and fatty acids. Oils, vitamins, minerals, therapeutic agents, exosomes, or any combination of the above. A combination may be selected from the group. In some preferred embodiments, one of the formulations The species or additional components may be essential oils or mixtures of essential oils, or exosomes. ru.

[0024] The basic composition and one or more additional components are found in the cell membrane or organs of mammals. To reduce the severity or alleviate the symptoms of diseases associated with injury, damage, or dysfunction of the Nella. It may be included in the formulation in an effective dose that reduces the amount. Associated with dysfunction, injury, or damage to cell membrane function. Diseases include, for example, pain, eczema, psoriasis, erythema, burns, cuts, bruises, boils, scars, and keloids. Unhealing wounds, acne, rosacea, allergies, arthritis, joint pain, cancer, neuropathy, melanin Taboric syndrome, infections, stomatitis, ulcers, ulcerative colitis (UC), mucositis, diverticulum Inflammation, celiac disease, colitis, Crohn's disease (CD), irritable bowel syndrome (IBS), inflammatory bowel Diseases (IBD), atherosclerosis, Alzheimer's disease (AD), Parkinson's disease (PD), gout, solar lentigines, senile pigment spots, skin atrophy, lichen sclerosus (LS), lichen planus (LP), asthma, chronic obstructive pulmonary disease (COPD), angina pectoris, coronary artery disease (CAD), hypertension Hypertensive disorders (HTN), dyslipidemia (HLD), diabetes mellitus (DM), metabolic syndrome, Insulin resistance, neuropathy, PMS, anxiety, depression, nightmares, insomnia, neuralgia, sciatica Menstrual pain, mastitis, conjunctivitis, spasmodic disorder, alcohol withdrawal symptoms, abnormal muscle tension, dryness, Fibromyalgia, alopecia, erectile dysfunction (ED), restless legs syndrome (RDS), multiple Developmental sclerosis (MS), abnormal sleep debt, osteopenia, osteoporosis, chronic disease anemia, urticaria, Hemorrhoids, chronic fatigue syndrome (CFS), leukoplakia, atrophic vaginitis, edema, severe lymphatic overload (lymph (load), sunburn, skin hyperpigmentation due to aging or previous trauma, or muscle spasms It is possible. Symptoms of the disease include, for example, pain, inflammation, skin irritation, rash, lesions, wrinkles, hyperpigmentation, etc. Lloyd's, scarring, itching, pruritus, indigestion, diarrhea, convulsions, cough, bronchospasm, discoloration, and The above may be a combination of or two or more of the above. The basic composition and additional components are Disrupting cell membrane function (e.g., of viruses, bacteria, fungi, insects, or parasites), This refers to cells, their intracellular organelles, or groups of cells (for example, those found in tissues). The formulation may also contain amounts that modulate cell membrane function to activate a healthy response. The formulation restores the appropriate amount of deficient cell membrane components, thereby promoting healthy cell signaling. It can also be formulated to promote this process.

[0025] The formulations include, for example, (i) a basic composition containing lipids including fatty acids, and (ii) a basic composition One or more additional components dispersed in a substance, such as phospholipids, ceramides, cholesterols. Oils, fatty acids, oils, vitamins, minerals, therapeutic agents, bioactive ingredients, exosomes, or It includes an additional component selected from the group consisting of any two or more combinations of the aforementioned items. Furthermore, the fatty acids in the basic composition are such that the fatty acid composition of the basic composition is similar to that of the cell membrane of mammalian sebum. or types that make the fatty acid composition identical or substantially similar to that of cell organelles and The basic composition, which is the quantity of the formulation, makes up approximately 30% to 99% of the volume. Fatty acids For example, myristic acid (C14:0), lauric acid (C12:0), palmitic acid ( C16:0), arachidonic acid (C20:4 n-6), stearic acid (C18:0), o Leic acid (C18:1 n-9), linoleic acid (C18:1 n-9), linoleic acid (C 18-3 n-9), crotonic acid (C4H6O2), myristoleic acid, palmitorene (C16:1) acid, sapenoic acid (C16:1 n-10), oleic acid (C18:1 n -9) Elaidic acid or trans-oleic acid (C18:1 n-9), Bacce Eicosenoic acid (C18:1 n-7), gadoline acid (C20:1 n-11), eicosenoic acid ( C20:1 n-9), erucic acid (C22:1 n-9), nervonic acid (C24:1 n -9) or a group consisting of two or more combinations of any of the above may be selected. The fatty acid composition of the basic composition may be the same as the fatty acid composition of the cell membrane of human cells. They may be substantially the same. Lipids are, for example, a mixture of coconut oil and macadamia nut oil. It may further contain emu oil and / or high-oleic sunflower seed oil. The seeds or additional ingredients include German chamomile oil, Roman chamomile oil, and Moroccan chamomile oil. It may contain a mixture of chamomile oils, the mixture constituting approximately 5% to 30% by volume of the formulation. ru.

[0026] The formulation may also include mixtures of individual fatty acids, and the fatty acids in the mixture and / or formulation may cause disease It is substantially the same as that of healthy human skin and / or sebum and / or cell membranes. They are combined in the mixture to have (i.e., approximate) fatty acid compositions. In some of these embodiments, the fatty acid composition of the mixture is such that it is found in human skin and / or or are combined to be substantially the same as sebum. Some of these embodiments In this context, fatty acids are a result of the composition of the mixture due to disease, poor diet, or other causes. Components of a cell, organelle, or exosome membrane that may have defects in such components. The mixture is combined to replenish the ceramides. The mixture contains, for example, about 0% to about 40% ceramides (e.g., For example, 13%, such as phosphatidylcholine, sphingomyelin, phosphatidyl Phospholipids such as tanolamine, phosphatidylserine, and phosphatidylinositol Fatty acids, including quality, make up approximately 5% to 99% (e.g., 47%); cholesterol, approximately 0% to 25%. Cholesterol (e.g., 7%), approximately 0% to approximately 25% cholesterol esters (e.g., 2%) ), approximately 0% to approximately 25% squalene (for example, 11%), approximately 0% to approximately 20% triglycerides Lido (e.g., 3%), approximately 5% to approximately 99% protein (e.g., 47%), and approximately 0 The mixture may contain approximately 30% (e.g., 17%) of wax esters by volume. The fatty acid composition of the mixture is substantially the same as that of healthy human skin and / or sebum. As such, myristic acid (C14:0), lauric acid (C12:0), palmitic acid (C 16:0), arachidonic acid (C20:4 n-6), stearic acid (C18:0), ole lic acid (C18:1 n-9), linoleic acid (C18:1 n-9), linoleic acid (C1 8-3 n-9), crotonic acid (C4H6O2), myristoleic acid, palmitorene ( C16:1 acid, sapenoic acid (C16:1 n-10), oleic acid (C18:1 n- 9) Elaidic acid or trans-oleic acid (C18:1 n-9), vaccin Acid (C18:1 n-7), Gadoleic acid (C20:1 n-11), Eicosenoic acid (C 20:1 n-9), erucic acid (C22:1 n-9), nervonic acid (C24:1 n- 9), or any combination of two or more of the above. The mixture may include cells To correct imbalances in membranes or cell organelle membranes, for example, defective membrane components This may also include compositions that are sufficient to supply. In some embodiments, oleic acid is a lipid. A percentage exceeding 50% of the fatty acid composition (for example, approximately 65%, approximately 70%, approximately 75%, approximately 80%, approximately They make up 85%, or about 95%, of the cell membrane. Generally, compounds transversely affect more than one set of cell membranes. Because it must be stopped, it penetrates intracellular organelles (for example, directly affecting cellular metabolism). To do this, a higher concentration of oleic acid than that of the cell membrane is required. Fatty acids themselves It may be incorporated into formulations in the form of oils, phospholipids, or mixtures of lipids.

[0027] The present invention, in part, contains palmitic acid, stearic acid, oleic acid, and linoleic acid. A formulation comprising a composition containing palmitic acid, wherein palmitic acid is present in an amount of about 20% to about 75% by weight of the composition. Stearic acid makes up about 11% to 13% by weight of the composition, and oleic acid It constitutes approximately 8% to 31% by weight of the composition, and linoleic acid constitutes approximately 15% to 31% by weight of the formulation. Constituting approximately 23% by weight, the formulation can traverse and / or be incorporated into the cell membrane. , and / or capable of modulating cell membrane composition and / or function, the formulation specifically The target is... In some embodiments, the mixture is... Except for the fact that it contains nic acid, it is similar to that of mammalian cell membranes (for example, human cell membranes). It may contain a certain fatty acid composition. In some embodiments, the concentration of oleic acid is adjusted, and the mixture This can promote various degrees of penetration into the compound that has been harmonized.

[0028] In a particular embodiment, the formulation is (i) a basic composition comprising a lipid containing a fatty acid, (ii) clove essential oil, cinnamon essential oil, rosemary essential oil, and eucalyptus oil dispersed in the basic composition It may contain a mixture including potassium essential oil, lemon essential oil, ravintsara essential oil, and cinnamon essential oil, and fat The oil is a mixture of high-oleic sunflower seed oil, coconut oil, and macadamia nut oil. Including clove essential oil, it makes up approximately 0.1% to 30% of the formulation by volume; cinnamon essential oil is also included in the formulation. It makes up approximately 0.1% to 30% by volume of the preparation; rosemary essential oil makes up approximately 0.1% by volume of the preparation. Eucalyptus essential oil makes up 30% by volume; it makes up approximately 0.1% to 30% by volume of the formulation. Mon essential oil makes up approximately 0.1% to 30% of the formulation; Ravintsara essential oil is used in the formulation. It makes up approximately 0.1% to 20% by volume of the preparation; cinnamon essential oil makes up approximately 0.05% to 20% by volume of the preparation. The formulation consists of a volume percentage; the basic composition constitutes approximately 50% to 99% of the formulation by volume. Approximately 0.05% to 20% by volume of frankincense essential oil and / or approximately 1% by volume It may further contain approximately 30% by volume of thyme essential oil. The formulation contains approximately 1% to 30% biosilique Approximately 0.04% to 20% German chamomile essential oil, approximately 1% to 20% Moroccan chamomile Chamomile essential oil, approximately 0.04% to approximately 20% Roman chamomile essential oil, approximately 0.04% to approximately 10% % jasmine essential oil, approximately 0.04% to approximately 10% lemongrass essential oil, approximately 1% to approximately 10% Coconut oil, macadamia oil (approximately 5% to 4%), and emu oil (approximately 10% to 80%) are also available in various forms by volume. May contain in units of [unspecified]. The preparation contains vitamin D, hyaluronic acid, vitamin E, vitamin A, glycerin. Phosphorus, ubiquinol, myrrh essential oil, frankincense essential oil, German chamomile essential oil, raw The formulation may further contain maca chamomile essential oil and Moroccan chamomile essential oil. It may further contain diatomaceous earth (FDGE) biosilicate.

[0029] The formulation comprises (i) a basic composition containing lipids including fatty acids, and (ii) German chamomile Essential oils: Moroccan chamomile essential oil, Roman chamomile essential oil, frankincense essential oil, myrrh Essential oils, jasmine essential oil, lemongrass essential oil, sweet orange essential oil, bitter orange essential oil Oil, rosemary essential oil, galangal essential oil, xiang mao essential oil, palmarosa A mixture containing essential oils, neroli essential oil, licorice extract, lecithin, and coconut oil may also contain; mixture These are dispersed in the basic composition, and the lipids are emu oil, coconut oil, and macadamia nut oil. The mixture contains oil, and the basic composition constitutes approximately 50% to 99% by volume of the formulation. The formulations include, for example, approximately 0.01% to approximately 3% German chamomile essential oil, approximately 0.01% to approximately 3% Moroccan chamomile essential oil, approximately 0.01% to approximately 3% Roman chamomile essential oil, approximately 0.01 %~approximately 10% frankincense essential oil, approximately 0.01%~approximately 10% myrrh essential oil, approximately 0.0 1% to approximately 2% jasmine essential oil, approximately 0.01% to approximately 2% lemongrass essential oil, approximately 0.01 Approximately 3% sweet orange essential oil, approximately 0.01% to 3% bitter orange essential oil, 0.01% to approximately 3% rosemary essential oil, approximately 0.01% to approximately 3% galangal essential oil, approximately 0 0.01% to approximately 3% Shanmao essential oil, approximately 0.01% to approximately 3% Palmarosa essential oil, approximately 0. 0.01% to approximately 3% neroli essential oil, approximately 0.01% to approximately 5% licorice extract, approximately 2% to approximately 9% Citin, approximately 0.01% to 2% coconut oil, approximately 0.01% to 5% macadamia nuts The oil may contain approximately 35% to 90% emu oil by volume. The formulation is food-grade silicic acid. It may further contain phytosomal earth (FDGE) biosilicate.

[0030] Administration of the formulations described herein modulates cell membrane composition and / or function. It may result in pain. In some embodiments, administration of the formulations described herein may result in pain This may result in a reduction of [the specified]. In some embodiments, administration of the formulations described herein is It may lead to improved wound healing. In some embodiments, the formulation described herein Administration may result in improvement or resolution of eczema. In some embodiments, as described herein Administration of the formulations described may result in improvement or resolution of psoriasis. In some embodiments Administration of the formulations described herein may result in an improvement in the appearance of scars. One embodiment In this context, administration of the formulations described herein may result in improved recovery from burns. In some embodiments, administration of the formulations described herein improves endocrine gland function. It may result in: In some embodiments, administration of the formulations described herein may result in serum lipids Profile improvement (e.g., increased HDL and / or decreased LDL and / or This may result in a decrease in triglycerides. In some embodiments described herein Administration of this formulation may result in improved circulation and alleviation of Raynaud's phenomenon symptoms. Embodiment In some cases, administration of the formulations described herein may result in an improvement in the function of the nervous system. In some embodiments, administration of the formulations described herein has the effect of improving concentration. It is possible. In some embodiments, administration of the formulations described herein may affect the appearance of the hair. This may lead to an improvement in quality. In some embodiments, the administration of the formulations described herein The result may give the appearance of healthy skin. In some embodiments, as described herein Administration of the formulation may result in the reduction or improvement of headache. In some embodiments, this specification The administration of the preparations described in this book is related to inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis). It may result in improvement of abdominal pain and diarrhea associated with and related to irritable bowel disease. Embodiments In some cases, administration of the formulations described herein may improve anxiety and / or depression. This may result in relief. In some embodiments, administration of the formulations described herein is This may lead to an improved experience of wearing masks. In some embodiments, as described herein Administration of the formulation may result in a reduction of nausea. In some embodiments, this specification Administration of the formulations described herein may result in improved mood. In some embodiments, Administration of the formulations described in the details may result in a decrease in appetite. In some embodiments, Administration of the formulations described herein may result in improvement of insomnia. Therefore, administration of the formulations described herein improves social anxiety in patients with social anxiety. Or it may result in relief. In some embodiments, administration of the formulations described herein. This refers to skin, nails, or body parts caused by fungi, bacteria, or viruses. This could lead to improvements in infectious disease control.

[0031] The present invention relates to a fatty acid composition substantially similar to that of healthy human skin and / or sebum. This specifically includes liquid formulations containing (approximately) fatty acid compositions.

[0032] In one embodiment, the present invention relates to the blending of oils (e.g., animal oils and / or vegetable oils). The present invention provides a formulation containing a mixture. The oil contained in the mixture of the present invention is, for example, emu oil, German Chamomile essential oil, Moroccan chamomile essential oil, Roman chamomile essential oil, coconut oil, macadamia Mia oil, jojoba wax, lime essential oil, grapefruit essential oil, blackberry seed oil, Blueberry seed oil, raspberry seed oil, yuzu essential oil, turmeric essential oil, garlic essential oil, goji berry seeds Sesame oil, jasmine essential oil, ginger essential oil, myrrh essential oil, orange essential oil, organic extra virgin olive oil Olive oil, clove essential oil, calamus essential oil, cassia essential oil, cinnamon essential oil, frankincense Lucrepe essential oil, rosemary essential oil, eucalyptus essential oil, linseed oil, lemon essential oil, lemongrass essential oil Shanmao essential oil, galangal root essential oil, licorice extract, pomegranate seed oil, ravintsara essential oil , bergamot essential oil, cinnamon essential oil, Bupleurum extract, Jasminum (M. officinale) essential oil, vanilla (vanilla planifolia) essential oil, and any of the above. Combinations may be selected from or from the group consisting of such combinations. Some of these embodiments include The preparation contains emu oil, German chamomile essential oil, Moroccan chamomile essential oil, and raw Maca chamomile essential oil, coconut oil, macadamia oil, jojoba wax, lime essential oil, grape Fruit essential oils, blackberry seed oil, blueberry seed oil, raspberry seed oil, yuzu extract Oil, turmeric essential oil, garlic essential oil, goji berry seed oil, jasmine essential oil, ginger essential oil, myrrh Essential oils, orange essential oil, organic extra virgin olive oil, clove essential oil, calamus essential oil Cassia essential oil, cinnamon essential oil, frankincense essential oil, rosemary essential oil, eucalyptus essential oil, A Mani oil, lemon essential oil, lemongrass essential oil, shan mao essential oil, galangal root essential oil, licorice extract Ingredients: Pomegranate seed oil, ravintsara essential oil, bergamot essential oil, cinnamon essential oil, Bupleurum falcatum. Bupleurum extract, Jasminum officinale essential oil, Vanilla planifol a) essential oils, etc., and a small number of combinations of the above selected from the group It contains at least one additional component.

[0033] In addition to the basic composition, the formulation of the present invention contains oil, phospholipids, ceramide, cholesterol, and lipids. Fatty acids, vitamins, minerals, amino acids, hyaluronic acid, Fusogen, fruits, seaweed, or Bio-fermentation products of other plants, therapeutic agents (for example, those approved by the US FDA for use in humans) (Approved drug), exosomes, bioactive ingredients, Dead Sea salts, organic pea protein Protein, organic brown rice protein, N-acetylcysteine, or a combination of two or more of the above. It may include at least one additional component selected from the group consisting of combinations.

[0034] In addition to the basic composition, the formulation contains biosilicate (e.g., food-grade diatomaceous earth (FG) DE)) and / or other pharmaceutically acceptable matrices may also be included. One embodiment In the section, the biosilicate and pharmaceutically acceptable matrix are used for an extended period. Provides the release of components of the formulation. Extended release is, for example, at least 10 hours, 12 hours. Intervals: 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours Intervals: 30 hours, 36 hours, 48 ​​hours, 60 hours, 72 hours, 96 hours, 5 days, 6 days, It may be provided for 7, 8, 9, or 10 days. Extended release is to the lesion area. After application of the formulation, for a maximum of 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, and 8 weeks. It may be offered for 9 weeks, 10 weeks, 11 weeks, 12 weeks, or longer.

[0035] The individual fatty acids or oils in the formulation of the present invention are, for example, to the cell membrane and / or Other phospholipids, ceramides, cholesterol, essential fatty acids, and free fats are transferred through the cell membrane. Incorporation of acids, additional oils, vitamins, minerals, bioactive ingredients, and additional therapeutic agents and / or as a carrier for delivery, and / or (ii) for example, cell membrane composition and / or as a therapeutic agent to correct functional deficiencies, and / or (iii) Expression of stem cell transcription factors Sox-2, Nanog, Oct4, Klf4, and c-Myc To stimulate (iv)COX2, NO, TNF-α, and iN OS, thromboxane B2, prostaglandin E2, leukotriene B4, IFNγ, Interleukin-1 (IL-1), IL-6, IL-8, IL-12, and PPAR (v) Production of anti-inflammatory cytokines to downregulate the expression of inflammatory markers such as gamma To stimulate, and / or (vi) pluripotent stem cells (e.g., skin cells, conjugate cells) It stimulates the production of cells that can differentiate into tissues, blood vessels, neurons, and various other cell types. Sea urchin, may act. The mixture, with or without at least one additional component, vegetable oil It may include only animal oil, only animal oil, or a combination of vegetable oil and animal oil. Preferred embodiment In this formulation, the formulation comprises a basic composition containing a mixture of fatty acids and at least one additional component. It includes. The fatty acids in the composition may be contained in the oil included in the formulation.

[0036] In some embodiments, the formulation of the present invention is used in conjunction with any conventional therapeutic agent (i.e., in humans) (A therapeutic agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of diseases in the United States.) It does not contain any of the substances listed above and is generally recognized as safe by the U.S. FDA. Contains only oils and / or other materials (GRAS) certified (Safe).

[0037] In some embodiments, the formulation of the present invention is a conventional therapeutic agent (i.e., a disease in humans). Contains a therapeutic agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of the patient. obtain.

[0038] In a particular embodiment, a formulation according to the present invention is as shown in Table 1 or other documents in this application. It contains a mixture of at least two of the components listed in the section. The amount and quantity are determined based on the guidelines provided below in this specification and the knowledge of those skilled in the art, Selected based on the desired symptoms and / or needs of the subject (e.g., a person requiring treatment). A mixture of any two (or more) components from Table 1 is selected. It is intended to be used in the formulation of [the substance].

[0039] [Table 1-1]

[0040] Table 1-2

[0041] Table 1-3

[0042] Table 1-4

[0043] Table 1-5

[0044] Table 1-6

[0045] Table 1-7

[0046] Table 1-8

[0047] Table 1-9

[0048] Table 1-10

[0049] Table 1-11

[0050] Table 1-12

[0051] Table 1-13

[0052] Table 1-14

[0053] Table 1-15

[0054] Table 1-16

[0055] Table 1-17

[0056] Table 1-18

[0057] Table 1-19

[0058] Table 1-20

[0059] Table 1-21

[0060] Table 1-22

[0061] Table 1-23

[0062] Table 1-24

[0063] Table 1-25

[0064] Table 1-26

[0065] Table 1-27

[0066] Table 1-28

[0067] Table 1-29

[0068] Table 1-30

[0069] Table 1-31

[0070] Table 1-32

[0071] Table 1-33

[0072] Table 1-34

[0073] Table 1-35

[0074] Table 1-36

[0075] Table 1-37

[0076] Table 1-38

[0077] Table 1-39

[0078] Table 1-40

[0079] Table 1-41

[0080] Table 1-42

[0081] Table 1-43

[0082] Table 1-44

[0083] Table 1-45

[0084] Table 1-46

[0085] Table 1-47

[0086] Table 1-48

[0087] Table 1-49

[0088] Table 1-50

[0089] Table 1-51

[0090] Table 1-52

[0091] Table 1-53

[0092] Table 1-54

[0093] Table 1-55

[0094] Table 1-56

[0095] Table 1-57

[0096] Table 1-58

[0097] Table 1-59

[0098] Table 1-60

[0099] Table 1-61

[0100] Table 1-62

[0101]

Table 1-63

[0102]

Table 1-64

[0103]

Table 1-65

[0104]

Table 1-66

[0105]

Table 1-67

[0106] In certain embodiments, the formulation comprises, in volume % units, about 3% to about 7% macadamia nut oil, about 0. 5% to about 1% coconut oil, and about 90% to about 99% emu oil. In some of these embodiments, the formulation comprises about 5% macadamia nut oil , about 0.7% coconut oil, and about 95% emu oil in volume % units. In these embodiments, the mixture may improve cell membrane composition and function and, when admixed with other substances, may impair or / and improve the ability to be incorporated into or penetrate beyond the membrane of the cell membrane or cell organelles.

[0107] In certain embodiments, the formulation comprises, in volume % units, about 0.03% to about 0.07% macadamia nut oil, about 0.005% to about 0.009% coconut oil, and about 90% to about 99% emu The mixture contains yu oil in volume percentage. In some of these embodiments, the formulation is about 0.05% macadamia nut oil, approximately 0.007% coconut oil, and approximately 99% emi It contains yu oil in units of volume %. In these embodiments, the mixture has a cell membrane composition and mechanism It can improve performance and, when mixed with other substances, can be incorporated into the cell membrane or the membrane of cellular organelles. It may impair and / or improve the ability of a formulation to be absorbed or penetrate beyond it. .

[0108] In a particular embodiment, the formulation contains approximately 3% to approximately 7% macadamia nut oil, approximately 0. 5% to approximately 1% coconut oil, and approximately 90% to approximately 99% high-oleic sunflower seed oil. The mixture contains a percentage by volume. In some of these embodiments, the formulation contains about 5% Cadamia nut oil, approximately 0.7% coconut oil, and approximately 95% high-oleic sunflower seed oil. The mixture contains cereal oil in volume percentage. In these embodiments, the mixture has cell membrane composition and function It can improve the properties of the cell membrane or cell organelle membrane when mixed with other substances. It may impair and / or improve the ability of a formulation to penetrate or penetrate beyond it.

[0109] In a particular embodiment, the formulation contains approximately 0.03% to approximately 0.07% macadamia vinegar. Coconut oil, approximately 0.005% to 0.009% coconut oil, and approximately 90% to 99% high-oil The mixture contains sunflower seed oil leic acid in percentage by volume. The formulation contains approximately 0.05% macadamia nut oil, approximately 0.007% coconut oil, and It contains approximately 99% high-oleic sunflower seed oil by volume. and the mixture can improve cell membrane composition and function, and when mixed with other substances, the ability of the preparation to be incorporated into or penetrate beyond the membrane of the cell membrane or cell organelles can be impaired and / or improved. 損ない得かつ / または向上させ得る。

[0110] In certain embodiments, the present invention relates to a preparation comprising a mixture containing about 70% to 85% olive oil, about 2% to about 7% essential oil of clove, about 2% to about 7% essential oil of cinnamon, about 2% to about 7% essential oil of rosemary , about 2% to about 7% eucalyptus essential oil, about 2% to about 7% lemon essential oil, about 0.05% to about 4% lavender essential oil, and about 0.05% to about 3% leaf cinnamon essential oil in volume %. In these embodiments, the mixture can exhibit, for example, antimicrobial, antiviral, and antifungal properties, as well as wound healing properties. 抗ウイルス、および抗真菌特性、ならびに創傷治癒特性を呈し得る。

[0111] In certain embodiments, the preparation comprises about 0.03% to about 0.07% macadamia nut oil, about 0.005% to about 0.009% coconut oil, about 2% to about 7% essential oil of clove , about 2% to about 7% essential oil of cinnamon, about 2% to about 7% essential oil of rosemary, about 2% to about 7% eucalyptus essential oil, about 2% to about 7% lemon essential oil, about 0.05% to about 4% lavender essential oil , about 0.05% to about 3% leaf cinnamon essential oil, and about 50% to about 95% high oleic acid sunflower seed oil in volume %. In these embodiments, the mixture can exhibit, for example, anti- microbial, antiviral, and antifungal properties, as well as wound healing properties.

[0112] In certain embodiments, the preparation comprises about 0.03% to about 0.07% macadamia nut oil, about 0.005% to about 0.009% coconut oil, about 2% to about 7% essential oil of clove Approximately 2% to 7% cinnamon essential oil, approximately 2% to 7% rosemary essential oil, approximately 2% to 7% yu - Potassium essential oil, approximately 2% to 7% lemon essential oil, approximately 0.05% to 7% ravintsara essential oil Approximately 0.05% to 7% cinnamon leaf essential oil, approximately 0.05% to 10% frankincense essential oil Approximately 0.05% to 10% myrrh essential oil, and approximately 50% to 95% high oleic castor oil. The mixture contains sausage seed oil in volume percentage. In these embodiments, the mixture is, for example, For example, it may exhibit antimicrobial, antiviral, and antifungal properties, as well as wound healing properties.

[0113] In a particular embodiment, the formulation contains approximately 0.03% to approximately 0.07% macadamia vinegar. Coconut oil, approximately 0.005% to 0.009% coconut oil, and approximately 2% to 7% clove essential oil. Approximately 2% to 7% cinnamon essential oil, approximately 2% to 7% rosemary essential oil, approximately 2% to 7% yu - Potassium essential oil, approximately 2% to 7% lemon essential oil, approximately 0.05% to 7% ravintsara essential oil Approximately 0.05% to 7% ravensara essential oil, approximately 0.05% to 7% bay leaf, approximately 0. 0.05% to approximately 7% cinnamon leaf essential oil, approximately 0.05% to approximately 7% rosalina essential oil, approximately 0.05% Approximately 7% niaouli essential oil, approximately 0.05% to 7% frankincense essential oil, approximately 0.05% Approximately 7% myrrh essential oil, approximately 4% to 30% peppermint essential oil, and approximately 0.5% to 5% spice Mint essential oil, approximately 0.05% to 3% wintergreen essential oil, and approximately 40% to 9 The mixture contains 5% high-oleic sunflower seed oil by volume. These embodiments In this context, the mixture may exhibit, for example, antimicrobial, antiviral, and antifungal properties, and may heal wounds. It may exhibit therapeutic properties, including bronchospasm, runny nose, cough, and / or the effects of wearing a mask. It may alleviate discomfort and / or irritation.

[0114] In a particular embodiment, the formulation contains approximately 0.03% to approximately 0.07% macadamia vinegar. Coconut oil, approximately 0.005% to 0.009% coconut oil, and approximately 2% to 7% clove essential oil. Approximately 2% to 7% cinnamon essential oil, approximately 2% to 7% rosemary essential oil, approximately 2% to 7% yu - Potassium essential oil, approximately 2% to 7% lemon essential oil, approximately 0.05% to 7% ravintsara essential oil Approximately 0.05% to 7% cinnamon essential oil, approximately 0.05% to 7% frankincense essential oil, Approximately 0.05% to 7% myrrh essential oil, approximately 1% to 17% white thyme essential oil, and approximately This contains a mixture that includes 50% to approximately 95% high-oleic sunflower seed oil by volume. In these embodiments, the mixture exhibits, for example, antimicrobial, antiviral, and antifungal properties. It is possible.

[0115] In a particular embodiment, the formulation contains approximately 0.2% to approximately 0.7% macadamia nut oil. Approximately 0.1% to 0.5% coconut oil, approximately 1% to 7% clove essential oil, approximately 1% to 7% cinnamon essential oil, approximately 1% to 7% rosemary essential oil, approximately 1% to 7% eucalyptus essential oil, Approximately 1% to 7% lemon essential oil, approximately 0.01% to 7% ravintsara essential oil, approximately 0.01 %~approximately 7% cinnamon essential oil, approximately 0.05%~approximately 7% frankincense essential oil, approximately 0.05% ~7% myrrh essential oil, approximately 1%~20% white thyme essential oil, and approximately 50%~9% The mixture contains 5% high-oleic sunflower seed oil by volume. These embodiments In this context, the mixture possesses, for example, antimicrobial, antiviral, and antifungal properties, as well as wound healing properties. It may exhibit healing properties.

[0116] In a particular embodiment, the formulation contains approximately 0.1% to approximately 5% macadamia nut oil, approximately 0.05% to approximately 2% coconut oil, approximately 2% to approximately 7% clove essential oil, approximately 2% to approximately 7% Cinnamon essential oil, approximately 2% to 7% rosemary essential oil, approximately 2% to 7% eucalyptus essential oil, approximately 2% ~7% lemon essential oil, approximately 0.05%~7% ravintsara essential oil, approximately 0.01%~ 7% cinnamon leaf essential oil, approximately 0.01% to approximately 7% frankincense essential oil, approximately 0.01% to approximately 7 % myrrh essential oil, approximately 1% to 17% white thyme essential oil, approximately 1% to 17% shamma Essential oil, approximately 1% to 17% of Cymbopogon citratus (lemon oil) Sunflower essential oil and approximately 30% to 95% high oleic sunflower seed oil (percentage by volume) The mixture includes, for example, an antimicrobial, antiviral agent. In these embodiments, the mixture may contain an antimicrobial agent or an antiviral agent. It may exhibit antifungal properties, as well as wound healing properties.

[0117] In a particular embodiment, the formulation contains approximately 0.1% to approximately 5% macadamia nut oil, approximately 0.01% to approximately 2% coconut oil, approximately 2% to approximately 7% clove essential oil, approximately 2% to approximately 7% Cinnamon essential oil, approximately 2% to 7% rosemary essential oil, approximately 2% to 7% eucalyptus essential oil, approximately 2% ~7% lemon essential oil, approximately 0.05%~7% ravintsara essential oil, approximately 0.01%~ 7% cinnamon leaf essential oil, approximately 0.01% to approximately 7% frankincense essential oil, approximately 0.01% to approximately 7 % myrrh essential oil, approximately 1% to 17% white thyme essential oil, approximately 1% to 17% shamma Essential oil, approximately 1% to 17% of Cymbopogon citratus (lemon oil) Coriander (grass) essential oil, approximately 1% to 17% coriander seed essential oil, and approximately 30% to 95% The mixture contains high-oleic sunflower seed oil in percentage by volume. The mixture possesses, for example, antimicrobial, antiviral, and antifungal properties, as well as wound healing properties. It can exhibit sexual characteristics.

[0118] In a particular embodiment, the present invention contains about 65% to 85% olive oil, and about 2% to about 7% grapefruit essential oil, 2% to approximately 7% clove essential oil, approximately 2% to approximately 7% cinnamon Essential oils, approximately 2% to 7% rosemary essential oil, approximately 2% to 7% eucalyptus essential oil, approximately 2% to 7% lemon essential oil, approximately 0.05% to 4% ravintsara essential oil, approximately 0.01% to 3% Contains cinnamon leaf essential oil and approximately 0.01% to 3% frankincense essential oil by volume. The subject is a formulation containing a mixture. In these embodiments, the mixture is, for example, an antimicrobial agent. It may exhibit antiviral and antifungal properties, as well as wound healing properties, and may be effective against microorganisms, viruses, or fungi. It may promote recovery from bacterial infections.

[0119] In a particular embodiment, the present invention relates to macadamia nuts containing about 0.2% to about 0.7% Oil, approximately 0.1% to 0.5% coconut oil, approximately 50% to 95% high-oleic sunflower seeds. Clove oil, approximately 1% to 12% grapefruit essential oil, 1% to 7% clove essential oil, 1% to approximately 7% cinnamon essential oil, approximately 1% to approximately 7% rosemary essential oil, approximately 1% to approximately 12% eucalyptus Potassium essential oil, approximately 1% to 12% lemon essential oil, approximately 1% to 12% frankincense essential oil, Approximately 1% to 12% myrrh essential oil, and approximately 1% to 12% shan mao essential oil, approximately 1% to 12% Rosalina essential oil, 1% to approximately 12% Palmarosa essential oil, approximately 1% to approximately 12% Ravintsara essential oil, approximately 1% to 12% ravensara essential oil, approximately 1% to 12% laurel Essential oil from tree leaves, approximately 1% to 12% niaouli essential oil, approximately 1% to 12% cinnamon leaf essential oil, approximately This applies to formulations containing mixtures that include 1% to approximately 12% white thyme essential oil by volume. In these embodiments, the mixture has properties such as antimicrobial, antiviral, and antifungal characteristics. It may exhibit properties that promote wound healing and may facilitate recovery from microbial, viral, or fungal infections. .

[0120] In a particular embodiment, the present invention comprises about 20% to 50% olive oil, about 40% to 55% high-oleic sunflower seed oil, approximately 0.001% to approximately 3% coconut oil, approximately 0.0 1% to approximately 5% macadamia nut essential oil, approximately 1% to approximately 7% clove essential oil, approximately 1% to approximately 7% cinnamon essential oil, approximately 1% to 7% rosemary essential oil, approximately 1% to 7% eucalyptus essential oil, Approximately 1% to 7% lemon essential oil, approximately 0.01% to 3% ravintsara essential oil, and approximately 0 0.001% to approximately 2% cinnamon leaf essential oil, approximately 0.01% to approximately 7% frankincense essential oil, 0 0.01% to approximately 7% white thyme essential oil, approximately 0.01% to approximately 7% rosalina essential oil, approximately 0.01% to approximately 7% palmarosa essential oil, approximately 0.01% to approximately 7% niaouli essential oil, approximately 0. 0.01% to approximately 7% bay leaf essential oil, approximately 0.01% to approximately 7% litsea essential oil, measured in percentage by volume. The present invention relates to formulations containing a mixture of the following: In these embodiments, the mixture is, for example, an anti- It may exhibit antimicrobial, antiviral, antifungal, antitrypanosomal, and wound healing properties. It may promote recovery from plant, viral, fungal, or trypanosomial infections.

[0121] In a particular embodiment, the present invention comprises about 20% to 50% olive oil, about 40% to 55% high-oleic sunflower seed oil, approximately 0.001% to approximately 3% coconut oil, approximately 0.0 1% to approximately 5% macadamia nut essential oil, approximately 1% to approximately 7% clove essential oil, approximately 1% to approximately 7% cinnamon essential oil, approximately 1% to 7% rosemary essential oil, approximately 1% to 7% eucalyptus essential oil, Approximately 1% to 7% lemon essential oil, approximately 0.01% to 7% ravintsara essential oil, and approximately 0 0.001% to approximately 7% cinnamon leaf essential oil, approximately 0.01% to approximately 7% frankincense essential oil, approximately 0.01% to approximately 7% myrrh essential oil, 0.01% to approximately 7% white thyme essential oil, approximately 0 Rosalina essential oil at 0.01% to approximately 7%, Palmarosa essential oil at approximately 0.01% to approximately 7%, approximately 0. 0.01% to approximately 7% niaouli essential oil, approximately 0.01% to approximately 7% bay leaf essential oil, approximately 0.01 Litsea essential oil at approximately 7%, Shan Mao essential oil at approximately 0.01% to 7%, and approximately 0.01% Approximately 7% cymbopogon citratus essential oil, approximately 0.01%~ This applies to formulations containing a mixture that includes 7% coriander seed essential oil by volume. In these embodiments, the mixture possesses, for example, antimicrobial, antiviral, antifungal, and antiparasitic properties. , and may exhibit wound healing properties, and may protect against microbial, viral, fungal, or parasitic infections. It may promote recovery.

[0122] In a particular embodiment, the present invention relates to sunflower varieties with approximately 40% to 65% high oleic acid content. Coconut oil, approximately 0.001% to 3% coconut oil, approximately 0.01% to 7% macadamia nut oil. Oil, approximately 1% to 10% clove oil, approximately 1% to 10% cinnamon essential oil, approximately 1% to 10% Rosemary essential oil, approximately 1% to 10% eucalyptus essential oil, approximately 1% to 10% lemon essential oil, Approximately 1% to 10% ravintsara essential oil, and approximately 10% to 10% cinnamon leaf essential oil, approximately 1 %~approximately 10% frankincense essential oil, 1%~approximately 10% myrrh essential oil, approximately 1%~approximately 1 0% White Thyme essential oil, approximately 0.01% to approximately 10% Rosalina essential oil, approximately 1% to approximately 10 % Shanmao essential oil, approximately 1% to approximately 10% Palmarosa grass (Cymbopogon martinii) Palmarosa essential oil, approximately 1% to 10% of Symbolopogon martini 'Sophia' (cy Mbopogon martinii var. sophia (gingergrass) essential oil, approximately 1% to 10% symbolic Lemongrass (Cymbopogon citratus) essential oil, approximately 1% to 10% Coriander seed essential oil, approximately 1% to 10% niaouli essential oil, approximately 1% to 10% bay leaf oil The essential oils are derived from the leaves of the plant, approximately 1% to 10% of litsea essential oil, and approximately 1% to 10% of neroli essential oil, by volume. This applies to formulations containing a mixture in units. In these embodiments, the mixture is, for example, It may exhibit antimicrobial, antiviral, antifungal, antiparasitic, and wound-healing properties, and microorganisms It may promote recovery from viral, fungal, or parasitic infections.

[0123] In a particular embodiment, the present invention provides about 2% to about 6% German chamomile essential oil, about This applies to formulations containing a mixture that contains 94% to approximately 98% emu oil by volume. In these embodiments, the mixture can reduce pain and inflammation.

[0124] In a particular embodiment, the present invention provides about 2% to about 5% German chamomile essential oil, about 0.01% to approximately 1% peppermint essential oil, approximately 0.01% to approximately 1% bridal garden oil Jerusalem Holy Oil (Bridal Garden Jerusalem anointing oil) (www.thenewjerusalem.co.jp) (by means of), and a formulation containing a mixture containing approximately 80% to 90% emu oil by volume. In these embodiments, the mixture can reduce pain and inflammation.

[0125] In certain embodiments, the present invention provides long-acting relief of pain and anxiety, and tissue repair. Minerals, amino acids, vitamins, and other components (e.g.) for the delivery of substances required in return. For example, biosilicates containing approximately 1% to 25% biosilicates supported with bioactive compounds, and approximately 0.01% ~Approximately 2% German chamomile essential oil, approximately 0.01%~3% Moroccan chamomile essential oil, approximately 0.01% to approximately 2% Roman chamomile essential oil, approximately 0.01% to approximately 2% jasmine essential oil, Approximately 0.01% to 2% lemongrass essential oil, approximately 70% to 99% emu oil by volume The subject is a formulation containing a mixture in which pain is present. In these embodiments, the mixture contains pain It can reduce inflammation.

[0126] In certain embodiments, the present invention provides long-acting relief of pain and anxiety, and tissue repair. Minerals, amino acids, vitamins, and other bioactive substances for the delivery of substances required in return. Approximately 15% to 25% biosilicate supported with the compound, and approximately 10% to 15% molossi Cochamomile essential oil, approximately 2% to 15% Roman chamomile essential oil, approximately 6% to 9% Jasmine Min essential oil, approximately 6% to 9% vanilla (vanilla planifolia) essential oil, approximately 50% to 99% This applies to formulations containing a mixture containing emu oil in volume percentage. The mixture may reduce pain and inflammation.

[0127] In certain embodiments, the present invention provides long-acting relief of pain and anxiety, and tissue repair. Minerals, amino acids, vitamins, and other bioactive substances for the delivery of substances required in return. Biosilicate supporting the compound, approximately 1% to 25%, and approximately 0.01% to 30% Chamomile essential oil, approximately 0.01% to approximately 30% Moroccan chamomile essential oil, approximately 0.01% Approximately 30% Roman chamomile essential oil, approximately 0.01% to approximately 2% jasmine essential oil, approximately 0.01 Approximately 2% lemongrass essential oil, approximately 2% to 4% coconut oil, and approximately 25% to 29% macadamia oil. A formulation containing a mixture of nut oil and emu oil, with approximately 20% to 70% by volume. In these embodiments, the mixture can reduce pain and inflammation.

[0128] In certain embodiments, the present invention provides long-acting relief of pain and anxiety, and tissue repair. Minerals, amino acids, vitamins, and other bioactive substances for the delivery of substances required in return. Biosilicate supporting the compound, approximately 1% to 25%, and approximately 0.01% to 30% Chamomile essential oil, approximately 0.01% to approximately 30% Moroccan chamomile essential oil, approximately 0.01% Approximately 30% Roman chamomile essential oil, approximately 0.01% to approximately 3% frankincense essential oil, approximately 0 0.01% to approximately 3% myrrh essential oil, approximately 2% to approximately 5% macadamia nut oil, approximately 0.01% Approximately 2% coconut oil, approximately 1% to 4% jasmine essential oil, approximately 1% to 4% lemongrass This applies to formulations containing essential oils and mixtures containing approximately 25% to 85% emu oil by volume. In these embodiments, the mixture can reduce pain and inflammation.

[0129] In certain embodiments, the present invention provides long-acting relief of pain and anxiety, and tissue repair. Minerals, amino acids, vitamins, and other bioactive substances for the delivery of substances required in return. Biosilicate supporting the compound, containing approximately 5% to 18%, and German Chamomile essential oil, approximately 0.01% to approximately 3% Moroccan chamomile essential oil, approximately 0.01% to approximately 3% % Roman chamomile, approximately 1% to 8% frankincense oil, approximately 1% to 8% myrrh Oil, approximately 2% to 27% macadamia nut oil, approximately 0.01% to 10% coconut oil, 0.01% to approximately 3% jasmine essential oil, approximately 0.01% to approximately 3% lemongrass essential oil, approximately 3 This applies to formulations containing mixtures that include 5% to approximately 85% emu oil by volume. In one embodiment, the mixture can reduce pain and inflammation.

[0130] In certain embodiments, the present invention provides long-acting relief of pain and anxiety, and tissue repair. Minerals, amino acids, vitamins, and other bioactive substances for the delivery of substances required in return. Biosilicate supporting the compound, approximately 2% to 25%, and approximately 0.01% to 30% Chamomile essential oil, approximately 0.01% to approximately 30% Moroccan chamomile essential oil, approximately 0.01% Approximately 30% Roman chamomile essential oil, approximately 0.01% to approximately 10% frankincense essential oil, 0.01% to approximately 10% myrrh essential oil, approximately 0.01% to approximately 2% jasmine essential oil, approximately 0.0 1% to approximately 2% lemongrass essential oil, approximately 0.01% to approximately 3% sweet orange essential oil, approximately 0.01% to approximately 3% bitter orange essential oil, approximately 0.01% to approximately 3% rosemary essential oil, Approximately 0.01% to 3% galangal essential oil, approximately 0.01% to 3% shan mao essential oil, approximately 0 0.01% to approximately 3% palmarosa essential oil, approximately 0.01% to approximately 3% neroli essential oil, approximately 0.01 Approximately 5% licorice extract, approximately 2% to 9% lecithin, and approximately 0.01% to 2% coconut. The oils consist of approximately 0.01% to 5% macadamia nut oil and approximately 25% to 90% emu oil. This applies to formulations containing a mixture in units of percentage. In these embodiments, the mixture is It can reduce pain and inflammation.

[0131] In a particular embodiment, the present invention provides long-acting delivery of substances required for tissue repair. Approximately 2% of the product contains minerals, amino acids, vitamins, and other bioactive compounds. ~25% biosilicate, approximately 0.01%~3% gallic acid, approximately 0.01%~3 0% German chamomile essential oil, approximately 0.01% to approximately 30% Moroccan chamomile essential oil, approximately 0 0.01% to approximately 30% Roman chamomile essential oil, approximately 0.01% to approximately 10% frankincense Myrrh essential oil (approximately 0.01% to 10%), jasmine essential oil (approximately 0.01% to 2%) Approximately 0.01% to 2% lemongrass essential oil, approximately 0.01% to 2% cinnamon essential oil, approximately 0. 0.01% to approximately 2% cinnamon leaf essential oil, approximately 0.01% to approximately 2% rosemary essential oil, approximately 0.01% ~3% sweet orange essential oil, approximately 0.01%~3% bitter orange essential oil, approximately 0 0.01% to approximately 3% rosemary essential oil, approximately 0.01% to approximately 2% ravintsara essential oil, approximately Galangal essential oil at a concentration of 0.01% to approximately 3%, Shanmao essential oil at a concentration of approximately 0.01% to approximately 3%, and approximately 0. 0.01% to approximately 2% gingergrass essential oil, approximately 0.01% to approximately 3% palmarosa essential oil, approximately 0.01% to approximately 2% geranium essential oil, approximately 0.01% to approximately 3% neroli essential oil, approximately 0.01 Approximately 5% licorice extract, approximately 0.01% to 2% ginger essential oil, approximately 2% to 9% le Citin, approximately 0.01% to 2% saturated Dead Sea salt solution, approximately 0.01% to 2% coconut oil Approximately 0.01% to 5% macadamia nut oil, approximately 35% to 90% emu oil by volume This applies to formulations containing a mixture in percentage units. In these embodiments, the mixture contains pain It can reduce pain and inflammation.

[0132] In a particular embodiment, the present invention provides long-acting delivery of substances required for tissue repair. Approximately 2% of the product contains minerals, amino acids, vitamins, and other bioactive compounds. ~25% biosilicate, approximately 0.01%~3% gallic acid, approximately 0.01%~3 0% German chamomile essential oil, approximately 0.01% to approximately 30% Moroccan chamomile essential oil, approximately 0 0.01% to approximately 30% Roman chamomile essential oil, approximately 0.01% to approximately 10% frankincense Myrrh essential oil (approximately 0.01% to 10%), jasmine essential oil (approximately 0.01% to 2%) Approximately 0.01% to 2% lemongrass essential oil, approximately 0.01% to 2% cinnamon essential oil, approximately 0. 0.01% to approximately 2% cinnamon leaf essential oil, approximately 0.01% to approximately 2% rosemary essential oil, approximately 0.01% ~3% sweet orange essential oil, approximately 0.01%~3% bitter orange essential oil, approximately 0 0.01% to approximately 3% rosemary essential oil, approximately 0.01% to approximately 2% ravintsara essential oil, approximately Galangal essential oil at a concentration of 0.01% to approximately 3%, Shanmao essential oil at a concentration of approximately 0.01% to approximately 3%, and approximately 0. 0.01% to approximately 2% gingergrass essential oil, approximately 0.01% to approximately 3% palmarosa essential oil, approximately 0.01% to approximately 2% geranium essential oil, approximately 0.01% to approximately 3% neroli essential oil, approximately 0.01 Approximately 5% licorice extract, approximately 0.01% to 2% ginger essential oil, approximately 0.01% to 1 0% peppermint essential oil, approximately 0.01% to approximately 7% spearmint essential oil, approximately 0.01% to approximately 1% wintergreen essential oil, approximately 2% to 9% lecithin, approximately 0.01% to 2% saturates Dead Sea salt solution, approximately 0.01% to 2% coconut oil, approximately 0.01% to 5% macadamia A formulation containing a mixture of nut oil and emu oil, with approximately 35% to 90% by volume. In these embodiments, the mixture can reduce pain and inflammation.

[0133] In a particular embodiment, the present invention provides long-acting delivery of substances required for tissue repair. Approximately 2% of the product contains minerals, amino acids, vitamins, and other bioactive compounds. ~25% biosilicate, approximately 0.01%~3% gallic acid, approximately 0.01%~3 0% German chamomile essential oil, approximately 0.01% to approximately 30% Moroccan chamomile essential oil, approximately 0 0.01% to approximately 30% Roman chamomile essential oil, approximately 0.01% to approximately 10% frankincense Myrrh essential oil (approximately 0.01% to 10%), jasmine essential oil (approximately 0.01% to 2%) Approximately 0.01% to 2% lemongrass essential oil, approximately 0.01% to 2% cinnamon essential oil, approximately 0. 0.01% to approximately 2% cinnamon leaf essential oil, approximately 0.01% to approximately 2% rosemary essential oil, approximately 0.01% ~3% sweet orange essential oil, approximately 0.01%~3% bitter orange essential oil, approximately 0 0.01% to approximately 3% rosemary essential oil, approximately 0.01% to approximately 2% ravintsara essential oil, approximately Galangal essential oil at a concentration of 0.01% to approximately 3%, Shanmao essential oil at a concentration of approximately 0.01% to approximately 3%, and approximately 0. 0.01% to approximately 2% gingergrass essential oil, approximately 0.01% to approximately 3% palmarosa essential oil, approximately 0.01% to approximately 2% geranium essential oil, approximately 0.01% to approximately 3% neroli essential oil, approximately 0.01 Approximately 5% licorice extract, approximately 0.01% to 2% ginger essential oil, approximately 0.01% to 1 0% turmeric essential oil, approximately 0.01% to approximately 10% black seed essential oil, approximately 2% to approximately 9% Citin, approximately 0.01% to 2% saturated Dead Sea salt solution, approximately 0.01% to 2% coconut oil Approximately 0.01% to 5% macadamia nut oil, approximately 35% to 90% emu oil by volume This applies to formulations containing a mixture in percentage units. In these embodiments, the mixture contains pain It can reduce pain and inflammation.

[0134] In a particular embodiment, the present invention provides long-acting delivery of substances required for tissue repair. Select from a group including minerals, amino acids, vitamins, and other bioactive compounds for this purpose. A biosilicate containing at least one component, in a concentration of approximately 2% to 10%, is used in a single volume % unit. This applies to formulations containing mixtures at a certain concentration. For example, a formulation containing approximately 0.01% to 7% ubiquitous compounds. Quinol (final concentration of approximately 30-50 mg / ml), approximately 0.01%-4% vitamin A ( (Final concentration of approximately 300-350 mcg / ml), approximately 0.01% to approximately 10% vitamin D (approximately (Final concentration of 690-730 IU / ml), approximately 0.01% to approximately 10% vitamin E (approximately 5%) Final concentration of d-alpha-tocopherol at 15 mg / ml, d-beta, d-gamma, The final concentration of the mixed tocopherol, including d-delta-tocopherol, is approximately 0.001. (1 mg / ml), approximately 0.01% to approximately 10% of vitamin K2 MK7 (approximately 10-40%) (Final concentration of mcg / ml), approximately 0.01% to approximately 25% vitamin C, approximately 0.01% to approximately 4 % alpha-arbutin, approximately 0.01% to 3% gallic acid, approximately 0.01% to 10% Frankincense essential oil, approximately 0.01% to 10% Myrrh essential oil, approximately 0.01% to 5% Kojic acid, approximately 0.01% to 10% licorice root extract, approximately 0.01% to 12% niacin Namamide, approximately 0.01% to approximately 6% of turmeric (Kaempferia galanga) essential oil, approximately 0.01 Approximately 5% niaouli essential oil, approximately 0.01% to 3% glutathione, approximately 0.01% to 1 2% hyaluronic acid, approximately 0.01% to 5% clove essential oil, approximately 0.01% to 5% yu Potassium essential oil, approximately 0.01% to 5% lemon essential oil, approximately 0.01% to 5% rosemary Essential oil, approximately 0.01% to 5% cinnamon essential oil, approximately 0.01% to 5% leaf cinnamon essential oil, approximately 0.0 1% to approximately 5% ravintsara essential oil, approximately 0.01% to approximately 3% palmarosa essential oil, approximately 0. 0.01% to approximately 5% macadamia nut oil, approximately 0.01% to approximately 3% coconut oil, approximately 2% to approximately 9% lecithin, approximately 1% to 9% vegetable glycerin, approximately 35% to 90% emu oil It may include. In these embodiments, the mixture has skin whitening properties and age spot fading properties. They may have a sexual nature.

[0135] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 10% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7%. Ubiquinol (final concentration of approximately 30-50 mg / ml), approximately 0.01%-4% vitamin Vitamin A (final concentration of approximately 300-350 mcg / ml), approximately 0.01% to approximately 10% D (final concentration of approximately 690-730 IU / ml), approximately 0.01% to approximately 10% vitamin E ( Final concentration of d-alpha-tocopherol at approximately 5-15 mg / ml, d-beta, d-cancer The final concentration of the mixed tocopherol, including M and d-delta-tocopherol, is approximately 0.0 (0.01-1 mg / ml), approximately 0.01% to approximately 10% of vitamin K2 MK7 (approximately 10 (Final concentration of ~40mcg / ml), approximately 0.01% to approximately 25% vitamin C, approximately 0.01% ~3% gallic acid, approximately 0.01%~3% saturated dead sea salt solution, approximately 0.01%~3% Glutathione, approximately 0.01% to 12% hyaluronic acid, approximately 0.01% to 10% sweetener Herb root extract, approximately 0.05% to 12% niacinamide, approximately 0.001% to 1% di Frankincense essential oil, approximately 0.01% to 10% % myrrh essential oil, approximately 0.01% to approximately 6% turmeric (kaempferia galanga) essential oil, approximately 0.01% to approximately 3% palmarosa essential oil, approximately 0.01% to approximately 5% clove essential oil, approximately 0. 0.01% to approximately 5% eucalyptus essential oil, approximately 0.01% to approximately 5% lemon essential oil, approximately 0.01% to approximately 5% rosemary essential oil, approximately 0.01% to 5% cinnamon essential oil, approximately 0.01% to 5% leaves Cinnamon essential oil, approximately 0.01% to 5% ravintsara essential oil, approximately 0.01% to 3% bitter Orange essential oil, approximately 0.01% to 3%; Sweet orange essential oil, approximately 0.01% to 5%. Niaouli essential oil, approximately 0.01% to 3% gingergrass essential oil, approximately 0.01% to 3% Turmeric essential oil, approximately 0.01% to 5% macadamia nut oil, approximately 0.01% to 5% corn Coconut oil contains approximately 0.01% to 3% lauric acid (in addition to the lauric acid in coconut oil), Approximately 2% to 9% lecithin, approximately 1% to 9% vegetable glycerin, approximately 35% to 90% It may contain emu oil. In these embodiments, the mixture may have anti-acne properties. It can also improve skin texture.

[0136] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 10% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7% Ubiquinol (final concentration of approximately 30-50 mg / ml), approximately 0.01%-3% retino Vitamin A content of approximately 0.01% to 4% (final concentration of approximately 300-350 mcg / ml) Approximately 0.01% to approximately 10% vitamin D (final concentration of approximately 690 to 730 IU / ml), approximately 0.01% to approximately 10% vitamin E (approximately 5-15 mg / ml of d-alpha-tocopherol) The final concentration of the mixture, including d-beta, d-gamma, and d-delta tocopherol. The final concentration of tocopherol is approximately 0.001 to 1 mg / ml, approximately 0.01% to approximately 1 0% Vitamin K2 MK7 (final concentration of approximately 10-40 mcg / ml), approximately 0.01% Approximately 25% vitamin C, approximately 0.01% to 3% gallic acid, approximately 0.01% to 3% saturated Dead Sea salt solution, approximately 0.01% to 3% glutathione, approximately 0.01% to 12% hyaluronic acid Licorice root extract (approximately 0.01% to 10%), niacin (approximately 0.05% to 12%) Amide, approximately 0.001% to 1% ginger essential oil, approximately 0.01% to 15% frankincense Incense essential oil, approximately 0.01% to 15% myrrh essential oil, approximately 0.01% to 6% argyrophilus Kaempferia galanga essential oil, approximately 0.01% to approximately 3% palmarosa essential oil, approximately 0.0 1% to approximately 3% rosemary essential oil, approximately 0.01% to approximately 3% bitter orange essential oil, approximately 0. 0.01% to approximately 3% sweet orange essential oil, approximately 0.01% to approximately 5% clove essential oil, approximately 0 0.01% to approximately 5% eucalyptus essential oil, approximately 0.01% to approximately 5% lemon essential oil, approximately 0.01% Approximately 5% rosemary essential oil, approximately 0.01% to 5% cinnamon essential oil, approximately 0.01% to 5% Cinnamon leaf essential oil, approximately 0.01% to 5% ravintsara essential oil, approximately 0.01% to 5% ni Melon essential oil, approximately 0.01% to 3% gingergrass essential oil, approximately 0.01% to 3% urea Coconut essential oil, approximately 0.01% to 5% macadamia nut oil, approximately 0.01% to 5% coconut oil Oil, approximately 0.01% to 3% lauric acid (in addition to the lauric acid in coconut oil), approximately 2% ~9% lecithin, approximately 1% to 9% vegetable glycerin, approximately 35% to 90% emu - May contain oil. In these embodiments, the mixture may have anti-acne properties. Furthermore, it can improve skin texture and the appearance of scars and keloids.

[0137] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7% Ubiquinol (final concentration of approximately 1-1000 mg / ml), approximately 0.01%-4% vitamin Min A (final concentration of approximately 300-350 mcg / ml), approximately 0.01% to approximately 10% vitamin Vitamin D (final concentration of approximately 690-730 IU / ml), approximately 0.01%-10% vitamin E (Final concentration of d-alpha-tocopherol at approximately 5-15 mg / ml, d-beta, d-ga The final concentration of the mixed tocopherols, including namal and d-delta-tocopherol, is approximately 0. (0.01-1 mg / ml), approximately 0.01%-10% vitamin K2 MK7 (approximately 1 (Final concentration of 0-40 mcg / ml), approximately 0.001% to approximately 10% saturated Dead Sea salt solution, approximately 0.01% to approximately 12% hyaluronic acid, approximately 0.01% to approximately 12% vegetable glycerin, approximately 0.01% to approximately 3% German chamomile essential oil, approximately 0.01% to approximately 5% Moroccan chamomile Chamomile essential oil, approximately 0.01% to 3% Roman chamomile essential oil, approximately 0.01% to 3% Jasmine Min essential oil, approximately 0.01% to 3% lemongrass essential oil, approximately 0.01% to 5% lemon essential oil Oil, approximately 0.01% to 5% eucalyptus essential oil, approximately 0.01% to 5% rosemary essential oil, Approximately 0.01% to 5% clove essential oil, approximately 0.01% to 5% cinnamon essential oil, approximately 0.01% ~5% cinnamon leaf essential oil, approximately 0.01%~5% ravintsara essential oil, approximately 0.01%~ 30% macadamia nut oil, approximately 0.01% to 5% coconut oil, approximately 15% to 90% It may contain emu oil. In these embodiments, the mixture is used to treat skin eczema, psoriasis, and other conditions. It may be particularly useful in treating uncontrollable rashes and wounds.

[0138] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7% Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-4% Vitamin A (final concentration of approximately 5700-6500 mcg / ml), approximately 0.01%-10% Vitamin D (final concentration of approximately 3000-4000 IU / ml), approximately 0.01%-10% Vitamin E (final concentration of d-alpha-tocopherol at approximately 25-35 mg / ml, d- The final mixed tocopherol including d-gamma and d-delta tocopherol. The concentration is approximately 0.001 to 1 mg / ml, and the vitamin K2 content is approximately 0.01% to 10%. MK7 (final concentration of approximately 50-100 mcg / ml), saturation of approximately 0.001% to 10% Dead Sea salt solution, approximately 0.01% to 20% hyaluronic acid, approximately 0.01% to 20% plant extracts. Glycerin, approximately 0.01% to 6% German chamomile essential oil, approximately 0.01% to 10% Moroccan chamomile essential oil, approximately 0.01% to approximately 6% Roman chamomile essential oil, approximately 0.01 %~approximately 3% jasmine essential oil, approximately 0.01%~approximately 3% lemongrass essential oil, approximately 0.01% ~5% lemon essential oil, approximately 0.01%~5% eucalyptus essential oil, approximately 0.01%~5% Rosemary essential oil, approximately 0.01% to 5% clove essential oil, approximately 0.01% to 5% cinnamon Essential oils, approximately 0.01% to 5% cinnamon leaf essential oil, approximately 0.01% to 5% ravintsara essential oil Approximately 0.01% to 20% frankincense essential oil, approximately 0.01% to 20% myrrh essential oil Oil, approximately 0.01% to 20% lecithin, approximately 0.001% to 5% gallic acid, approximately 0.0 0.01% to approximately 5% turmeric essential oil, approximately 0.01% to approximately 30% macadamia nut oil, approximately 0.0 These products may contain 1% to approximately 5% coconut oil and approximately 15% to approximately 90% emu oil. In terms of form, the mixture is particularly useful for treating skin eczema, psoriasis, unspecified rashes, and wounds. It may be useful.

[0139] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7%. Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-4% Vitamin A (final concentration of approximately 5700-6500 mcg / ml), approximately 0.01%-10% Vitamin D (final concentration of approximately 3000-4000 IU / ml), approximately 0.01%-10% Vitamin E (final concentration of d-alpha-tocopherol at approximately 25-35 mg / ml, d- The final mixed tocopherol including d-gamma and d-delta tocopherol. The concentration is approximately 0.001 to 1 mg / ml, and the vitamin K2 content is approximately 0.01% to 10%. MK7 (final concentration of approximately 50-100 mcg / ml), saturation of approximately 0.001% to 10% Dead Sea salt solution, approximately 0.01% to 20% hyaluronic acid, approximately 0.01% to 20% plant extracts. Glycerin, approximately 0.01% to 6% German chamomile essential oil, approximately 0.01% to 20% Moroccan chamomile essential oil, approximately 0.01% to approximately 6% Roman chamomile essential oil, approximately 0.01 %~approximately 3% jasmine essential oil, approximately 0.01%~approximately 3% lemongrass essential oil, approximately 0.01% ~5% lemon essential oil, approximately 0.01%~5% eucalyptus essential oil, approximately 0.01%~5% Rosemary essential oil, approximately 0.01% to 5% clove essential oil, approximately 0.01% to 5% cinnamon Essential oils, approximately 0.01% to 5% cinnamon leaf essential oil, approximately 0.01% to 5% ravintsara essential oil Approximately 0.01% to 20% frankincense essential oil, approximately 0.01% to 20% myrrh essential oil Oil, approximately 0.01% to 20% lecithin, approximately 0.001% to 5% gallic acid, approximately 0.0 0.01% to approximately 5% turmeric essential oil, approximately 0.001% to approximately 5% Xanthoxyrum koreanum Nakai (Zanthoxylum coreanum nakai) essential oil (Wang Cho Pi or Korean Lime Tree) Approximately 0.01% to 30% macadamia nut oil, approximately 0.01% to 5% coconut oil, It may contain approximately 15% to 90% emu oil. In these embodiments, the mixture is made from the skin. It may be particularly useful in treating skin eczema, psoriasis, unspecified rashes, and wounds; itchy organisms It may reduce academic causes.

[0140] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7%. Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-4% Vitamin A (final concentration of approximately 5700-6500 mcg / ml), approximately 0.01%-10% Vitamin D (final concentration of approximately 3000-4000 IU / ml), approximately 0.01%-10% Vitamin E (final concentration of d-alpha-tocopherol at approximately 25-35 mg / ml, d- The final mixed tocopherol including d-gamma and d-delta tocopherol. The concentration is approximately 0.001 to 1 mg / ml, and the vitamin K2 content is approximately 0.01% to 10%. MK7 (final concentration of approximately 50-100 mcg / ml), approximately 0.01% to approximately 25% vitamin C, approximately 0.01% to 4% alpha-arbutin, approximately 0.01% to 5% kojic acid, Approximately 0.01% to 10% licorice root extract, approximately 0.01% to 10% ginger root extract Approximately 0.01% to 10% ginger root essential oil, approximately 0.01% to 12% niacin Mido, approximately 0.01% to 6% essential oil of turmeric (Kaempferia galanga), approximately 0.01% ~5% niaouli essential oil, approximately 0.01%~5% palmarosa essential oil, approximately 0.01%~ 3% glutathione, approximately 0.001% to approximately 10% saturated dead sea salt solution, approximately 0.01% to approximately 20% hyaluronic acid, approximately 0.01% to approximately 20% vegetable glycerin, approximately 0.01% to approximately 6% German chamomile essential oil, approximately 0.01% to approximately 10% Moroccan chamomile essential oil, approximately 0 0.01% to approximately 6% Roman chamomile essential oil, approximately 0.01% to approximately 3% jasmine essential oil, approximately 0.01% to approximately 3% lemongrass essential oil, approximately 0.01% to approximately 5% lemon essential oil, approximately 0.0 1% to approximately 5% eucalyptus essential oil, approximately 0.01% to approximately 5% rosemary essential oil, approximately 0.01% ~5% clove essential oil, approximately 0.01%~5% cinnamon essential oil, approximately 0.01%~5% leaves Cinnamon essential oil, approximately 0.01% to 5% ravintsara essential oil, approximately 0.01% to 20% flax Incense essential oil, approximately 0.01% to 20% myrrh essential oil, approximately 0.01% to 20% rhesus Citin, approximately 0.001% to 5% gallic acid, approximately 0.001% to 5% turmeric essential oil, approximately 5% to 20% kelp bio-fermented product (fermented seaweed extract), approximately 0.01% to approximately 30% Macadamia nut oil, approximately 0.01% to 5% coconut oil, approximately 15% to 90% emu - May contain oil. In these embodiments, the mixture is used for eczema, psoriasis, and unspecified It may be particularly useful in treating rashes and skin wounds. The mixture has anti-aging and skin-brightening properties. It is formulated to provide cosmetic and moisturizing properties.

[0141] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 1%. Retinol, approximately 0.01% to approximately 7% ubiquinol (approximately 30 to 1000 mg / ml) Final concentration: approximately 0.01% to approximately 4% vitamin A (approximately 5700 to 6500 mcg / ml). Final concentration: approximately 0.01% to approximately 10% vitamin D (approximately 3000 to 4000 IU / ml). Final concentration), approximately 0.01% to approximately 10% vitamin E (approximately 25-35 mg / ml of d-alpha) Final concentrations of tocopherol, d-beta, d-gamma, and d-delta tocopherol The final concentration of the mixed tocopherols, including the ru, is approximately 0.001 to approximately 1 mg / ml. Vitamin K2 MK7 (0.01% to approximately 10% final concentration of approximately 50-100 mcg / ml) ), approximately 0.01% to 25% vitamin C, approximately 0.01% to 4% alpha-arbutin Approximately 0.01% to 5% kojic acid, approximately 0.01% to 10% licorice root extract, approximately 0.0 1% to approximately 10% ginger root extract, approximately 0.01% to approximately 10% ginger root essential oil, approximately 0.01% to approximately 12% niacinamide, approximately 0.01% to approximately 6% turmeric (kaempf Eria galanga essential oil, approximately 0.01% to 5% Niaouli essential oil, approximately 0.01% to 5% Palmarosa essential oil, approximately 0.01% to 3% glutathione, approximately 0.001% to 10% Saturated Dead Sea salt solution, approximately 0.01% to approximately 20% hyaluronic acid, approximately 0.01% to approximately 20% Vegetable glycerin, approximately 0.01% to 6% German chamomile essential oil, approximately 0.01% to 1 0% Moroccan chamomile essential oil, approximately 0.01% to approximately 6% Roman chamomile essential oil, approximately 0. 0.01% to approximately 3% jasmine essential oil, approximately 0.01% to approximately 3% lemongrass essential oil, approximately 0.0 1% to approximately 5% lemon essential oil, approximately 0.01% to approximately 5% eucalyptus essential oil, approximately 0.01% to approximately 5 % rosemary essential oil, approximately 0.01% to 5% clove essential oil, approximately 0.01% to 5% Cinnamon essential oil, approximately 0.01% to 5% leaf cinnamon essential oil, approximately 0.01% to 5% ravintsara Essential oil, approximately 0.01% to 20% frankincense essential oil, approximately 0.01% to 20% mill La essential oil, approximately 0.01% to 20% lecithin, approximately 0.001% to 5% gallic acid, approximately 0 0.001% to approximately 5% turmeric essential oil, approximately 5% to 20% kelp bio-fermented product (fermented seaweed Extract, approximately 0.01% to 30% macadamia nut oil, approximately 0.01% to 5% coconut oil The mixture may contain about 15% to 90% emu oil. In these embodiments, the mixture may be mixed. The substance may be particularly useful in treating skin eczema, psoriasis, and unspecified rashes, as well as wounds. The mixture is formulated to provide anti-aging, skin-brightening, and cosmetic moisturizing properties. It will be done.

[0142] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 70% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to approximately 1% Retinol, approximately 0.01% to approximately 7% ubiquinol (approximately 30 to 1000 mg / ml) Final concentration: approximately 0.01% to approximately 4% vitamin A (approximately 5700 to 6500 mcg / ml). Final concentration: approximately 0.01% to approximately 10% vitamin D (approximately 3000 to 4000 IU / ml). Final concentration), approximately 0.01% to approximately 10% vitamin E (approximately 25-35 mg / ml of d-alpha) Final concentrations of tocopherol, d-beta, d-gamma, and d-delta tocopherol The final concentration of the mixed tocopherols, including the ru, is approximately 0.001 to approximately 1 mg / ml. Vitamin K2 MK7 (0.01% to approximately 10% final concentration of approximately 50-100 mcg / ml) ), approximately 0.01% to 25% vitamin C, approximately 0.01% to 4% alpha-arbutin Approximately 0.01% to 5% kojic acid, approximately 0.01% to 10% licorice root extract, approximately 0.0 1% to approximately 10% ginger root extract, approximately 0.01% to approximately 10% ginger root essential oil, approximately 0.01% to approximately 12% niacinamide, approximately 0.01% to approximately 6% turmeric (kaempf Eria galanga essential oil, approximately 0.01% to 5% Niaouli essential oil, approximately 0.01% to 5% Palmarosa essential oil, approximately 0.01% to 3% glutathione, approximately 0.001% to 10% Saturated Dead Sea salt solution, approximately 0.01% to approximately 20% hyaluronic acid, approximately 0.01% to approximately 20% Vegetable glycerin, approximately 0.01% to 6% German chamomile essential oil, approximately 0.01% to 1 0% Moroccan chamomile essential oil, approximately 0.01% to approximately 6% Roman chamomile essential oil, approximately 0. 0.01% to approximately 3% jasmine essential oil, approximately 0.01% to approximately 3% lemongrass essential oil, approximately 0.0 1% to approximately 5% lemon essential oil, approximately 0.01% to approximately 5% eucalyptus essential oil, approximately 0.01% to approximately 5 % rosemary essential oil, approximately 0.01% to 5% clove essential oil, approximately 0.01% to 5% Cinnamon essential oil, approximately 0.01% to 5% leaf cinnamon essential oil, approximately 0.01% to 5% ravintsara Essential oil, approximately 0.01% to 20% frankincense essential oil, approximately 0.01% to 20% mill La essential oil, approximately 0.01% to 20% lecithin, approximately 0.001% to 5% gallic acid, approximately 0 0.001% to approximately 5% turmeric essential oil, approximately 5% to 20% kelp bio-fermented product (fermented seaweed Extract, approximately 0.01% to 30% macadamia nut oil, approximately 0.01% to 5% coconut oil Nut oil may contain approximately 15% to 90% emu oil. This mixture has anti-aging and skin-beautifying properties. It can be particularly useful for brightening and for its cosmetic moisturizing properties. The formulation can be used, for example, for facial care. It can be used as a mask.

[0143] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7% Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-4% Vitamin A (final concentration of approximately 5700-6500 mcg / ml), approximately 0.01%-10% Vitamin D (final concentration of approximately 3000-4000 IU / ml), approximately 0.01%-10% Vitamin E (final concentration of d-alpha-tocopherol at approximately 25-35 mg / ml, d- The final mixed tocopherol including d-gamma and d-delta tocopherol. The concentration is approximately 0.001 to 1 mg / ml, and the vitamin K2 content is approximately 0.01% to 10%. MK7 (final concentration of approximately 50-100 mcg / ml), approximately 0.01% to 5% vitamin C C, approximately 0.01% to 10% niacinamide, approximately 0.01% to 3% glutathione Approximately 0.001% to 10% saturated Dead Sea salt solution, approximately 0.01% to 30% hyaluronic acid Acid, approximately 0.01% to 30% vegetable glycerin, approximately 0.01% to 20% lecithin, Approximately 5% to 30% kelp bio-fermented product (fermented seaweed extract), approximately 0.01% to approximately 30% Macadamia nut oil, approximately 0.01% to 5% coconut oil, approximately 15% to 90% emi May contain oil. These preparations are particularly useful in the treatment of burns. They are suitable for burn areas. It is intended to be applied to intact, non-erythematous skin near the burned area, rather than within the burn itself.

[0144] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7%. Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-4% Vitamin A (final concentration of approximately 5700-6500 mcg / ml), approximately 0.01%-10% Vitamin D (final concentration of approximately 3000-4000 IU / ml), approximately 0.01%-10% Vitamin E (final concentration of d-alpha-tocopherol at approximately 25-35 mg / ml, d- The final mixed tocopherol including d-gamma and d-delta tocopherol. The concentration is approximately 0.001 to 1 mg / ml, and the vitamin K2 content is approximately 0.01% to 10%. MK7 (final concentration of approximately 50-100 mcg / ml), approximately 0.01% to approximately 25% vitamin C, approximately 0.01% to 1% licorice root extract, approximately 0.01% to 1% ginger root extract The ingredients include approximately 1% to 10% ginger root essential oil, and approximately 0.01% to 5% niacinamide. Approximately 0.01% to approximately 6% essential oil of turmeric (Kaempferia galanga), approximately 0.01% to approximately 3 % glutathione, approximately 0.001% to approximately 10% saturated dead sea salt solution, approximately 0.01% to approximately 3 0% hyaluronic acid, approximately 0.01% to approximately 30% vegetable glycerin, approximately 0.01% to approximately 1 0% German chamomile essential oil, approximately 0.01% to approximately 10% Moroccan chamomile essential oil, approximately 0 0.01% to approximately 10% Roman chamomile essential oil, approximately 0.01% to approximately 3% jasmine essential oil, Approximately 0.01% to 3% calamus essential oil, approximately 0.01% to 5% lemon essential oil, approximately 0.01 Approximately 5% eucalyptus essential oil, approximately 0.01% to 5% rosemary essential oil, approximately 0.01% Approximately 5% clove essential oil, approximately 0.01% to 5% cinnamon essential oil, approximately 0.01% to 5% leaf pulp. Cinnamon essential oil, approximately 0.01% to 5% ravintsara essential oil, approximately 0.01% to 20% furan Incense essential oil, approximately 0.01% to 20% myrrh essential oil, approximately 0.01% to 20% reci Chin, approximately 0.001% to 5% gallic acid, approximately 0.001% to 5% turmeric essential oil, approximately 5 %~20% kelp bio-fermented product (fermented seaweed extract), approximately 0.01%~30% Cadamia nut oil, approximately 0.01% to 5% coconut oil, approximately 15% to 90% emu They may contain oil. These formulations are particularly useful in treating burns. They are used within the burn area. Rather, it is intended to be applied to intact, non-erythematous skin near the burned area.

[0145] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7%. Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-4% Vitamin A (final concentration of approximately 5700-6500 mcg / ml), approximately 0.01%-10% Vitamin D (final concentration of approximately 3000-4000 IU / ml), approximately 0.01%-10% Vitamin E (final concentration of d-alpha-tocopherol at approximately 25-35 mg / ml, d- The final mixed tocopherol including d-gamma and d-delta tocopherol. The concentration is approximately 0.001 to 1 mg / ml, and the vitamin K2 content is approximately 0.01% to 10%. MK7 (final concentration of approximately 50-100 mcg / ml), approximately 0.01% to approximately 25% vitamin C, approximately 0.01% to 1% licorice root extract, approximately 0.01% to 1% ginger root extract The ingredients include approximately 1% to 10% ginger root essential oil and approximately 0.01% to 10% niacinamide. Approximately 0.01% to 1% of the following vitamins: B1, B2, B5, B6, B7, and B9. Each contains approximately 0.01% to 6% essential oil of turmeric (Kaempferia galanga), and approximately 0.01% ~3% glutathione, approximately 0.001%~10% saturated dead sea salt solution, approximately 0.01% ~Approximately 30% hyaluronic acid, approximately 0.01%~30% vegetable glycerin, approximately 0.01% Approximately 10% German chamomile essential oil, approximately 0.01% to 10% Moroccan chamomile essential oil Approximately 0.01% to 10% Roman chamomile essential oil, approximately 0.01% to 3% jasmine Essential oils, approximately 0.01% to 3% calamus essential oil, approximately 0.01% to 15% lemon essential oil, approximately 0.01% to approximately 15% eucalyptus essential oil, approximately 0.01% to approximately 15% rosemary essential oil, approximately 0.01% to approximately 15% clove essential oil, approximately 0.01% to approximately 15% cinnamon essential oil, approximately 0.01 Approximately 15% cinnamon leaf essential oil, approximately 0.01% to approximately 15% ravintsara essential oil, approximately 0.01 %~approximately 25% frankincense essential oil, approximately 0.01%~approximately 25% myrrh essential oil, approximately 0.0 1% to approximately 20% lecithin, approximately 0.001% to approximately 5% gallic acid, approximately 0.001% to approximately 5 % turmeric essential oil, approximately 5%-20% kelp bio-fermented product (fermented seaweed extract), approximately 0. 0.01% to approximately 30% macadamia nut oil, approximately 0.01% to approximately 5% coconut oil, approximately 15% It may contain approximately 90% emu oil. These preparations are particularly useful for wound healing. These are applied not to the wounded skin itself, but to the intact, non-erythematous skin surrounding the wound. It is intended.

[0146] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 3%. Alpha-lipoic acid (final concentration of approximately 100 to 1000 mg / ml), approximately 0.01% to 3 % calcium (final concentration of approximately 100 to 1000 mg / ml), approximately 0.01% to 7% Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-4% Vitamin A (final concentration of approximately 5700-6500 mcg / ml), approximately 0.01%-10% Vitamin D (final concentration of approximately 3000-4000 IU / ml), approximately 0.01%-10% Vitamin E (final concentration of d-alpha-tocopherol at approximately 25-35 mg / ml, d- The final mixed tocopherol including d-gamma and d-delta tocopherol. The concentration is approximately 0.001 to 1 mg / ml, and the vitamin K2 content is approximately 0.01% to 10%. MK7 (final concentration of approximately 50-100 mcg / ml), approximately 0.01% to approximately 25% vitamin C, approximately 0.01% to 1% licorice root extract, approximately 0.01% to 1% ginger root extract The ingredients include approximately 1% to 10% ginger root essential oil and approximately 0.01% to 10% niacinamide. Approximately 0.01% to 1% of the following vitamins: B1, B2, B5, B6, B7, and B9. These are approximately 0.01% to 6% of turmeric (kaempferia galanga) essential oil, and approximately 0.01% to Approximately 6% geranium essential oil, approximately 0.01% to 3% glutathione, approximately 0.001% to 1 0% saturated dead sea salt solution, approximately 0.01% to approximately 30% hyaluronic acid, approximately 0.01% to approximately 3 0% vegetable glycerin, approximately 0.01% to approximately 10% German chamomile essential oil, approximately 0.01 Approximately 10% Moroccan chamomile essential oil, approximately 0.01% to 10% Roman chamomile essential oil Oil, approximately 0.01% to 3% jasmine essential oil, approximately 0.01% to 3% calamus essential oil, approximately 0.01% to approximately 15% lemon essential oil, approximately 0.01% to approximately 15% eucalyptus essential oil, approximately 0.0 1% to approximately 15% rosemary essential oil, approximately 0.01% to approximately 15% clove essential oil, approximately 0.0 1% to approximately 15% cinnamon essential oil, approximately 0.01% to approximately 15% leaf cinnamon essential oil, approximately 0.01% to approximately 1 5% ravintsara essential oil, approximately 0.01% to approximately 25% frankincense essential oil, approximately 0.0 1% to approximately 25% myrrh essential oil, approximately 0.01% to approximately 20% lecithin, approximately 0.001% to approximately 5% gallic acid, approximately 0.001% to 5% turmeric essential oil, approximately 5% to 20% kelp bio-derived Fermented product (fermented seaweed extract), approximately 0.01% to approximately 30% macadamia nut oil, approximately 0. These products may contain 0.1% to approximately 5% coconut oil and approximately 15% to approximately 90% emu oil. The agent is used to treat wound healing, particularly pitting edema, lymphedema, and nerve damage. They are particularly useful for the intact, non-erythematous skin covering the lesion area. This is intended to be the case.

[0147] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7%. Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-5% Tamin A (final concentration of approximately 5700-10,000 mcg / ml), approximately 0.01%-10 % Vitamin D (final concentration of approximately 3,000 to 8,000 IU / ml), approximately 0.01% to approximately 1 0% Vitamin E (final concentration of d-alpha-tocopherol: approximately 25-500 mg / ml) Mixed tocopherols including d-beta, d-gamma, and d-delta tocopherols The final concentration of the vitamin is approximately 0.001 to 3 mg / ml, and the vitamin concentration is approximately 0.01% to 10%. Min K2 MK7 (final concentration of approximately 50-1000 mcg / ml), approximately 0.01% to approximately 25 % Vitamin C, approximately 0.01% to 1% Licorice root extract, approximately 0.01% to 1% Ginger Ginger root extract, approximately 1% to 10% ginger root essential oil, approximately 0.01% to 10% niacin Cinamide, approximately 0.01% to 1% of the following vitamins: B1, B2, B5, B6, B7, Each of B9 contains approximately 0.01% to 6% essential oil of turmeric (Kaempferia galanga), 0.01% to approximately 3% glutathione, approximately 0.001% to approximately 10% saturated dead sea salt solution, approximately 0.01% to approximately 30% hyaluronic acid, approximately 0.01% to approximately 30% vegetable glycerin, approximately 0.01% to approximately 10% German chamomile essential oil, approximately 0.01% to approximately 10% Moroccan chamomile Meal essential oil, approximately 0.01% to approximately 10% Roman chamomile essential oil, approximately 0.01% to approximately 3% Jasmine essential oil, approximately 0.01% to 20% calamus essential oil, approximately 0.01% to 15% le Mon essential oil, approximately 0.01% to 15% eucalyptus essential oil, approximately 0.01% to 15% rosemary Lee essential oil, approximately 0.01% to 15% clove essential oil, approximately 0.01% to 15% cinnamon essential oil Approximately 0.01% to 15% cinnamon leaf essential oil, approximately 0.01% to 15% ravintsara essential oil Approximately 0.01% to 25% frankincense essential oil, approximately 0.01% to 25% myrrh essential oil Oil, approximately 0.01% to 20% lecithin, approximately 0.001% to 5% gallic acid, approximately 0.0 0.1% to approximately 5% turmeric essential oil, approximately 5% to 20% kelp bio-fermented product (extract from fermented seaweed) (Material), approximately 0.01% to 30% macadamia nut oil, approximately 0.01% to 5% coconut These preparations may contain oil, approximately 15% to 90% emu oil. These preparations are used for wound healing, etc. It is particularly useful for improving the appearance of keloid and scar tissue. Intended for application to Lloyd's or scar tissue.

[0148] In certain embodiments, the present invention relates to long-acting pain relief and, for example, tissue Minerals, amino acids, vitamins, and other bioactive substances for the delivery of substances required for repair. Approximately 15% to approximately 25% of a compound supported with at least one component selected from the group including sex compounds. This applies to formulations containing mixtures with biosilicates in volume percentage. The formulations contain approximately 10% ~30% Moroccan chamomile essential oil, approximately 2%~30% Roman chamomile essential oil, approximately 0 0.01% to approximately 3% German chamomile essential oil, approximately 6% to approximately 9% jasmine essential oil, approximately 0.0 5% to approximately 5% cinnamon essential oil, approximately 5% to approximately 20% frankincense essential oil, approximately 5% to approximately 20% % myrrh essential oil, approximately 2% to 4% coconut oil, approximately 25% to 35% macadamia nut The oil may contain approximately 30% to 99% emu oil. In certain embodiments, the present invention This refers to formulations with half the listed strength. These formulations are for leukoplakia and tongue disease. It may be particularly useful in treating plaques.

[0149] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. The formulations contain approximately 0.01% to 0.05%. Ubiquinol (final concentration of approximately 1-5 mg / ml), approximately 0.01%-0.05% vitamin Vitamin A (final concentration of approximately 50-100 mcg / ml), approximately 0.01%-0.05% vitamin N-D (final concentration of approximately 100-400 IU / ml), approximately 0.01%-0.05% vitamin E (final concentration of d-alpha-tocopherol at approximately 5-15 mg / ml, d-beta, d - The final concentration of the mixed tocopherols, including gamma and d-delta tocopherol, is approximately Vitamin K2 M (0.001 to approximately 1 mg / ml), approximately 0.01% to approximately 0.05% K7 (final concentration of approximately 20-50 mcg / ml), approximately 0.01% to 30% Moroccan camouflage Chamomile essential oil, approximately 0.01% to 30%; Roman chamomile essential oil, approximately 0.01% to 20%. German chamomile essential oil, approximately 1% to 9% lecithin, approximately 0.05% to 5% gallic acid Approximately 1% to 20% frankincense essential oil, approximately 1% to 20% myrrh essential oil, approximately 2% Approximately 4% coconut oil, approximately 25% to 35% macadamia nut oil, approximately 30% to 99% May contain emu oil. These preparations are used for ulcerative colitis / inflammatory bowel disease / irritable bowel disease. It may be particularly useful for treatment.

[0150] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to approximately 20% % Moroccan chamomile essential oil, approximately 0.01% to approximately 0.05% jasmine essential oil, approximately 0.0 1% to approximately 5% orange essential oil, approximately 10% to approximately 40% saturated dead sea salt solution, approximately 1% to approximately 9% Lecithin, approximately 0.05% to 5% gallic acid, approximately 1% to 20% frankincense extract Oil, approximately 1% to 20% myrrh essential oil, approximately 2% to 4% coconut oil, approximately 10% to 15% These formulations may contain macadamia nut oil and emu oil, approximately 30% to 99%. It may be particularly useful in treating restless legs syndrome and muscle spasms.

[0151] In a particular embodiment, the present invention provides about 0.01% to about 2% Moroccan chamomile Essential oil, approximately 1% to 3% coconut oil, approximately 4% to 7% macadamia nut oil, approximately 1% to 3% vegetable glycerin, approximately 0.01% to 5% melatonin (approximately 100 to 160 mcg) (relative to the final concentration of the spray), and approximately 80% to 99% emu oil in volume percentage. This refers to formulations containing mixtures containing [the specified ingredient]. These formulations are used to treat jet lag and insomnia. It may be particularly useful and administered as a nasal spray for targeted delivery to the vascular system closest to the brain. It can be used (for example, one spray per nostril 30 minutes before the desired bedtime).

[0152] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 2% to 30% of at least one component selected from the above is used. This applies to formulations containing mixtures in percentage units. For example, formulations containing approximately 0.01% to 7%. Ubiquinol (final concentration of approximately 30-1000 mg / ml), approximately 0.01%-4% Vitamin A (final concentration of approximately 5700-6500 mcg / ml), approximately 0.01%-10% Vitamin D (final concentration of approximately 3000-4000 IU / ml), approximately 0.01%-10% Vitamin E (final concentration of d-alpha-tocopherol at approximately 25-35 mg / ml, d- The final mixed tocopherol including d-gamma and d-delta tocopherol. The concentration is approximately 0.001 to 1 mg / ml, and the vitamin K2 content is approximately 0.01% to 10%. MK7 (final concentration of approximately 50-100 mcg / ml), saturation of approximately 0.001% to 10% Dead Sea salt solution, approximately 0.01% to 20% ginger essential oil, approximately 0.01% to 20% ginger Ginger extract, approximately 2% to 10% licorice root extract, approximately 0.05% to 15% polygona Polygonum multifloridum extract, approximately 0.05% to approximately 15% Cordyceps extract, approximately 0.05% to 15% Bupleurum. Extract, approximately 0.01% to 3% of turmeric (Kaempferia galanga) essential oil, approximately 0.01% ~5% lemon essential oil, approximately 0.01%~5% eucalyptus essential oil, approximately 0.01%~15% Rosemary essential oil, approximately 0.01% to 5% clove essential oil, approximately 0.01% to 5% meat Cinnamon essential oil, approximately 0.01% to 5% cinnamon leaf essential oil, approximately 0.01% to 5% ravintsara essential oil Oil, approximately 0.01% to 20% frankincense essential oil, approximately 0.01% to 20% myrrh Essential oil, approximately 0.01% to 6% pine needle essential oil, approximately 0.01% to 10% lecithin, approximately 0.0 0.01% to approximately 5% gallic acid, approximately 0.001% to approximately 5% turmeric essential oil, approximately 0.01% to approximately 3 0% macadamia nut oil, approximately 0.01% to 5% coconut oil, approximately 15% to 90% These formulations may contain emu oil. These preparations may be particularly useful in treating alopecia.

[0153] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 5% to 70% of a component supported by at least one component selected from the above is used. A formulation containing a mixture in units of percentage, wherein the biosilicate is Polygonum multif Polygonum multifloridum (approximately 0.05% to 15% capacity), Nomushita Cordyceps extract (approximately 0.05% to 15% by volume), Bupleurum falcatum (Approximately 0.05% to 15% by volume), licorice root extract (approximately 2% to 10% by volume) 1:1:1:1 mixture, approximately 0.01% to approximately 7% ubiquinol (approximately 30-1000 mg / (Final concentration in ml), approximately 0.01% to approximately 4% vitamin A (approximately 5700 to 6500 mcg / ml) (Final concentration in ml), approximately 0.01% to approximately 10% vitamin D (approximately 3000-4000 IU / ml) (Final concentration in ml), approximately 0.01% to approximately 10% vitamin E (approximately 25-35 mg / ml d - Final concentrations of alpha-tocopherol, d-beta, d-gamma, and d-delta-tocopherol The final concentration of the mixed tocopherols, including ferol, is approximately 0.001 to 1 mg / ml. (, approximately 0.01% to approximately 10% vitamin K2 MK7 (approximately 50-100 mcg / ml) (Final concentration), approximately 0.001% to approximately 10% saturated dead sea salt solution, approximately 0.01% to approximately 20% Ginger essential oil, approximately 0.01% to 20% ginger extract, approximately 2% to 10% licorice Root extract, approximately 0.05% to 15% Polygonum multiflora. Loridum extract, approximately 0.05% to approximately 15% Cordyceps extract, approximately 0.0 5% to approximately 15% Bupleurum extract, approximately 0.01% to approximately 3% Ironwood Kaempferia galanga essential oil, approximately 0.01% to 5% lemon essential oil, approximately 0.01% to 5% 5% eucalyptus essential oil, approximately 0.01% to 15% rosemary essential oil, approximately 0.01% to 5% % clove essential oil, approximately 0.01% to 5% cinnamon essential oil, approximately 0.01% to 5% cinnamon leaf extract Oil, approximately 0.01% to 5% ravintsara essential oil, approximately 0.01% to 20% frankincense Sense essential oil, approximately 0.01% to 20% myrrh essential oil, approximately 0.01% to 6% pine needle essential oil, Approximately 0.01% to 10% lecithin, approximately 0.001% to 5% gallic acid, approximately 0.001 Approximately 5% turmeric essential oil, approximately 0.01% to 30% macadamia nut oil, approximately 0.01% This applies to formulations containing approximately 5% coconut oil and approximately 15% to 90% emu oil. These formulations may be particularly useful in treating alopecia. They are effective for treating bald scalps. They can be incorporated into the system. In some embodiments, they ideally dilate the scalp blood vessels. It is massaged into the scalp, accompanied by exposure to heat (for example, by a near-infrared lamp). It can be left for at least 30 minutes.

[0154] In a particular embodiment, the present invention relates to the long-term action of substances required for tissue repair, for example. A group of substances containing minerals, amino acids, vitamins, and other bioactive compounds for sexual delivery. A biosilicate containing approximately 5% to 40% of at least one component selected from the above is used. A formulation containing a mixture in units of percentage, wherein the biosilicate is Polygonum multif Polygonum multifloridum (approximately 0.05% to 15% volume), Mishima Ico (bupleurum) (approximately 0.05% to approximately 15% by volume) 1:1:1:1 mixture, approximately 0 0.01% to approximately 7% ubiquinol (final concentration of approximately 30 to 1000 mg / ml), approximately 0.0 1% to approximately 4% vitamin A (final concentration of approximately 5700 to 6500 mcg / ml), approximately 0.0 1% to approximately 10% vitamin D (final concentration of approximately 3000 to 4000 IU / ml), approximately 0.0 1% to approximately 10% vitamin E (approximately 25-35 mg / ml of d-alpha-tocopherol) Final concentration, mixed tocopherols including d-beta, d-gamma, and d-delta tocopherols The final concentration of ferrol is approximately 0.001 to 1 mg / ml, and approximately 0.01% to 10 % Vitamin K2 MK7 (final concentration of approximately 50-100 mcg / ml), approximately 0.001% ~Approximately 10% saturated Dead Sea salt solution, approximately 0.01%~20% ginger essential oil, approximately 0.01 Approximately 20% ginger extract, approximately 2% to 10% licorice root extract, approximately 0.05% 15% Polygonum multifloridum extract, approximately 0.0 5% to approximately 15% Cordyceps extract, approximately 0.05% to approximately 15% Mishimasa Bupleurum extract, approximately 0.01% to 3% of turmeric (Kaempferia galanga) Essential oils, approximately 0.01% to 5% lemon essential oil, approximately 0.01% to 5% eucalyptus essential oil, approximately 0 0.01% to approximately 15% rosemary essential oil, approximately 0.01% to approximately 5% clove essential oil, approximately 0. 0.01% to approximately 5% cinnamon essential oil, approximately 0.01% to approximately 5% leaf cinnamon essential oil, approximately 0.01% to approximately 5% Ravintsara essential oil, approximately 0.01% to approximately 20% frankincense essential oil, approximately 0.01% ~Approximately 20% myrrh essential oil, approximately 0.01% to 6% pine needle essential oil, approximately 0.01% to 10% Lecithin, approximately 0.001% to 5% gallic acid, approximately 0.001% to 5% turmeric essential oil, Approximately 0.01% to 30% macadamia nut oil, approximately 0.01% to 5% coconut oil, 15% to approximately 90% emu oil, approximately 20% to approximately 90% decyl glucoside (sugars and plant extracts) Nonionic surfactants derived from organic oils, very gentle and non-irritating, good for sensitive skin. (Sex), approximately 20% to approximately 90% sodium lauroyl lactylate (coconut oil and coconut oil) A formulation containing a nonionic surfactant derived from summer milk (which provides a soothing sensation) is used. These formulations are intended for use in shampoos and conditioners for the treatment of hair loss. Particularly useful for integration. In some embodiments, they can be massaged into the scalp. It can be left for a sufficient amount of time to allow for absorption.

[0155] In a particular embodiment, the formulation contains approximately 1% to approximately 3% macadamia nut oil, approximately 0. 0.1% to approximately 0.2% coconut oil, approximately 1% to approximately 3% lemongrass essential oil, approximately 1% to approximately 3% German chamomile essential oil, approximately 1% to 3% Roman chamomile essential oil, approximately 1% to 3% A blend containing rocco chamomile essential oil and approximately 80% to 99% emu oil by volume. Contains substances. These preparations may be particularly useful as galactagogues. In some embodiments... These are located in the axilla and upper chest (milk) to promote breast milk production in breastfeeding mothers. It can be applied topically (away from the neck).

[0156] In a particular embodiment, the formulation contains approximately 5% to approximately 12% aqueous extract of kaffir lime leaves. Approximately 10% to 24% galangal water extract, approximately 5% to 12% lemongrass water extract The extract contains approximately 0.1% to 2% essential oil from kaffir lime leaves and approximately 0.2% to 4% galangal. Essential oils, approximately 0.1% to 2% lemongrass essential oil, approximately 0.01% to 2% yuzu essential oil, 0.01% to approximately 2% rosemary essential oil, approximately 2% to approximately 30% black seed essential oil, approximately 2 %~approximately 40% fish oil, approximately 0.01%~approximately 2% palmarosa essential oil, approximately 0.01%~approximately 2% Niaouli essential oil, approximately 0.01% to 2% spearmint essential oil, approximately 0.01% to 2% co Leander seed essential oil, approximately 0.01% to 2% geranium essential oil, approximately 0.01% to 2% Zanthoxylum armatum essential oil, approximately 0.01% to 2% Turmeric essential oil, approximately 0.01% to 2% garlic essential oil, approximately 2% to 10% ginger essential oil Approximately 0.01% to 2% lemon essential oil, approximately 1% to 2% ubiquinol, approximately 0.01% Approximately 2% yuzu essential oil, approximately 0.01% to 2% cassia essential oil, approximately 0.01% to 2% cinnamon leaf Essential oils, approximately 0.01% to 2% lime essential oil, approximately 0.01% to 2% grapefruit essential oil Oil, approximately 2% to 5% macadamia nut oil, approximately 0.5% to 1% coconut oil, and approximately These formulations contain a mixture of 30% to approximately 99% emu oil by volume. Diseases / Dyslipidemia / Obesity / Coronary artery disease / Metabolic syndrome / Atherosclerosis It may be particularly useful in treating hypertriglyceridemia. In some embodiments They are administered orally (for example, 1 gram every morning).

[0157] In a particular embodiment, the formulation contains approximately 5% to approximately 75% frankincense essential oil, approximately 5% to approximately 50% myrrh essential oil, approximately 5% to approximately 10% vanilla essential oil, approximately 0.1% to approximately 10% Bitter orange essential oil, approximately 0.2% to 12% lemon balm (melissa) essential oil, approximately 0. 1% to approximately 20% glycine (relative to a final concentration of approximately 0.5 g / ml to approximately 1 g / ml), approximately 0.01% to approximately 2% cinnamon essential oil, approximately 0.01% to approximately 2% lemon essential oil, approximately 0.01% to approximately 2% eucalyptus essential oil, approximately 0.01% to 2% clove essential oil, approximately 0.01% to 2% la Vintsara essential oil, FDG containing approximately 0.01% to 30% of compounds for tissue repair. E biosilicate, approximately 0.01% to approximately 2% German chamomile essential oil, approximately 0.01% to approximately 2% lecithin, approximately 0.01% to 2% flaxseed oil, approximately 0.01% to 0.05% alcohol Falipoic acid (final concentration of approximately 100 mg / ml to approximately 1000 mg / ml), approximately 0.01% Approximately 2% gallic acid (final concentration of approximately 10 mg / ml to approximately 70 mg / ml), approximately 0.01% Approximately 2% Roman chamomile essential oil, approximately 0.01% to approximately 2% Moroccan chamomile essential oil, approximately 0 0.01% to approximately 2% jasmine essential oil, approximately 0.01% to approximately 2% neroli essential oil, approximately 10% to approximately 20% grape seed extract (standardized against 95% proanthocyanidins), approximately 10% to approximately 20% grape skin extract (standardized against 95% proanthocyanidins) (t) Approximately 5% to 12% of kaffir lime leaf water extract, approximately 10% to 24% of galangal Water extract of [unclear], approximately 5% to 12% lemongrass water extract, approximately 0.1% to 2% cacao Lime leaf essential oil, approximately 0.2% to 4% galangal essential oil, approximately 0.1% to 2% lemon Grass essential oil, approximately 0.01% to 2% yuzu essential oil, approximately 2% to 40% fish oil, approximately 0.01 Approximately 2% palmarosa essential oil, approximately 0.01% to 2% niaouli essential oil, approximately 0.01% Approximately 2% spearmint essential oil, approximately 0.01% to approximately 2% coriander seed essential oil, approximately 0.01 Approximately 2% geranium essential oil, approximately 0.01% to 2% Zantoxyrrum almatum ( Zanthoxylum armatum essential oil, approximately 0.01% to approximately 2% turmeric essential oil, approximately 0.01% to approximately 2% % garlic essential oil, approximately 0.01% to 2% lemon essential oil, approximately 0.01% to 2% yuzu essential oil Oil, approximately 0.01% to 2% cassia essential oil, approximately 0.01% to 2% lime essential oil, approximately 0.0 1% to approximately 2% grapefruit essential oil, Cordyceps extract (approximately 0.05 ml) Amount % to approximately 5% by volume, Bupleurum (approximately 0.05% to approximately 5% by volume), Ubiquinol at approximately 0.01% to 5% (final concentration of approximately 30 to 1000 mg / ml), approximately 0 0.01% to approximately 4% vitamin A (final concentration of approximately 5700 to 6500 mcg / ml), approximately 0 0.01% to approximately 10% vitamin D (final concentration of approximately 3000 to 4000 IU / ml), approximately 0 0.01% to approximately 5% vitamin B3 (final concentration of approximately 500 to 4000 mg / ml), approximately 0. 0.1% to approximately 5% niacinamide (final concentration of approximately 500 to 4000 mg / ml), approximately 0 0.01% to approximately 5% vitamin C (final concentration of approximately 1000 to 4000 mg / ml), approximately 0. 0.1% to approximately 10% vitamin E (approximately 25-35 mg / ml of d-alpha-tocopherol) The final concentration of the mixture containing d-beta, d-gamma, and d-delta tocopherols. The final concentration of copherol is approximately 0.001 to 1 mg / ml, approximately 0.01% to 1 0% Vitamin K2 MK7 (final concentration of approximately 50-100 mcg / ml), approximately 0.001 %~approximately 10% saturated Dead Sea salt solution, approximately 0.01%~approximately 20% ginger essential oil, approximately 0.0 1% to approximately 20% ginger extract, approximately 2% to approximately 5% licorice root extract, approximately 0.01% to approximately 30% rosemary essential oil, approximately 0.01% to 20% cinnamon leaf essential oil, approximately 2% to 30% Black seed essential oil, approximately 2% to 5% macadamia nut oil, approximately 0.5% to 1% coconut oil This contains a mixture of nut oil and emu oil, each containing approximately 30% to 99% by volume. These preparations are for diabetes / dyslipidemia / obesity / metabolic syndrome / high triglycerides Blood pressure / Insulin resistance / Abnormal sleep debt / Insulin resistance / Osteopenia / Osteoporosis / Chronic They may be particularly useful in treating anemia caused by sexually transmitted diseases. In some embodiments, they are It is administered orally (for example, 1 gram every morning).

[0158] In a particular embodiment, the formulation contains approximately 5% to approximately 75% frankincense essential oil, approximately 5% to approximately 50% myrrh essential oil, approximately 5% to approximately 10% vanilla essential oil, approximately 0.1% to approximately 10% Bitter orange essential oil, approximately 0.2% to 12% lemon balm (melissa) essential oil, approximately 0. 1% to approximately 20% glycine (relative to a final concentration of 1 g / ml), approximately 0.01% to approximately 1% Rosemary essential oil, approximately 0.01% to 1% cinnamon essential oil, approximately 0.01% to 1% lemon essential oil Oil, approximately 0.01% to 1% cinnamon essential oil, approximately 0.01% to 1% eucalyptus essential oil, approximately 0. 0.01% to approximately 1% clove essential oil, approximately 0.01% to approximately 1% ravintsara essential oil, approximately 2% to Approximately 5% macadamia nut oil, approximately 0.5% to 1% coconut oil, and approximately 30% to 9% Contains a mixture containing 9% emu oil by volume. These formulations address abnormal sleep debt. They may be particularly useful for treatment. In some of these embodiments, they are administered orally. (For example, 1 gram every morning.)

[0159] In a particular embodiment, the formulation contains a Cordyceps extract (approximately 0.05%). Capacity % to approximately 5%, Bupleurum (approximately 0.05% to approximately 5%) Approximately 0.01% to approximately 5% ubiquinol (final concentration of approximately 30 to 1000 mg / ml), approximately 0.01% to approximately 4% vitamin A (final concentration of approximately 5700 to 6500 mcg / ml), approximately 0.01% to approximately 10% vitamin D (final concentration of approximately 3000 to 4000 IU / ml), approximately 0.01% to approximately 5% vitamin B3 (final concentration of approximately 500 to 4000 mg / ml), approximately 0 Niacinamide at a concentration of approximately 0.01% to 5% (final concentration of approximately 500 to 4000 mg / ml), 0.01% to approximately 5% vitamin C (final concentration of approximately 1000 to 4000 mg / ml), approximately 0 0.01% to approximately 10% vitamin E (approximately 25-35 mg / ml of d-alpha-tocopherol) The final concentration of the mixture, including d-beta, d-gamma, and d-delta tocopherol. The final concentration of tocopherol is approximately 0.001 to approximately 1 mg / ml, approximately 0.01% to approximately 10% Vitamin K2 MK7 (final concentration of approximately 50-100 mcg / ml), approximately 0.00 A 1% to approximately 10% saturated Dead Sea salt solution, approximately 0.01% to approximately 20% ginger essential oil, approximately 0. 0.01% to approximately 20% ginger extract, approximately 2% to approximately 5% licorice root extract, approximately 0.01% Approximately 30% rosemary essential oil, approximately 0.01% to 20% cinnamon leaf essential oil, approximately 2% to 30% Black seed essential oil, approximately 2% to 5% macadamia nut oil, approximately 0.5% to 1% co This product contains a mixture of cone oil and emu oil, approximately 30% to 99% by volume. These preparations are particularly useful in treating osteopenia, osteoporosis, and chronic disease anemia. It is possible. In some embodiments, they are administered orally (for example, 1 to 4 grams every morning). ).

[0160] In certain embodiments, the formulation contains approximately 5% to 20% Dead Sea salt hydrated biosilice Approximately 10% to 25% Dead Sea salts restored with filtered and sterilized water, and approximately 10% to 20% blue Dou seed extract (standardized to 95% proanthocyanidins), approximately 10%~ 20% grape skin extract (standardized to 95% proanthocyanidins), approximately 1 0% to approximately 20% resveratrol (with a potency yield of at least 8%) (Standardized), approximately 10% to 20% filtered sterile water, approximately 5% to 30% lecithin, Approximately 50% to 90% emu oil, approximately 1% to 3% macadamia nut oil, and approximately 0. A mixture containing 0.1% to approximately 0.2% coconut oil by volume. In this context, the formulation improves neurological function and reduces amyloid-beta peptide aggregation. It is particularly useful in preventing dementia, Alzheimer's disease, and Parkinson's disease. It can be formulated into capsules so that approximately 1g to 4g can be taken orally per day. In the embodiment, the composition may be as described above, but near the cerebrovascular system To deliver the bioactive ingredients, administer as a 1ml nasal spray 1 to 4 times a day. As provided, the formulation was prepared using 1000 ml of vegetable glycerin instead of lecithin. It is possible.

[0161] In any one of the formulations listed herein, the formulation is characterized by the strength of the additional components in the formulation. It can be diluted with the basic composition to half its original concentration.

[0162] In any one of the formulations listed herein, the formulation is one or more exo Exosomes may include some. Exosomes, for example, for localized and / or extended release, For example, it can be supported on a biosilicate (e.g., FDGE biosilicate).

[0163] Any of the formulations listed herein contains approximately 1% to approximately 45% food-grade diatomaceous earth (F May contain a DGE biosilicate or another pharmaceutically acceptable matrix. In some parts of the morphology, to create fractions that provide extended release of one or more components. In addition, one or more components can be pre-supported on the biosilicate.

[0164] The formulations include topical preparations (e.g., solutions, emulsions (e.g., oil / oil-type emulsions), creams, May be contained in ointments or balms. Formulations include shampoos, conditioners, masks, Facial cleanser, body soap, cleanser, toner, wrinkle cream, age spot fading cream serums, dental preparations, gum, floss, nasal sprays, sunscreens, self-tanning products. Products, galactagogues, needle-free vaccines, needle-free drugs (e.g., transdermal insulin), henna preparations Moisturizers, preparations for keloids and scars, eyelash and eyebrow growth stimulating serums, hair gloss Hair spray, hair mousse, hair mask, for example, when mixed with a PDE5 inhibitor, erectile dysfunction Topical cream for intestinal dysfunction, ulcerative colitis / Crohn's disease, irritable bowel disease Oral preparations intended for use in treating the endometrium, or HIV mucositis, aphthous ulcers Preparations for ulcers, diverticulitis, colitis, and other mucosal irritations, and for treating abnormal sleep debt. Oral preparations for treating osteoporosis, osteopenia, and chronic disease anemia. Products, diabetes / obesity / dyslipidemia / hypertriglyceridemia / metabolic syndrome / To prevent the onset or progression of atherosclerosis / coronary artery disease in prediabetic patients. Oral preparations taken orally to improve or delay insulin sensitivity Oral preparations for treating Alzheimer's disease, Parkinson's disease, or multiple sclerosis Oral preparations taken orally to prevent or slow the progression of cancer, and also to prevent the onset of cancer. Oral preparations to prevent or slow the progression of asthma and chronic obstructive pulmonary disease. Inhalation spray preparation for treating the disease (COPD), for the treatment of lichen sclerosing (LS) Topical preparations, topical preparations for the treatment of lichen planus (LP), to reduce Raynaud's phenomenon Topical preparations for reducing swelling and lymphedema, and for promoting rapid wound healing. Topical preparations for delivering natural antimicrobial agents to wounds to promote the treatment of ear or eye infections. A set of intravenous antibiotics to treat the condition, when applied to the left chest, quickly alleviates chest pain. A topical gel that can reduce hypertension when applied across large blood vessels to prevent stroke. A topical preparation that can quickly alleviate headaches, applied to the head and neck area to relieve headaches. It can also be incorporated into topical preparations, etc. This preparation or a modified version thereof can be mixed with existing pharmaceuticals. Combined, delivery may be enhanced. The term "pharmaceutical" as used herein refers to human and / or other substances. or vitamins, minerals, and Contains drugs.

[0165] The formulation may also be an oral formulation. In some of these embodiments, the formulation is administered orally. It is incorporated into the membrane of the gastrointestinal tract, but is not absorbed into the systemic circulation. In another embodiment, The agent is absorbed into a systemic formulation in an amount that provides the intended effect (e.g., a therapeutically beneficial effect). In some embodiments, the formulation may also be coated onto a substrate. The substrate is, for example, Nanoparticles, food-grade diatomaceous earth (FGDE), or a pharmaceutically acceptable matrix It is possible. The substrate consists of phospholipids, ceramides, cholesterol, fatty acids, oils, vitamins, and minerals. Ingredients, amino acids, hyaluronic acid, fusogen, bio-fermented products of fruits or plants, additional therapeutic agents Therapeutic agents (for example, drugs approved by the U.S. FDA for use in humans), or The formulation may include a combination of two or more of the aforementioned items. The formulation may be, for example, an ointment or another topical compound. It may be in the form of a manufactured product, or administered orally, intranasally, intravenously, intramuscularly, or during invasive surgery. It can be formulated as a suppository or administered via other routes.

[0166] The fatty acid composition of the formulation allows the formulation to be incorporated into the following cells, which can cross the cell membranes of the following cells. Disclosed herein to make them jellyable, modulable, or reversible It can be prepared using the following basic compositions and additional components: skin cells, brain cells, fibroblasts Cells, endothelial cells (cells that line blood vessels), macrophages, immune cells, red blood cells, white blood cells (white blood cell), lymphocyte, leukocyte, liver cell, neuron, asthma Oligodendrocytes, microglia, oligodendrocytes, bronchial endothelial cells, respiratory interstitial cells, bronchial Cells including olfactory bulb neurons, adipocytes, cutaneous fibroblasts, muscle cells, cardiomyocytes, pancreatic islet cells, Brunner's gland cells in the duodenum (which secrete enzymes and alkaline mucus), all Glandular cells, goblet cells of the respiratory mucosa (which secrete mucus), goblet cells of the digestive tract (which secrete mucus), small Foveolar cells (which secrete mucus), chief cells (which secrete pepsinogen), parietal cells ( Pancreatic acinar cells (secrete bicarbonate and digestive enzymes), small intestine To cells (which secrete lysozyme), type II lung cells (which secrete surfactant), Club cells of the lung, type I lung cells, epithelial cells of all organs, acinar cells of the pancreas, Pancreatic interductal cells, intestinal brush border cells with microvilli, enteroendocrine cells, K cells (gastric suppression cells) L cells (secrete peptides), glucagon-like peptide-1, peptide YY3-36, oxy Syntomodulin and glucagon-like peptide-2 secrete I cells (cholecysts) G cells (secretes kinin), G cells (secretes gastrin), enterochromaffin cells (secretes serotonin) Enterochromaffin-like cells (secrete histamine), N cells (secrete S cells (secretin secretion), D cells (somatostatin secretion) (Secreting), Mo cells or M cells (secreting motilin), megakaryocytes, bone marrow cells, osteocytes osteoclasts, osteoblasts, mast cells, thyroid epithelial cells, parafollicular cells of the thyroid gland, and parathyroid gland cells. Cells, eosinophilic cells, alpha cells of the pancreas (which secrete glucagon), beta cells of the pancreas (I (Secretes lanceol and amylin), delta cells of the pancreas (secretes somatostatin) P, also known as epsilon cells (which secrete ghrelin) and gamma cells of the pancreas. P cells (which secrete pancreatic polypeptides), salivary gland mucus cells, salivary gland serous cells, and in the tongue Von Ebner gland cells, mammary gland cells (which secrete breast milk), lacrimal gland cells (which secrete tears), ear In the ear canal, there are ear canal gland cells (which secrete earwax) and eccrine sweat gland cells (which secrete glycoproteins). Eccrine sweat gland cells (secrete small molecules), apocrine sweat gland cells (decompose odor secretions) It secretes (is sensitive to sex hormones), and is a specialized sweat gland of Moll cells in the eyelids. glands, sebaceous gland cells (which secrete lipid-rich sebum), Bowman's gland cells in the nose, olfactory epithelial cells Cells, hair cells, hair follicle cells, endogenous stem cells of each organ, adrenocorticotropic hormone-producing cells, gonads Stimulating hormone-producing cells, prolactin-producing cells, melanocyte-stimulating hormone-producing cells, Tomatotropin-producing cells, thyroid-stimulating hormone-producing cells, macrocellular neurosecretory cells (oxyto) (Secreting thyrotropin-releasing hormones), small cell neurosecretory cells (which secrete thyrotropin-releasing hormones) N, corticotropin-releasing hormone, vasopressin, oxytocin, neurotensin, Adrenal chromaffin cells, keratinocytes, epidermal basal cells (and secrete prolactin), Cells, melanocytes, hair follicle cells (trichocytes) (which produce hair and nail cells), medullary hair Stem cells, cortical hair stem cells, keratin hair stem cells, Hakusuri layer root sheath cells, Henle layer root sheath cells, Hair follicle sheath hair cells, cornea, tongue, mouth, nasal cavity, distal anal canal, distal urethra, distal vaginal surface epithelial cells; Basal cells (stem cells of the cornea, tongue, mouth, nasal cavity, distal anal canal, distal urethra, and distal vagina), saliva Interductal duct cells of glands, linear duct cells of salivary glands, mammary duct cells of mammary glands, ameloblasts (dental enamel (Secretes and deposits dentin), odontoblasts (secretes and forms tooth dentin), cement Tooth blasts (which secrete and form dental cementum), auditory hair cells of the organ of Corti, Corti Extraaural hair cells of the organ, basal cells of the olfactory epithelium (stem cells for olfactory neurons), cold sensitivity Sexual primary sensory neurons, thermosensitive primary sensory neurons, Merkel cells in the epidermis, olfactory receptors Neurons, pain-sensitive primary sensory neurons, photoreceptor rod cells, blue-sensitive photoreceptors in the eye Cone cells, green-sensitive cone cells of the eye's photoreceptors, red-sensitive cone cells of the eye's photoreceptors, intrinsic Receptive primary sensory neurons, chemoreceptor glomus cells (blood pH sensors) in the carotid body outer hair cells of the ear's vestibular system (accelerometer and gravity sensors), taste receptor cells of taste buds, choline Adrenergic neurons, adrenergic neurons, peptide-glucan neurons, cortisol Endocosal cells of the organ, extrinsal cells of the organ of Corti, endodigital cells of the organ of Corti, extrinsal cells of the organ of Corti Cells, border cells of the organ of Corti, vestibular supporting cells, taste bud supporting cells, olfactory epithelial supporting cells, olfactory nerve Sheath cells, Schwann cells, satellite glial cells, intestinal glial cells, interneurons, basket cells , cartwheel cell, stellate cell, Golgi cell, granule cell, Lugaro cell, unipolar brush cell Multinotti cells, Chandelier cells, Cajal-Retius cells, Double Bouquet cells Neurogliaform cells, retinal horizontal cells, amacrine cells, stellate amacrine cells, Spinal interneurons, Renshaw cells, chief cells, spindle neurons, fork neurons ¹¹, cone cell, place cell, lattice cell, speed cell, head direction cell, Betz cell, star Cells, border cells, bushy cells, Purkinje cells, medium spiny neurons, ependymal cells Tanicytes, pituitary cells, lens cells, prelentic epithelial cells, corneal epithelial cells, crystallin Lens fiber cells, white adipocytes, brown adipocytes, beige adipocytes, and other adipocytes , liver adipose cells, adrenal cortical cells, zona glomerulosa cells (which secrete mineralocorticoids), fasciculations Cells of the zona reticularis (which secrete glucocorticoids), cells of the zona reticularis (which secrete androgens), The inner theca cells of the follicle (which secrete estrogen), and the corpus luteum (progesterone) of a ruptured follicle. (Secretions of ointment), granulosa corpus luteum cells, follicular corpus luteum cells, Leydig cells of the testis (testicular cells) (Secretes telone), seminal vesicle cells (secretes semen), prostate cells (secretes components of semen) (, bulbourethral gland cells (secretes mucus), Bartholin's gland cells (secretes vaginal fluid), Lithorne Glandular cells (which secrete mucus), endometrial cells (which secrete carbohydrates), juxtaglomerular cells (Lenny (Secretes urinary tract), uterine muscle cells, macula compacta cells of the kidney, peripolar cells of the kidney, mesangiocarcinoma of the kidney Mu cells, parietal epithelial cells, podocytes, proximal tubular brush border cells, loop of Henle thin segment To cells, distal renal tubular cells, renal collecting duct cells, chief cells, interstitial cells, transitional epithelial cells (bladder (to support), seminal vesicle duct cells, prostate duct cells, efferent duct cells, epididymal principal cells, Epididymal basal cells, lunar epithelial cells of the ear's vestibular system (which secrete proteoglycans), corneum Interdental epithelial cells (which secrete the tectonic membrane covering hair cells), loose connective tissue fibroblasts, fascia Cells of the cornea, corneal fibroblasts (corneal stromal cells), tendon fibroblasts, bone marrow reticular tissue fibroblasts, non Epithelial fibroblasts, pericytes, hepatic stellate cells (Ito cells), nucleus pulposus cells of the intervertebral disc, hyaline cartilage cells Cells, fibrochondrocytes, elastochondrocytes, osteoblasts / osteocytes, bone progenitor cells (of osteoblasts) Stem cells, vitreous cells of the vitreous humor of the eye, stellate cells of the perilymphatic space of the ear, pancreatic stellate cells, red skeletal muscle cells Cells (slow-twitch muscle), white skeletal muscle cells (fast-twitch muscle), intermediate skeletal muscle cells, nuclear sac cells of muscle spindles, nuclei of muscle spindles Chain cells, muscle satellite cells (muscle stem cells), cardiac muscle cells, SA nodule cells, Purkinje fibrillation cells smooth muscle cells, iris myoepithelial cells, exocrine gland myoepithelial cells, monocytes, each type of tissue or In organ-associated connective tissue macrophages, epidermal Langerhans cells, and lymphoid tissue Dendritic cells, neutrophils and precursors (myeloblasts, promyelocytes, myelocytes, metamyelocytes), eosinophils T cells, granulocytes and precursors (basophilic granulocytes and precursors), helper T cells, regulatory T cells Cells, cytotoxic T cells, natural killer T cells, B cells, plasma cells, natural killer Hematopoietic stem cells and their precursors (committed progenitors) for cells, blood, and the immune system, eggs Progenitor cells, oocytes, spermatocytes, spermatocytes, spermatogonia (stem cells for spermatocytes), sperm cells Cells, nurse cells, granulosa cells (in the ovary), Sertoli cells (in the testes), epithelial cells Reticular cells (in the thymus), as well as interstitial kidney cells.

[0167] The present invention is, in part, sufficient to alleviate one or more symptoms of a disorder in a patient. The step involves administering a preparation containing a mixture of fatty acids to patients who require it, in terms of quantity and duration. The invention further relates to methods for treating disorders, including p. In one embodiment, the mixture is , a fatty acid composition that is substantially the same as (i.e., approximates) that of human skin and sebum To possess.

[0168] This invention relates to diseases associated with injury, damage, or dysfunction of cell membrane function in mammals. Further focus on methods for treating symptoms. Related to dysfunction, injury, or damage to cell membrane function. Related conditions include, for example, pain, eczema, psoriasis, erythema, burns, cuts, bruises, boils, scars, and more. Lloyd's, non-healing wounds, acne, rosacea, allergies, arthritis, joint pain, cancer, neuropathy - Metabolic syndrome, infectious diseases, stomatitis, ulcers, ulcerative colitis (UC), mucositis Diverticulitis, celiac disease, colitis, Crohn's disease (CD), irritable bowel syndrome (IBS), inflammation Intestinal disease (IBD), atherosclerosis, Alzheimer's disease (AD), Parkinson's disease Son's disease (PD), gout, solar lentigines, senile pigment spots, skin atrophy, lichen sclerosus (LS), flatus Lichen planus (LP), asthma, chronic obstructive pulmonary disease (COPD), angina pectoris, coronary artery disease (CAD) Hypertension (HTN), dyslipidemia (HLD), diabetes mellitus (DM), insulin resistance, Tabolic syndrome, neuropathy, PMS, anxiety, depression, nightmares, insomnia, abnormal sleep Sleep debt, neuralgia, sciatica, mastitis, conjunctivitis, convulsive disorder, alcohol withdrawal symptoms, Abnormal muscle tone, dryness, osteoporosis, osteopenia, chronic disease-related anemia, fibromyalgia, alopecia, erectile dysfunction ED, Restless Legs Syndrome (RDS), Multiple Sclerosis (MS), Measles, hemorrhoids, chronic fatigue syndrome (CFS), leukoplakia, edema, severe lymphatic overload, sunburn, atrophy It could be vaginitis, hyperpigmented skin due to aging or previous trauma, or muscle spasms. Symptoms include, for example, pain, inflammation, skin irritation, rash, lesions, wrinkles, hyperpigmentation, keloids, scars, Itching, itching, indigestion, diarrhea, convulsions, cough, bronchospasm, discoloration, and the aforementioned A combination or a group consisting of two or more types may be selected.

[0169] The present invention is, in part, sufficient to alleviate one or more symptoms of a disorder in a patient. A mixture of oils, including animal and vegetable oils, is prescribed to patients who require it in sufficient quantity and for an extended period. Methods for treating disorders, including the step of administering a formulation containing the present invention, are also covered. One embodiment In this case, the mixture is substantially the same as that of human skin and sebum (i.e., approximate). It has a fatty acid composition. In certain embodiments, the formulation is administered topically. In the embodiments, the formulation is administered orally, intranasally, intravenously, intramuscularly, or during invasive surgery. It may be administered as a suppository or via other routes of administration.

[0170] The present invention, in part, aims to diversify and improve the chemical activity of biologically active compounds. Therefore, it is subjected to fermentation (by bacteria, fungi, or other microorganisms), and then the disease Oils that enhance the delivery of such compounds in order to treat, improve, or enhance Mixtures of or modified vegetable oils, animal oils, plants, and minerals It contains a mixture of naturally occurring compounds found in exosomes or other organic materials. Methods of treating the disorder, including the step of administering a drug, are also covered. Multiple aspects of the disease. A combination of medications designed to address this, delivered topically, orally, intranasally, intravenously, or intramuscularly. It can be administered in combination via other routes, such as intramuscularly, as a suppository, or during open surgery. I can agree.

[0171] The disorders that can be treated with the formulations of the present invention include, among others, abnormal muscles. Tension, abnormal sleep debt, acne, alcohol withdrawal symptoms, allergies, alopecia, Alzheimer's disease - Diseases (AD), angina / chest pain, aphthous ulcers, arthritis (e.g., rheumatoid arthritis, osteoarthritis) (e.g., psoriatic arthritis), chemotherapy-induced joint pain, autoimmune diseases Joint pain caused by friction, joint pain caused by trauma, asthma, atherosclerosis, Anxiety, sores, bronchospasm, bruises, burns, mouth ulcers, cancer, celiac disease, chronic fatigue syndrome (CFS), chronic obstructive pulmonary disease (COPD), colitis, conjunctivitis, coronary artery disease (CAD), Cough, seizures / muscle spasms, Crohn's disease (CD), cuts on the skin, depression, dermatitis, diabetes (DM), diaper rash, diverticulitis, eczema, edema, epilepsy and other convulsive disorders, chronic Persistent nasal dryness can lead to nosebleeds, erectile dysfunction (ED), erythema, fibromyalgia, gingivitis, and pain. Colds, hair loss, healing of tattoos or other skin wounds, hemorrhoids, HIV mucositis, high cholesterol Bloody dyslipidemia (HLD), hyperchromemia, hypertension (HTN), hypertriglyceridemia, Increased muscle tone, indigestion, infections, inflammatory bowel disease (IBD), insomnia, irritable bowel syndrome (IBD) BS), itching, keloids, leukoplakia, lichen planus (LP), lichen sclerosing (LS), lymphedema Tumor, mastitis, metabolic syndrome, mucositis, insulin resistance, multiple sclerosis (M S) Rhinitis, neuralgia, neuropathic pain, neuropathy (numbness / sensory abnormalities), nightmares, Unhealing wounds, obesity, otitis externa, otitis media, osteopenia, osteoporosis, chronic disease-related anemia, pain, Kinson's disease (PD), peripheral neuropathy, pharyngitis, insufficient immune function, premenstrual syndrome Group (PMS), pruritic rash, psoriasis, rash, restless legs syndrome (RLS), rosacea, Scarring (including keloids and atrophic scars), sciatica, senile lentigines, localized corticosteroids Skin atrophy, skin lesions, social anxiety, sunspots, stroke due to excessive use of tycosteroids. Sunburn, localized infections (impetigo, staphylococcal, streptococcal, and fungal infections), ulcers Ulcers, ulcerative colitis (UC), unspecified skin irritation, hives, atrophic vaginitis, wounds, wrinkles, dryness It includes, but is not limited to, axillary dysplasia (dry skin). The formulation contains surfactant. To address or improve tissue production (reducing atelectasis in patients who have recently undergone surgery) It would be useful in causing this, etc.; to promote lung maturation in newborns, acetylcholine To address phosphorus deficiency, to improve nutrient absorption, free radical production and flame To slow down aging by reducing the symptoms, free radical production and inflammation Atherosclerosis reduces the risk or progression of cancer by reducing it. By improving the treatment of acute cerebral and myocardial infarctions (e.g., stroke and heart attack), It can also be formulated to reduce the risk of )

[0172] In one particular embodiment, the formulation is administered topically. In another embodiment, the formulation , intranasal cavity, intravenous, intramuscular, during invasive surgery, or by suppository or spray It may be administered. [Brief explanation of the drawing]

[0173] [Figure 1] This figure illustrates that pain is a multifactorial problem. (Image obtained from https: / / st.depositphotos.com / 1812149 / 2267 / i / 450 / depositphotos_22674323-stock-photo-full-body-pain.jpg). [Figure 2] This is a diagram showing the chemical structure and 3-D model of a phospholipid. (Obtained from https: / / classconnection.s3.amazonaws.com / 624 / flashcards / 3771624 / gif / 1164999854bc1-143EF30B3E26DF055A4.gif). [Figure 3] This is a schematic representation of phospholipids. (Obtained from https: / / s3-us-west-2.amazonaws.com / courses-images / wp-content / uploads / sites / 1842 / 2017 / 05 / 26154139 / figure-05-01-03a.jpeg). [Figure 4] This figure shows that phospholipids self-associate into bilayer structures or micelles. (Obtained from https: / / qph.fs.quoracdn.net / main-qimg-2417fafb8e6c3b90319bc5675c5a32c3-c). [Figure 5]This figure illustrates that phospholipids can form micelles and liposomes (which can act as carriers for therapeutic molecules, including transmembrane proteins), as well as bilayer sheets that make up cell membranes. (Obtained from https: / / 3.bp.blogspot.com / -8TKWDN8jY5g / UDhU0b3NbEI / AAAAAAAABR4 / fkcPx9Tj0ss / s1600 / F02-20.JPG). [Figure 6] This is a 3D model of a human cell cut in half to reveal its contents. Note the phospholipid bilayer (pink) that forms the cell surface / cell membrane. (Obtained from https: / / static.turbosquid.com / Preview / 2014 / 05 / 19__18_04_31 / human%20cell%20max%202.jpgd9d481ff-258d-4a3b-8b31-fd0373c15409HD.jpg). [Figure 7] This is a cross-sectional view of a human cell membrane showing transmembrane proteins. (Obtained from https: / / pixfeeds.com / images / 21 / 511840 / 1200-86007545-cell-membrane.jpg). [Figure 8] This figure illustrates how extracellular signals can lead to intracellular changes in cell behavior. (Obtained from https: / / croteaubio.files.wordpress.com / 2011 / 12 / cell-to-cell-communication-9-7281.jpg). [Figure 9] This figure shows that the epidermal growth factor receptor undergoes heterodimerization and induces proliferation. (Obtained from http: / / biochemistry.utoronto.ca / wp-content / uploads / 2014 / 10 / Cell-Signaling-Stagljar-670x504.jpg). [Figure 10] This is a simplified schematic diagram of cell signaling using transmembrane receptors. [Figure 11]This diagram illustrates how ligands (chemical messengers from outside the cell) bind to receptors when they find their counterparts, generating signals that reach the cell and direct the nucleus, the cell's command center, to act (for example, directing the cell to grow uncontrollably). [Figure 12] This figure shows that several chronic diseases are associated with abnormal cellular lipid composition. [Figure 13] This figure illustrates that exogenously supplied phospholipids, sphingolipids, and fatty acids can be incorporated into existing cell membranes and used to create new cells. [Figure 14] This figure shows that exogenously supplied phospholipids, sphingolipids, and fatty acids are incorporated into the cell membrane and raise the threshold required for cellular signaling. [Figure 15] This figure shows that exogenously supplied phospholipids, sphingolipids, and fatty acids confer the ability of therapeutic compounds to cross normally hydrophobic cell membranes. Once inside the cell, they can direct the cell's command center (nucleus) to suppress inflammation, arrest oncogenes, and so on. [Figure 16] This is a diagram showing many types and shapes of diatoms. See photograph, thanks to photographer Kent Wood (obtained from http: / / www.illinoisscience.org / wp-content / uploads / 2017 / 11 / diatom-007-2400-copy.jpg). [Figure 17] This is an example of a diatom with an intricate three-dimensional structure and pores useful for compounding multiple compounds. See photograph, thanks to photographer Steve G. Schmeissner (obtained from http: / / 3.bp.blogspot.com / -qAQfLhi8Ty8 / Ubs7sgBjXDI / AAAAAAAAAeo / ANMfoJ2FHQw / s320 / 26-diatom-sem-steve-gschmeissner.jpg). [Figure 18]This figure shows diatoms being loaded with minerals, amino acids, vitamins, and bioactive compounds, and then coated with a substance that imparts permeability to human skin and cell membranes. [Figure 19] This diagram illustrates the sustained release of therapeutic substances into the skin and across cell membranes. Delivery of these raw materials promotes cell and tissue repair. [Figure 20] This is a scanning electron microscope image of an unsupported diatom, along with a schematic diagram. See the image, thanks to photographer Steve G. Schmeissner (obtained from http: / / 3.bp.blogspot.com / -qAQfLhi8Ty8 / Ubs7sgBjXDI / AAAAAAAAAeo / ANMfoJ2FHQw / s320 / 26-diatom-sem-steve-gschmeissner.jpg). [Figure 21] This is a schematic diagram of a diatom with many open pores. It demonstrates the amino acids located inside the pores. [Figure 22] This is a schematic diagram of a diatom carrying multiple active ingredients. [Figure 23] This is a schematic diagram of a diatom that releases multiple active ingredients over a two-week period. [Figure 24] This figure shows the additive effect of the long-term fraction (biosilicate carrying the active ingredient). [Figure 25] This figure illustrates that pluripotency can be induced by stimulation of four transcription factors in terminally differentiated cells, potentially leading to the development of multiple other cell types. (Obtained from http: / / 2.bp.blogspot.com / -j9cpH1VCTFU / TiVeGabbeoI / AAAAAAAAAkI / W4c86aZASIY / s640 / ipscs.jpg). [Figure 26]This figure shows that embryo-derived totipotent stem cells give rise to pluripotent stem cells capable of generating multiple cell types (obtained from https: / / lh5.googleusercontent.com / -jZ3YrRhTVRU / TXhVpt4GvxI / AAAAAAAAAB4 / pJoGVRefPwk / s1600 / pluripotent-stem-cells.jpg). [Figure 27] This figure illustrates the reprogramming of somatic cells into pluripotent stem cells using four transcription factors (Yamanaka transcription factors). [Modes for carrying out the invention]

[0174] definition The description of the range of values ​​is, unless otherwise indicated herein, that each separate value falling within the range is... It is merely intended to function as a simple way to refer to values ​​individually, and each is a distinct value. This is incorporated herein as if it were described individually herein. The endpoints of all regions are included within the region and can be combined independently. All methods described herein, unless otherwise indicated herein or in context, Unless there is a clear contradiction, it can be carried out in the appropriate order. The use of language such as "etc." (e.g., "etc.") is intended merely as an example and not as a claim otherwise. To the extent that this invention is not limited to any claim, the language used herein is free from any limitations. Elements that are not present should not be considered as essential for the practical application of this invention.

[0175] The terms "a" and "an" do not indicate a limitation of quantity, but rather refer to a specific amount. Represents the existence of at least one item.

[0176] In this specification, the term "about" is equal to the upper limit of this range (i.e., +20%). The value and the value equal to the lower limit (i.e., -20%) are written immediately after the term "approximately". This means a value within 20% (±20%) of the stated value. For example, the phrase "approximately 100". This includes any number between 80 and 120, including 80 and 120.

[0177] The terms "substantially similar" and "substantially similar" are used herein with respect to the fatty acid composition of the formulations. The terms "substantially identical" and "substantially the same" mean that the formulations are substantially the same as the cell membrane or olm To cross and / or incorporate the ganella, or to modulate the function of the exosome This means that it contains fatty acids of a type and quantity that makes it possible to "substantial" The terms "similar to," "substantially identical," and "substantially the same" apply to cells or The fatty acid composition is identical to that of the organelle membrane; and that of the cell or organelle membrane. Although not identical, the formulation crosses and / or incorporates the membrane of a cell or organelle. It is still possible to allow them to be created and / or modulate the function of exosomes. It includes a fatty acid composition that is used herein for the membranes of cells or organelles. A fatty acid combination that is "substantially similar," "substantially identical," or "substantially the same" as the other. For example, it contains a higher amount of oleic acid than emu oil (for example, more than emu oil) Because it contains at least 1.5 to 2 times higher amounts, it differs from the fatty acid composition of emu oil. It does not include that.

[0178] The term "organelle" refers to a lipid bilayer within a cell that performs a specific function. Organelles refer to differentiated structures within cells. Organelles are usually viewed under a microscope as individual structures or objects. Visible below. Examples would include ribosomes, mitochondria, vacuoles, etc.

[0179] As used herein, the term "exosome" refers to a membrane-bound extracellular vesicle. It tastes good.

[0180] As used herein, the term “essential oil” refers to the characteristic features of the plant from which it is obtained. Volatile oils obtained by chemical extraction from plants that typically possess a fragrance or flavor. This refers to a mixture of volatile oils and other substances. Essential oils are obtained from just one part of a plant. This is possible (for example, ginger root essential oil vs. bay leaf essential oil). Essential oils are bioactive compounds. The extraction process may vary depending on the solvent used, for example, CO2 extraction vs. aqueous extraction vs. Alcohol extraction can produce different mixtures or proportions of bioactive compounds derived from the same plant. .

[0181] The terms "short-chain fatty acids" or "short-chain triglycerides" as used herein This means that the fatty acid or triglyceride contains fewer than 6 carbon atoms.

[0182] The terms "medium-chain fatty acids" or "medium-chain triglycerides" as used herein This means that the fatty acid or triglyceride contains 6 to 12 carbon atoms.

[0183] The terms "long-chain fatty acids" or "long-chain triglycerides" refer to fatty acids or triglycerides. This means that the lid contains more than 12 carbon atoms.

[0184] The terms "medium-chain triglyceride" or "MCT oil" as used herein are defined as follows: The coconut oil fraction contains caproic acid (C6), caprylic acid (C8), and capric acid (C10). ), and fatty acids containing 6 to 12 carbon atoms, including lauric acid (C12) It means that it is composed of these. These MCTs are liquid at room temperature and are metabolized. It does not require a carrier molecule, and when used according to the present invention, the cell membrane and mitochondria It can easily cross both of these substances, where it can be directly metabolized. Some of these fatty acids , possesses other properties and provides additional benefits (for example, lauric acid has antibacterial properties) For example, in order to inhibit *Propionibacterium acnes*, in the acne preparation according to the present invention (Can be used in this way).

[0185] As used herein, the term "liquid skin" refers to the formulation of the present invention. This refers to an embodiment of the basic composition.

[0186] The term "vegan liquid skin" as used in this formulation refers to the formulation of the present invention. This refers to an embodiment of the basic composition.

[0187] As used herein, the term “high-oleic sunflower seed oil” means at least This refers to sunflower oil containing 80% oleic acid.

[0188] The term "sunflower seed oil" refers to sunflower oil containing approximately 20% oleic acid. .

[0189] Detailed explanation Delivery system: In one embodiment, the present invention relates in part to a delivery system comprising a mixture of fatty acids. In a particular embodiment, the mixture contains emu oil. Emu oil is used for pain relief. and other naturally occurring substances that provide useful anti-inflammatory properties in the treatment of other inflammatory diseases. In addition to its quality, it has a high concentration (up to 47%) of oleic acid. The fatty acid portion derived from emu. The composition of Centage is such that it contains only a small amount of oleic acid compared to 31% of human skin. Except for a high percentage (47%), it is quite comparable to that of human skin. This is shown (see Tables 2A and 2B). This similarity in composition to human skin is, This is then prepared to act as a carrier for other lipids and aqueous components. For example, In certain embodiments, emu oil can be mixed with a medically active compound, which can be used on human skin. and a selection of vegetable oils configured to mimic the fatty acid profile of sebum (hereafter) It can be combined with "Liquid Skin" and thereafter they combine with existing skin cells. It can be absorbed or used as raw material to create new cells. Similarly, By using a mixture of vegetable oils that approximates the fatty acid profile of human skin and sebum. This makes it possible to create "vegan liquid skin." It's easy to refer to. In this disclosure, “liquid skin” encompasses mixtures of both types.

[0190] In addition, additional phospholipids, ceramides, cholesterol, and essential oils are added to the existing cell membrane. The incorporation of free fatty acids requires proximity to function in signal conversion, which is necessary for cells. This creates distance between pain and inflammation receptors within the membrane (see Figures 8-14). ). This reduces the opportunity for transmembrane receptors to interact with pain signals. This will likely result in an increase in the pain threshold.

[0191] Diabetes (PMID 23878791, PMID 30216387) and cancer (PM Many disease conditions, such as ID 30413053 and PMID 31379986, involve the cell membrane This is driven by and results from an imbalance of lipids and phospholipids (PMID). (29410529). Dietary intake of fatty acids alters the fatty acid profile of human cell membranes. This then affects transmembrane proteins such as mechanosensitive ion channels, and This alters cellular function (PMID 30867417). In addition, lipids in the human forebrain. The quality profile is strictly maintained throughout healthy adult life, but declines in old age. As shown (PMID 28958038). Other macronutrient diets Intake affects the overall fatty acid profile of the cell membrane. Therefore, what you want If the goal is to restore and maintain health, then the nutritional value of our foods and our medicines Taking nutritional composition into consideration is of paramount importance.

[0192] Therefore, in one embodiment, the present invention is partly based on healthy human skin and sebum. A mixture of various oils that mimics, restores, or modulates the acid profile It is customized to deliver medically active compounds for the treatment of multiple diseases. The target is the resulting mixture.

[0193] To further illustrate these concepts, and in the treatment of disease, healthy human skin / The composition of the oil is identical, substantially similar, modulable, and can be modified. To emphasize the importance of variable oil hybrids, the following information is based on basic cell biology. It will be provided.

[0194] Phospholipids are derived from simple organic molecules such as fatty acids, phosphate groups, glycerol, and choline. These are phospholipids that make up the cell membrane; as shown in Figure 2, they are the basic components of the cell membrane. It is a unit.

[0195] Due to the complexity of their chemical structure, phospholipids are most complex, as shown in Figure 3. It is typically represented as a ball-like structure with two tail sections.

[0196] It should be noted that phospholipids are organized into a bilayer structure or further into micelles (spheres) with water. It can self-react within itself.

[0197] Cells are essentially giant bilayer liposomes (see Figure 6), and they are The cell nucleus, the cell's command center that houses oxyribonucleic acid or DNA (in Figure 6) (shown in yellow) the cellular mechanisms (to see the parts that make up the engine of a car) Many smaller organelles, or "mini-organs," are similar to lifting a car hood. The organelles house the nucleus, specifying how it functions, what proteins it produces, etc. (Think of it as a hub that exerts influence). Any cell individually activates a specific DNA sequence, and the cell It can produce proteins that send signals to other cells. The DNA sequence is activated in the wrong order. If this occurs, or if the system of checking and balancing is lost, it may be cancer or other Disease can occur. Similarly, cells have functions to recognize that they have been damaged. When it loses its normal capacity, it loses the ability to self-destruct (apoptosis) in an orderly manner. Failure to do so can also lead to disease. Therefore, the cell surface is designed to detect signals from outside the cell. It is crucial for it to advance towards the nucleus of the sea urchin cell and alter the cell's activity and function. A healthy cell membrane is necessary for signals from inside the cell to be properly transmitted to the environment outside the cell. Signaling from one cell can affect the activity of other cells, either locally or remotely. It has the ability to make changes.

[0198] If a small square is cut from the surface of a human cell membrane, many proteins spread across the cell surface... Proteins, lipids, signaling proteins, ceramides, cholesterol, receptors, and others The presence of biologically active molecules; and each of these molecules is involved in various cellular pathways (cell division, cell division, etc.). It is important in signal transduction related to splenic death, inflammation, cancer, diabetes, etc. You will find that some are located only in the outer or inner lobe of the cell membrane (Figure 7).

[0199] Information from outside the cell is transmitted via reactions in the outer layer of the cell membrane and embedded in the membrane. This leads to changes in cell receptors, which in turn lead to changes inside the cell and in genes within the cell. This leads to expression and protein production (Figure 8).

[0200] For example, this cross-section of a cell shows EGFR (epidermal growth factor receptor) embedded in the cell membrane. This is shown (Figure 9). EGFR is important in cell proliferation. EGFR signaling Dysregulation can lead to unregulated cell growth, cancer, and metastasis.

[0201] In Figure 9, the EGFR receptor is an extracellular signal (EGFR-specific ligament) outside the cell. The ions have an effect on the cell nucleus (the cell's command center) (when the cell begins to divide). In order to deliver "commands," they must move closely together in the cell membrane. Note that it does not (replace phospholipids to do so). Similar receptors, Other biological processes exist in mammals that govern pain.

[0202] The cell membrane interprets signals from the external environment and provides instructions that drive the cell's behavior. This is the site that is converted. A healthy cell membrane has a regional domain (generally called a "lipid raft"). It is composed of a mixture of lipids, proteins, and sugars organized into (see Figure 7). (To be illuminated), it is related to cellular behavior such as growth, cell division, pain, cell differentiation, or cell death. It functions to send signals in multiple ways (PMID 31052427). The specific subcompartments have different lipid compositions (PMID 31052427) If altered due to diet or genetic defects, it can lead to changes in cellular function and metabolism. And ultimately, as just a few examples, cancer (PMID 30518103), Diabetes mellitus (PMID 29462590, 28742512), Alzheimer's disease (PMI) D 31379503), neuroinflammation (PMID 31862695), and pain management Changes (PMID 31862695, PMID 29459435) can lead to chronic diseases. Garu.

[0203] Fatty acids and other plant-derived compounds have the ability to be inserted into human cell membranes. For example, n-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) Saturated fatty acids; and plant-derived polyphenols such as curcumin (diferuloylmethane). Sexual and terpenoid phytochemicals spread across cell membranes and disrupt cellular signaling. It has the ability to do so. EPA, DHA, and curcumin were found to be separately or in one study When used together, they can cause atypical / precancerous stem cells in animal models of colorectal cancer. It reduced the number of cells (PMID 16475686, 29860560). The mechanism involves lipid rafts (rich in signaling proteins) necessary for transmembrane signaling. It was a fragmentation of the cell surface region.

[0204] Similarly, "liquid skin" (a mixture of oils that approximate the fatty acid composition of human cell membranes and sebum) A possible mechanism by which a substance can treat a medical condition (e.g., pain) is that it is inserted into the cell membrane. This reduces the likelihood that paired or multimeric receptors will interact with each other. This is achieved by disrupting signal transduction that occurs on the cell surface (see Figures 10-14). I want to be treated that way.

[0205] Transmembrane receptors are involved in Brownian motion (in liquids or gases, caused by the influence of molecules in the surrounding medium). Following the random movement of microscopic particles suspended in the air, they migrate in multiple directions along the surface of the cell. However, in this case, they are limited to the plane of the cell membrane surface until they encounter a suitable counterpart. Mergerization (see transmembrane protein-protein interactions in Figure 11) or When multimerization occurs (formation of multiprotein clusters), a new signaling receptor, docking, is formed. A g area may be formed (see Figure 12).

[0206] The pain mechanism involves the multimerization of two or four transmembrane proteins. For example, transient receptor potential (TRP) channels ultimately transmit signals for pain. Superficial transmembrane ion channels that are activated in response to chemical or physical stimuli. These are family channels. There are four of these channels embedded on the cell surface in the cell membrane. It is made up of four subunits. The four individual subunits have channels on the cell surface. Before it can form and allow ions to flow and transmit pain signals, it closes to the formation. They must find each other in order to contain, resulting in a cloverleaf-like pattern. If there are more phospholipids incorporated exogenously into the surface, then four subunits ( The chances of (submit) finding each other and binding to form a channel are reduced (transmembrane channel Exogenous phospholipids reduce changes in protein interactions, and decrease intracellular signaling. For examples, please refer to Figures 13-14. Essentially, the net effect is on the patient. It is to increase the pain threshold, because the chance encounter of pain receptors is multimerized This is because it will take longer to enable the transformation and docking process. Please note. Unlike opioid pain medications, the mechanism targeted by this invention is respiratory Inhalation suppression (which can frequently lead to unintended death), as well as decreased heart rate, nausea, and Activating mu-opioid receptors, which are associated with the undesirable side effect of constipation. stomach.

[0207] Multiple disease processes (e.g., cancer, psoriasis, eczema, etc.) involve cell surface lipids, ceramides, and ri It shows a deficiency or imbalance of lipids (PMID 29410529). Fatty acid profile File disruption is caused by processed foods containing excessive amounts of omega-6 polyunsaturated fatty acids, which are unhealthy and prone to inflammation. The combination of modern dietary habits and highly sensitive genetic characteristics, along with the anti-inflammatory response when taken in, This is due to a combination of the accompanying deficiency of omega-3 polyunsaturated fatty acids that provide the answer (PMID). (29860560). Directly incorporates cell surface lipids and other cell membrane components into the cell membrane. Restoring these diseases is achieved by blocking abnormal cell signaling. It can be useful in limiting and preventing it.

[0208] Notably, this includes diabetes, cancer, psoriasis, eczema, chronic pain, fibromyalgia (to name a few examples) Patients with chronic diseases such as ) can benefit from topical application of "Liquid Skin," and potentially from In particular, to deliver disease-specific therapeutic drugs to affected tissues, for each specific disease state The incorporation of "Liquid Skin" when customized will likely bring benefits. This could mean (see Figure 15). Any disease involving subunit transmembrane receptors The disease can potentially be targeted using the present invention. As of 2019, there are more than 4,333 species. There is a known transmembrane protein (PMID 31874615), and furthermore, deep learning methods This is what is being discovered (computer-aided protein structure modeling, PMID). 33336200). As a result, protein-protein interactions and signaling There are countless diseases caused by dysregulation of cell membrane composition that leads to altered signal transmission. These diseases can be treated by restoring a healthy fatty acid profile to the cell membrane. It can be saved in the present.

[0209] In addition, using exogenous phospholipids and other lipid mixtures such as liquid skin, Food-grade diatomaceous earth (FGDE) and other naturally occurring biosilicate nanoparticles are immersed in the material. It can impart permeability. FGDE is a living organism of single-celled diatom microalgae ranging from 1.9 μm to 180 μm. These are compatible, non-toxic, porous biosilicate skeletal remains. They come in many complex shapes. and has a surface (see Figure 16), which makes them microdrug delivery systems It is useful as a stem (PMID 31618958), and poorly water-soluble substances such as quercetin and It is particularly useful in the delivery of substances with low oral bioavailability (PMID 31496). 698) It is useful for extending drug delivery (PMID 316618958), It is useful in the treatment of metastatic cancer (PMID 31330820), and it is effective in treating cancer It requires the sustained ability to regain control of occupied intracellular signaling pathways (PMID 2). 5239399).

[0210] FGDE is safe to eat, but avoid working with FGDE when it is dry. This is dangerous. Therefore, in certain embodiments, interstitial lung disease caused by silicosis is prevented. To do this, when handling it in a well-ventilated space, wear an N95 mask and keep your nose clear. And the mouth must be covered. If it is ingested orally after it has been coated, FGD E should pass through the digestive tract unchanged and not enter the bloodstream. Diatoms have osmotic properties. Unless coated with a substance that imparts this property, if applied to the skin as a clay paste, the skin will not be affected. It does not penetrate the skin. Diatoms have many pores and a complex three-dimensional architecture. Furthermore, it is ideal for supporting multiple bioactive compounds (Figure 17).

[0211] In a particular embodiment, the present invention may, in part, make the surface of a diatom capable of forming bonds. This study targets diatoms hydrated in a Dead Sea salt solution, which are in a state where they can carry minerals. In some of these embodiments, hydrated diatoms are found to contain amino acids, vitamins, and other bioactive substances. The chemical compounds are sequentially supported (see Figures 18-19 and 20-22), and then, It is coated with a mixture of oils that will impart the ability to penetrate the skin and cell membranes (Figure 18). ~19). Alternatively, a single bioactive component can be immobilized on hydrated diatoms; these individual Combining a mixture of diatoms supported on these materials may provide benefits in target diseases. In some embodiments, the hydrated, coated, and supported diatoms are subjected to, for example, about 5 seconds. For a duration of 8 weeks or more, the supported compound is released and the therapeutic effect is provided. (See Figure 23). In some embodiments, the supported components are nano It takes about 2-4, 2-6, or 2-8 weeks, or longer, to dissociate from the particles. (See Figures 23-24).

[0212] Therefore, the present invention, in part, provides a delayed-release delivery system for multiple biologically active compounds. The use of natural biosilicate nanoparticles (food-grade diatomaceous earth, i.e., FGDE) , and subsequently alter cellular function and / or one or more symptoms of a medical condition. With the aim of delivering compounds that alleviate symptoms and reduce their severity, the skin and cell membranes are targeted. Coating these supported particles with a liquid skin that imparts penetration ability is also an option. This is an elephant (see Figures 18-19).

[0213] Some of the coated nanoparticles can penetrate the intercellular space in the skin, while others are coated... It should be noted that the nanoparticles can penetrate the cell membrane and enter the cell. The nanoparticles promote healing and stem cell regeneration, for example, over a period of at least 2 to 4 weeks. In conjunction with bioactive compounds, minerals, amino acids, and vitamins are essential for tissue regeneration and repair. It will slowly deliver essential nutrients such as those mentioned above (see Figures 18-19). .

[0214] In the recipe provided below, the diatoms are coated with all the diatoms. It is added in a proportion that makes it the rate-determining component, and the majority of the preparation is It should also be noted that it may have an immediate effect (for example, penetration into the skin and cell membranes). The active compound surrounded by the lipid mixture to be conferred (see Figure 15).

[0215] Finally, the lipid coating that enables tissue penetration plays an additional role: pain relief It can be added to the cell membrane surface to raise the threshold of NAL transmission (Figures 15 and 15). 19) Over time, and by being placed on warm human skin, the exercise is provided. Along with energy, the supported components, held together by reversible bonding, last for, for example, about 1 minute. Gradually release for a duration of 8 weeks or more (e.g., at least 2-8 weeks) It can be released; on the other hand, components coated with lipid coatings can impart immediate effects. Each application of the preparation may have an additive effect due to the long duration of its action (Figures 23-24). (See below). Therefore, for example, the goal of immediate relief of pain and inflammation is achieved, On the other hand, over several weeks, the active elements required for tissue regeneration and repair are released over a long period of time. Provides: With each application, the patient should only use the treatment in the area where recovery and healing are needed. It will likely increase many nutrients (see Figure 24). Even if there are any, Due to its partial, non-systemic application, side effects are expected to be limited.

[0216] A single diatom contains numerous tiny structures on which compounds can reside and form temporary bonds. Due to the open pores, numerous bioactive compounds, minerals, amino acids, and vitamins are released. It can carry (see Figure 20).

[0217] Lipid composition percentage of pooled human sebum analyzed by thin-layer chromatography The ingredients are ceramide (13%), fatty acids (47%), cholesterol (7%), and cholesterol Luester (2%), squalene (11%), triglycerides (3%), and wax Ester (17%) (PMID 12677098), approximately 50% was phospholipid. In a particular embodiment, the preparation of the present invention is performed according to the disease being targeted. These ratios are followed, along with adjustments to the constituent elements.

[0218] In certain embodiments, the fatty acid composition of the present invention is that of healthy human sebum and / or It mimics the fatty acid composition of subcutaneous fat. The composition of healthy human sebum and subcutaneous fat is similar to that of some oils. The composition is provided in Tables 2A and 2B.

[0219] [Table 2-1]

[0220] [Table 2-2]

[0221] [Table 3-1]

[0222] [Table 3-2]

[0223] In a particular embodiment, the formulation is provided in Table 2A, containing human sebum, human sebum, and other components. Contains a mixture of oils that match the fatty acid composition of cells or human diabetic cells. For encapsulation in the mixture. The oil may be selected from the oils listed in Table 2B or other oils. The oil is combined in specific amounts. In addition, the fatty acid composition of the individual oils used differs from that of the oils used and is more appropriate for the intended purpose. This provides a certain fatty acid composition.

[0224] For example, in a particular embodiment, the formulation includes (i) macadamia nuts and coconut (ii) a mixture of (ii) emu oil or high-oleic sunflower seed oil. Obtain. Macadamia nuts and cocoa to emu oil or high oleic sunflower seed oil. The addition of corn oil results in a concentration of oleic acid substantially identical to that in human cell membranes (or This results in a fatty acid composition containing a higher (than) oleic acid concentration, and therefore, mammalian cells To the cell membrane, and / or to the intracellular space, and / or to intracellular organelles, The permeability of the agent and its components can be promoted and / or improved. In some cases, emu oil (as found in liquid skin) or high oleic castor oil Macadamia nut and coconut oil (as found in vegan liquid skin) The addition of oleic acid increases the oleic acid content in human cell membranes by at least five times compared to that in mammalian cells (e.g.) For example, mixing into the cell membrane of mammalian cells, into the intracellular space, or into intracellular organelles. This results in greater penetration of the therapeutic substance. The compound penetrates more than one set of cell membranes across the cell membrane. Because it must be stopped, it penetrates intracellular organelles (for example, directly affecting cellular metabolism). To achieve this, a higher concentration of oleic acid may be required.

[0225] Taking into consideration the information provided herein, including Tables 1, 2A, and 2B, If you are an expert, you can adjust the fatty acid composition of a mixture by using various oils in specific amounts. It may be possible to adjust and provide the desired fatty acid composition and / or formulation without excessive experimentation. .

[0226] In certain embodiments, the composition contains emu oil. The amount of emu oil is about 1% to about 99%, approximately 2% to approximately 99%, approximately 5% to approximately 98%, approximately 10% to approximately 96%, approximately 15% to approximately 96% %, approximately 20% to 95%, approximately 25% to 95%, approximately 30% to 95%, approximately 40% to 95% It may contain approximately 45% to 95% or 60% to 95% of its volume in percentage units.

[0227] Considering patients who may be opposed to animal-derived emu oil, in a particular embodiment, this invention In some cases, the composition is similar to that found in healthy human skin and subcutaneous fat. This applies to the use of organic vegetable oil mixtures to achieve the file (PMID 2387). 8791). The fatty acid profile of the formulation is determined by the formulation and the route of administration. It should be noted that it may be optimized for specific diseases in which it is intended. In a particular embodiment, oleic acid is involved in neurodevelopment (in adulthood). Because it is a necessary component of myelin sheath formation (for the formation of new neurons), The formulation is made from organic high-oleic sunflower seed oil with a high oleic acid content of 75-91%. It may contain and is used as a useful topical preparation for stimulating peripheral neuron growth. Some of the vegetable oils that can be used in the formulations of the present invention are listed in Table 2B above. This healthy oil contains polyphenols (antioxidants), vitamins, and essential fats. This includes olive oil, as well as linseed oil and coconut oil, due to the additional benefits of fatty acids. .

[0228] Oleic acid is hypothesized to be the fatty acid most responsible for the excellent osmotic properties of emu oil. It imparts its penetrating properties to the substances mixed in it. Emu oil is a keratin It destabilizes the rufa-helix structure (PMID 28527392) and causes lipids in the skin. It interacts with fat (PMID 28527394) and promotes skin regeneration (PMID 15837639, PMID 15567771, PMID 27069472) Therefore, it has been demonstrated that it can penetrate approximately 3 mm into human skin and deliver the active ingredient (PI). (MD 27178879, PMID 28527394). Application of pure emu oil alone. It has been found to have anti-inflammatory and therefore analgesic effects. This effect is due to the present invention In detail, for example, depending on the intended target, the profile can be detailed for humans or mammals. To make it more closely resemble that of a spore membrane, cell, organelle, or exosome, By mixing mu oil with one or more additional oils (e.g., vegetable oil), The fatty acid composition of mu oil can be modified to improve its properties.

[0229] Inflammatory diseases (to name a few, cancer, multiple sclerosis, diabetes, atherosclerosis, In certain embodiments of the treatment of coronary artery disease and obesity, etc., according to the present invention Emu oil, used in combination with one or more additional oils, can help reduce inflammation in white blood cells. It is possible to change from an exacerbating M1 phenotype to an anti-inflammatory M2 phenotype.

[0230] In a particular embodiment, emu in combination with one or more additional oils The ability to use oil to reprogram differentiated skin cells back to a stem cell-like precursor state. Stem cell markers containing Sox-2, Nanog, Oct4, Klf4, and c-My c can be adjusted upward. This property alone can accelerate the healing time of injured skin. It may be useful in maintaining youthful and healthy skin. It may also be useful in treating cancer. It may also be useful in treatment, (reprogramming cancer stem cells into a naive stem cell-like state is This can lead to selective apoptosis of cancer stem cells (which have sustained damage and are transformed into tumor cells). (Normal stem cells that produce tumor-forming cells).

[0231] In a particular embodiment, any component of the formulation is, for example, a specific state of pain. Because it provides benefits to the body through its effects, it is considered an active ingredient.

[0232] For example, oleic acid is remarkable in that it enables excellent delivery of substances to the human body. While it plays a role in this, it also reduces anger (treating one of the emotional aspects of pain). (and on the other hand, it increases mitochondrial function (PMID 23446891), and intracellular acid It reduces chemo-stress (PMID 31802387), and therefore reduces inflammation and swelling. Therefore, it reduces pain.

[0233] Additional application: There are many applications where the techniques outlined above can be used, for example, with pain. A non-restrictive enumeration of their potential practical applications is listed in Table 1 above. Both the liquid skin and vegan liquid skin mimic the fatty acid profile of human skin and cell membranes. Designed to mimic the movement, it facilitated the transport of miscible compounds into the epidermis and into cells. To address cell membranes with severe to moderate deficiencies in acid and other components in general. Each comes in high and low concentration versions of Liquid Skin and Vegan Liquid Skin, respectively. We designed the product. Using the food-grade diatomaceous earth (FGDE) loading technology described above, Create supported nanoparticles that promote the delayed release of active compounds into injured or affected tissue. It is possible. However, the FGDE carrying technology according to the present invention is not limited to pain. It can be modified as needed for the specific disease being treated. The addition of substances allows for immediate pain relief, in addition to delayed release for long-term pain relief, for example. The design is rounded to achieve this.

[0234] Potential applications / examples include the following (for each of these, long-term effects): The sexual and / or short-acting components may be formulated as described herein. (ru).

[0235] Pain preparations: This invention relates to vegan, non-vegan, prescription strength, and This includes a variety of preparations that can be used to treat pain, including over-the-counter preparations.

[0236] In a particular embodiment, the present invention provides a formulation for the treatment of pain. The formulation is For example, this could include: i. (Any of the pain formulations described herein + ULDN), in a particular embodiment Therefore, this is likely a prescription strength that incorporates ultra-low dose naltrexone. Therefore, ULDN = <1 ug per dose per day. For low-dose naltrexone, refer to Table 1. I want to be illuminated. ii. (Any of the pain preparations described herein), in a particular embodiment, This would likely be available over-the-counter without ultra-low dose naltrexone.

[0237] The formulation is used for, for example, osteoarthritis pain, rheumatoid arthritis pain, neuropathic pain, superficial pain, and muscle pain. It can be used for various types of pain, including muscle aches and headaches.

[0238] In a particular embodiment, the formulation is used by applying the formulation to the affected area, It can treat pain and tension in superficial muscles.

[0239] In a particular embodiment, the formulation is used to affect the affected area. The application of this formulation can treat pain and tension in deep muscles, joints, or ligaments. The application of the agent may be preceded and / or accompanied by exposure to a red / near-infrared lamp. / or it may follow. Exposure is, for example, 600nm~1100nm or 600nm This can be m~2500nm. Exposure to light in this wavelength range may stimulate stem cells and cells By activating the chromophore, metabolism can be improved, electron transport can be increased, and mitochondria can be enhanced. Stimulating increased membrane potential and ATP production, and increased vasodilation by >400%, leading to an influx of immune cells. This can promote cell survival, and all of these can improve cell survival, increase stem cell proliferation and migration, and accelerate This leads to accelerated wound healing, reduced pain, and reduced oxidative stress and inflammation (PMID 28). 748217). For as long as it can withstand, approximately 30 minutes or longer, from the target tissue. The use of a red / near-infrared lamp from approximately 10 inches away is the mechanism outlined above. By increasing absorption and bioactivity through the process, liquid skin contains This will further enhance the effectiveness of the formulation (PMID 28748217).

[0240] In a particular embodiment, the present invention relates to a dilution of any of the pain formulations listed above. A massage oil containing a ion is provided. In some embodiments, the concentration of the diluted formulation is Approximately 5% to 90% of the pain medications listed above (for example, any of the pain medications listed above) (For example, 10% of the formulation described above for infants). A particular embodiment In this context, massage oil may be used during lymphatic drainage and / or acupressure massage. ru.

[0241] In a particular embodiment, the formulation contains alpha-lipoic acid (0.05% to 15% by volume). ) may further contain palmitoyl ethanolamide (5% to 30% by volume), This is because both of these are used for pain relief, and myrrh (0.0005% to 1% by volume) This is to provide a synergistic effect (PMID 30696240). In some embodiments, Natural sources of palmitoylethanolamide and alpha-lipoic acid may be used.

[0242] Neuropathy preparations In a particular embodiment, the present invention treats neuropathy as described above. The present invention provides a formulation for therapeutic purposes. The formulation comprises the basic composition described above and one or more of the above-described components. It contains the following additional components.

[0243] hair removal preparations In a particular embodiment, the present invention, as described above, for treating hair loss The formulation is provided. The formulation consists of the basic composition described above and one or more additional components. This includes minutes. This can be applied to the scalp, and the effect lasts for about 30 minutes or as long as it can be tolerated. It lasts longer and is enhanced by applying near-infrared light from approximately 10 inches away from the scalp. It is possible.

[0244] Scalp mask In a particular embodiment, the present invention, as described above, for treating hair loss The present invention provides a mask formulation comprising the basic composition described above and one or more additives. Contains additives. This can be applied to the scalp, and the effect lasts for approximately 30 minutes, as long as it can be tolerated. It lasts longer, and is achieved by applying near-infrared light from approximately 10 inches away from the scalp. It can be enhanced.

[0245] shampoo In a particular embodiment, the present invention, as described above, for treating hair loss The present invention provides a shampoo formulation comprising the basic composition described above and one or more of the above. It contains the following additional ingredients. The shampoo can also be used as a hair mask, lather it up, and then... Place this on your scalp and allow the long-acting fraction to penetrate the scalp.

[0246] Scalp serum: In a particular embodiment, the present invention, as described above, for treating hair loss This scalp serum can be applied directly to the scalp and left on for approximately 30 minutes, as long as it can be tolerated. Or longer, applying near-infrared light from approximately 10 inches away from the scalp. Therefore, it can be further increased. In a particular embodiment, after applying the serum, for example, According to the invention, hair can be washed with shampoo, and for example, according to the present invention, conditioner It can be processed in this way.

[0247] Facial preparations: In certain embodiments, the present invention relates to skin texture, health, as described above. The invention also provides formulations for improving cell regeneration. The formulations are based on the basic composition described above. and includes one or more additional components.

[0248] Anti-aging beauty moisturizing cream In certain embodiments, the present invention relates to skin texture, health, as described above. The present invention provides a formulation for moisturizing the skin, which also contains ingredients that improve cell regeneration. This comprises the basic composition described above and one or more additional components.

[0249] Wrinkle serum In certain embodiments, the present invention relates to skin texture, health, as described above. The present invention provides a formulation for moisturizing the skin, which also contains ingredients that improve cell regeneration. This comprises the basic composition described above and one or more additional components.

[0250] toner In certain embodiments, the present invention relates to skin texture, health, as described above. The present invention provides a formulation for moisturizing the skin, which also contains ingredients that improve cell regeneration. It comprises the basic composition described above and one or more additional components. The formulation is rose It can be diluted to 10% in water and sprayed onto the face as a facial toner.

[0251] Facial cleanser In certain embodiments, the present invention relates to skin texture, health, as described above. The present invention provides a formulation for moisturizing the skin, which also contains ingredients that improve cell regeneration. The formulation comprises the basic composition described above and one or more additional components. It may be diluted to % and may contain plant-based surfactants.

[0252] Aging spot fading cream In certain embodiments, the present invention reduces hyperpigmentation as described above. A formulation for coloring is provided. The formulation consists of the basic composition described above and one or more of them. It includes an additional numerical component.

[0253] Face / Neck Serum In certain embodiments, the present invention relates to skin texture, health, as described above. The present invention provides a formulation for moisturizing the skin, which also contains ingredients that improve cell regeneration. The formulation comprises the basic composition described above and one or more additional components. It can be diluted to 20% in a bio-fermented product and used as a night serum.

[0254] mask In certain embodiments, the present invention relates to skin texture, health, as described above. and higher concentrations of FDG enable the extended release of components to enhance cell regeneration. The present invention provides a formulation for providing a higher concentration of the component in E. The formulation is based on the above description. The composition and one or more additional components. This mask is used with or without heating. It can be applied to the face, body, or scalp and can be washed off after absorption for approximately 20-30 minutes.

[0255] Bus mud The bath mud formulation is the same as the mask formulation. A thin coat of the formulation is applied to the body and face. It can be applied to the skin and dried in a high-temperature sauna or using a heater in the bathroom. After the mud has completely dried, the preparation is washed away, and in certain embodiments, the rejuvenated skin It can be demonstrated.

[0256] Burn / Wound Healing In certain embodiments, the present invention, as described above, treats injuries or burns When applied to intact skin adjacent to burned or wounded skin, it promotes the regeneration of burned or wounded skin. We provide formulations for locally delivering essential nutrients. The formulations are based on the basic combination described above. The product contains one or more additional components. These formulations are used for exosomes and medicine. When used in combination with honey, it may promote regeneration and prevent infection. Burn / wound preparations are It can be carried in a porous bandage placed on the intact skin surrounding the wound area, but safety measures Therefore, it would not be applied directly to wounded skin.

[0257] Acne preparation In certain embodiments, the present invention provides a formulation for preventing and treating acne. The formulation comprises the basic composition described above and one or more additional components. These formulations, as described above, do not induce antibiotic resistance in p. acnes. May contain ingredients that suppress (p. acne).

[0258] Rash preparation In certain embodiments, the present invention, as described above, treats eczema, psoriasis, and The present invention provides a formulation for treating rashes, including nonspecific dermatitis or skin rashes. It comprises the basic composition described above and one or more additional components.

[0259] Allergy / itch relief preparation In certain embodiments, the present invention relates to IL-4-mediated obesity as described above. It reduces cell degranulation, and therefore, includes eczema, psoriasis, nonspecific itching, and urticaria. The present invention provides a formulation for reducing itching and allergic responses associated with rashes. It comprises the basic composition described above and one or more additional components.

[0260] PMS preparation In certain embodiments, the present invention relates to pain and rest as described above. The present invention provides a formulation for treating increased muscle tone. The formulation comprises the basic composition described above and The formulation contains one or more additional ingredients. The formulation is used, for example, to treat premenstrual syndrome (PMS). It can be applied to the lower abdomen.

[0261] Lactation preparation In a particular embodiment, the present invention stimulates breast milk production as described above. The present invention provides a formulation for which the formulation comprises the basic composition described above and one or more additions. Contains the active ingredient.

[0262] Joint pain preparation In a particular embodiment, the present invention, as described above, for treating pain The formulation is provided. The formulation consists of the basic composition described above and one or more additional components. The preparation includes 5 to 15 minutes of near-infrared light per joint, as described above. It can be used.

[0263] antimicrobial preparations In a particular embodiment, the present invention prevents skin infections as described above. And to provide a formulation for treatment. The formulation is a basic composition described above and one or It contains several additional components.

[0264] Dental / Gum Preparation / Floss Oil In a particular embodiment, the present invention prevents infectious diseases and The present invention provides a formulation for treatment. The formulation comprises the basic composition described above and one or more of the following: Contains several additional ingredients. Apply a few drops of this formulation to ribbon floss before flossing. It can prevent and treat gingivitis.

[0265] Needle-free vaccines and pharmaceuticals In certain embodiments, the present invention enables the transdermal penetration of other substances as described above. The present invention provides a formulation for improving the above. The formulation is a basic composition and one or It contains multiple additional components. In a particular embodiment, Liquid Skin + Vaccine Alternatively, a half-bubble sticker filled with medicine (for example, insulin) can be absorbed. It can be adhered to the skin until it is removed.

[0266] Self-tanning preparations In certain embodiments, the present invention enables the transdermal penetration of other substances as described above. The present invention provides a formulation for improving the above. The formulation is a basic composition and one or It contains several additional components. In a particular embodiment, it forms a final concentration of 75%. Together with concentrated black tea and henna, the mixture can form a final concentration of 25%. The solution can be applied evenly to the peeled skin, left for 2 hours, and then exposed to ultraviolet light. It can provide the appearance of tanned skin without the associated skin damage.

[0267] Sunscreen preparation In certain embodiments, the present invention enables the transdermal penetration of other substances as described above. The present invention provides a formulation for improving the above. The formulation is a basic composition and one or It contains several additional components. In a particular embodiment, an immediate-acting sunscreen special Red raspberry seed oil (SPF) forms a final concentration of approximately 25% to 30% for sexual purposes. Along with 25-50%, carrot seed oil (SP) forms a final concentration of approximately 25%-30%. Together with F35~40), the formulation can form a final volume of approximately 25% to 30%. In a specific embodiment, for a longer-lasting, sustained-release natural sunscreen effect, carrot seeds Supported with raspberry seed oil and red raspberry seed oil (approximately 1% to 20% of the final volume) The addition of FGDE diatoms may be considered.

[0268] Henna preparation In certain embodiments, the present invention enables the transdermal penetration of other substances as described above. and provides formulations to improve retention. The formulations consist of the basic composition described above and It includes one or more additional components. In certain embodiments, it provides a longer-lasting design. In order to lead to the final volume, the basic composition is formed with henna, which makes up about 70% to 75% of the final volume. It can make up about 25% to 30% of the amount. Alternatively, before applying the henna design, apply the preparation to the skin. It can be applied and absorbed for several minutes.

[0269] Tattoo moisturizer In certain embodiments, the present invention relates to wound healing, skin quality, etc., as described above. We provide a skin moisturizing formulation containing ingredients that improve sensation, health, and cell regeneration. The formulation comprises the basic composition described above and one or more additional components. The formulation is applied to the intact skin surrounding the newly placed tattoo to minimize scarring. It can suppress irritation, deeply moisturize, and optimize the integrity and healing of tattoos.

[0270] Keloid and scar preparations In certain embodiments, the present invention relates to wound healing, skin quality, etc., as described above. We provide formulations to improve sensation, health, and cell regeneration. The formulations are as described above. It comprises a basic composition and one or more additional components. The application of this formulation is to improve the appearance of scars. It can lead to improvement.

[0271] Ulcerative colitis / inflammatory bowel disease / irritable bowel syndrome / celiac disease preparations In a particular embodiment, the present invention, when taken orally as described above, The present invention provides a formulation for improving the healing of injured mucous membranes of the gastrointestinal tract. The formulation is as described above. It comprises a basic composition and one or more additional components. Capsules having various solubility coefficients. The lu can be used to target the proximal, intermediate, and distal regions of the gastrointestinal tract.

[0272] Restless legs and spasm preparations In certain embodiments, the present invention, when applied locally as described above, The present invention provides a formulation for providing a bioactive compound required for muscle relaxation. The formulation is as described above. It comprises the listed basic composition and one or more additional components.

[0273] Formula for diabetes / dyslipidemia / obesity / hypertriglyceridemia / metabolic syndrome In a particular embodiment, the present invention, when taken orally as described above, To improve insulin resistance, dyslipidemia, hyperglycemia, and hypertriglyceridemia The present invention provides a formulation comprising the basic composition described above and one or more additional components. Contains ingredients.

[0274] Diabetes / Dyslipidemia / Obesity / Hypertriglyceridemia / Metabolic syndrome / Ins Phosphate resistance / Abnormal sleep debt / Osteopenia / Osteoporosis / Chronic disease anemia Combination 2 In a particular embodiment, the present invention, when taken orally as described above, Insulin resistance, dyslipidemia, hyperglycemia, hypertriglyceridemia, obesity, metabolic syndrome It improves syndrome, abnormal sleep debt, osteopenia, osteoporosis, and chronic disease anemia. The present invention provides a formulation for which the formulation comprises the basic composition described above and one or more additives. Contains additive components.

[0275] Abnormal Sleep Debt Formula 1 In a particular embodiment, the present invention, when taken orally as described above, The present invention provides a formulation for reducing abnormal sleep debt. The formulation is a basic composition described above. and includes one or more additional components.

[0276] Combination for osteopenia / osteoporosis / chronic anemia 1 In a particular embodiment, the present invention, when taken orally as described above, Insulin resistance, dyslipidemia, hyperglycemia, hypertriglyceridemia, obesity, metabolic syndrome It improves syndrome, abnormal sleep debt, osteopenia, osteoporosis, and chronic disease anemia. The present invention provides a formulation for which the formulation comprises the basic composition described above and one or more additives. Contains additive components.

[0277] Leukoplakia / Tongue lesions / Oral and vaginal mucosal healing preparations In certain embodiments, the present invention, when applied locally as described above, The present invention provides a formulation for improving mucosal lesions. The formulation is a basic composition described above. and includes one or more additional components.

[0278] Pitting edema / severe lymphatic load In certain embodiments, the present invention, when applied locally as described above, The present invention provides a formulation for improving pitting edema and / or lymphedema.

[0279] Since trademarks will be determined later, each preparation used herein is a combination It should be noted that this is referred to by the name of the fabric. For example, in relation to the treatment of pain, The agent represents Pain Preparation 1.0, version 1.0, for the next version. It is specified as 2.0, etc.

[0280] [Example 1] Pain Preparation 1.0 (PP1): PP1 is 5 ml of German chamomile in 4 fl ounces of thoroughly mixed emu oil. It was an essential oil. The inventors have found that even though it was applied distally, it was effective in the central nervous system. Because it was recognized that it could exert its effect on the CNS system, German chamomile essential oil ( We compared it with Roman chamomile essential oil. We examined emu oil, which penetrates deeply and is mixed within it. It was used for its ability to deliver the harmonized components.

[0281] Other topical preparations purchased from the market failed, but this formulation was tested and relieved abnormal muscle tension. I found it to be effective in achieving harmony.

[0282] The formulation has also been found to be effective in alleviating insomnia, and it is due to the mild anti-inflammatory properties of the formulation. This is thought to be due to anxiety traits.

[0283] The formulation is for patients with chronic neck pain due to multiple neck injuries who do not have a history of neck surgery. It has also been found to be effective in other cases. Patients use it along with other natural methods of pain management. Using PP1 and near-infrared (NIR) light, it was found to be effective in treating pain. Ta.

[0284] PP1 is for those seeking a natural, localized solution for pain, particularly those with refractory pain after multiple cervical surgeries. The treatment was also tested in patients with neck pain. Patients received opioid analgesic tablets and patches. They tried it but it didn't work. The patient applied PP1 to the neck and shortly after application it It was found to be effective in relieving pain.

[0285] PP1 can be used alone or with a near-infrared (NIR) lamp (approximately 600nm to 2500nm) They can be used in combination. Using an NIR lamp, for example, once or for as long as it can withstand. For 5-60 minutes, at approximately 10 inches from the skin, it may be possible to dilate blood vessels within seconds of applying the light. It can increase local blood flow by up to 400% (PMID 28935419).

[0286] PP1 had a distinctive scent. Cold-pressed orange essential oil, as well as peppermint. The fragrance of PP1 was enhanced by adding essential oils first; the use of fragrant essential oils was beneficial. It was intended for encapsulation within a pharmaceutical formulation. This led to the design of Preparation 2.0.

[0287] [Example 2] Pain Preparation 2.0 (PP2): The PP2 version contains 40 drops (2 ml) of high-quality cold-pressed orange essential oil. 10 drops (0.5 ml) of peppermint essential oil, and 10 drops from www.thenewjerusalem.co. Add 20-30 drops (1) along with (0.5 ml) Bridal Garden Jerusalem Holy Oil. Contains approximately 1.5 ml of German chamomile oil. The remainder is a final volume of up to 1 fl ounce. It was emu oil up to that point. 12 bottles of PP2 were distributed to 12 subjects, and they were new They agreed that the new formulation had a pleasant smell and was more effective than the original formulation.

[0288] PP2 was applied at night to two patients with cervical rigidity, and they subsequently... They reported relief of stiffness and pain. The patient's pain level was 0 / 10 the following morning, and both patients reported relief of stiffness and pain. They said they slept well, felt relaxed, and their neck muscles were no longer stiff.

[0289] PP2 was also tested in a patient who had suffered from severe eczema for the past six years. His hands were It was covered in shriveled, dry, thickened, bleeding skin. He gave PP2 to him After applying it to his hands (three applications over 48 hours), he noticed that the lesions on his skin were visibly softer. The skin became thinner and had a more normal texture, which was an improvement. There was slight bleeding. It was closed. He applied a sealing barrier cream to the top overnight and then applied PP2 to his damp hands. In that case, he noticed an additional improvement. His previously lesioned skin was almost smooth after the third application. It had a soft feel.

[0290] [Example 3] Pain Preparation 3.0 (PP3): PP3 is used as the immediate-acting portion for rapid pain relief, as well as Moroccan chamomile oil. , terpenoids found in German chamomile oil and Roman chamomile oil, sesquiterpenoids Bioactive substances such as ions and flavonoids; as well as minerals and amino acids required for tissue repair. Designed to have a long-acting moiety that will continuously release anoacids and vitamins. The long-acting portion may provide effects for at least 2 to 8 weeks (PMID 316). (18958).

[0291] Food-grade diatomaceous earth (FGDE) and other naturally occurring micron-sized biosilicic acid These biosilicates were intended for use in PP3. It is formed, does not require toxic chemicals to produce, is chemically inert, and can be incorporated. It is safe tolerated by living organisms for use in or topical application, and supports pharmaceutically active compounds. It has a large surface area, thermal stability, and most importantly, it does not interfere with their natural functions. It acts safely as an inert carrier for pharmaceutically active compounds without causing harm (PMID 3161). 8958).

[0292] In addition, supporting pharmaceutically active compounds on these biosilicates is possible. Hydrated diatoms / biosycetes in a sequential order that allows for the attachment of pharmaceutically active substances to the licate. It is only necessary to incubate the licate with the compound of interest (PMID). 31618958). In other embodiments, only one of the hydrated biosilicates is added. The active compound can be supported; a mixture of such single-supported biosilicates can be a standard This may be considered depending on the desired effect in the organization.

[0293] Sequential incubation with other substances expands the complex with each new additional substance. The intention was to make a significant difference. A single complex or multiple supported complexes in liquid When mixed with skin to promote absorption into the skin, the pharmaceutically active substance changes over time and with body temperature. The temporary bonds that hold them together break, releasing the individual active components into the tissue that needs repair. It will be released. This process takes time for the bond to break (and the kinetic / thermal energy increases). It is a sustained-release substance because it requires additional action (for example, supply through contact with the human body). This delayed release of the substance will give PP3 a longer duration of effectiveness.

[0294] The design process involves first creating the long-acting portion, followed by the immediate-acting portion (including anxiolytics). This involves adding these, because they are readily available for immediate effectiveness. Therefore, it should be done. The purpose is immediate pain relief, as well as to the specific tissues that need it. Minerals, amino acids, vitamins, and bioactive substances that promote tissue regeneration and repair. It has the extended release of plant-derived flavonoids, terpenoids, sesquiterpenes, etc. Therefore, with each application, the tissue directly provides the raw materials required for tissue formation and repair. It should be supplied and promote healing and recovery.

[0295] PP3 could be fabricated in multiple strengths (see Table 3 for sample recipes). stomach).

[0296] [Table 4]

[0297] For precise drop-by-drop dosing, the mixture should be placed in a 15 ml dark glass (e.g., green or The blue color is because these are darker and protect from light when mixed in the drip bottle. It would be wise to do so (for rollerball tops, where it would be difficult to quantify the amount used). hand).

[0298] [Example 4] Steps for preparing PP3 Prepare a German chamomile essential oil-grain alcohol mixture for a long-acting portion: 1) Add 4 ml of 120 proof grain to 4 fl ounces (118 ml) of German chamomile essential oil. Add an alcohol to preserve chamazulene and bisabolol. Mix well. Use Leave it at room temperature for at least one hour before use.

[0299] Prepare a Roman chamomile essential oil-grain alcohol mixture for the long-acting portion: 1) Add 1 ml of 120 proof grain to 1 fl ounce (30 ml) of Roman chamomile essential oil. Add alcohol to preserve chamazulene and bisabolol. Mix well. Let stand. Do so. Leave at room temperature for at least one hour before use.

[0300] Prepare a German chamomile essential oil-grain alcohol mixture for the short-acting portion: 1) Add 0.5 ml of 190 plu to 4 fl ounces (118 ml) of German chamomile essential oil. Add grain alcohol to preserve chamazulene and bisabolol. Mix well. Leave at room temperature for at least one hour before use.

[0301] Prepare a Roman chamomile essential oil-grain alcohol mixture for the short-acting portion: 1) Add 0.5 ml of 190 plu to 4 fl ounces (118 ml) of Roman chamomile essential oil. Add grain alcohol to preserve chamazulene and bisabolol. Mix well. Leave it to stand. Leave it at room temperature for at least one hour before use.

[0302] Prepare a Moroccan chamomile oil-grain alcohol mixture for the short-acting portion: 1) Add 1 ml of 190 proof to 8 fl oz (236 ml) of Moroccan chamomile essential oil. Add grain alcohol to preserve chamazulene and bisabolol. Mix well. Leave it as is. Leave it at room temperature for at least one hour before use.

[0303] Prepare a Dead Sea salt solution: 1) Take the baking dish, cover it with aluminum foil, and place the shiny side up. 2) Spread several cups of Dead Sea salt in a 1-inch layer. 3) Illuminate the salt layer with a near-infrared light bulb, positioning the bulb at a distance of 3'' or less from the salt surface. Ensure that all salt surfaces are exposed to light. 4) Irradiate the salts with NIR light for at least 1 hour. 5) Dilute in purified water at a 1:10 ratio (100g of salts in 1000ml of purified water). At room temperature. Allow approximately 10-15 minutes for the salts to dissolve. 6) Let it cool and store it in a glass bottle with a lid. Store any remaining salts. Turn off the NIR light. vinegar.

[0304] Prepare a saturated dead sea salt solution: 1) Add 1 cup of Dead Sea salt to 2 cups of water in a large glass bottle and stir thoroughly. Mix it with the other ingredients. 2) Heat in a microwave at high temperature for 3 minutes, then stir thoroughly to mix completely. 3) Heat in a microwave at high temperature, repeating every minute, stirring until the liquid visibly boils. This allows more salts to dissolve in the solution. 4) Let it cool down and stir thoroughly. 5) Keep covered at room temperature overnight. 6) Gently pour or pipette the supersaturated salt solution into a separate glass bottle with a lid. Then, leave the remaining undissolved salt layer at the bottom. 7) Cover and store the supersaturated salt solution at room temperature.

[0305] Prepare sacred oil: 1) Pour 10ml of organic extra virgin olive oil into a container with a safe dropper lid. Divide the contents into dark glass bottles and protect them from light. 2) Add 5 ml of organic myrrh essential oil. 3) Add 2.5 ml of organic cinnamon essential oil. 4) Add 2.5 ml of organic calamus essential oil. 5) Add 5 ml of organic cassia essential oil. 6) Add 5 ml of organic frankincense essential oil. 7) Mix well. The total volume should be 30 ml. 8) Keep in a dark glass bottle with a secure drip lid and protect from light. 9) Store in a cool place away from light.

[0306] Preparing traditional Chinese medicine herbs: 1) Combine the following in a glass quart bottle with a lid: 2) Organic ginger essential oil 120ml 3) Organic Chinese licorice (Glycyrrhiza uralensis) (part of the dried herbs) (120ml) Extract in 3 parts water and mix with vegetable glycerin herbal extract. 4) Organic Bupleurum Chinese (with vegetable glycerin as a carrier) Using this method, 1 part Bupleurum is mixed with 3 parts pharmaceutical-grade alcohol. (Extract into purified water) 240ml 5) The total volume is 480 ml.

[0307] Prepare the seed and orange oil mixture: 1) In an amber glass bottle with a lid, combine the following: 2) 60ml of cold-pressed organic pomegranate seed oil 3) 30ml of cold-pressed organic orange essential oil 4) 10ml of cold-pressed organic black seed essential oil 5) Organic clove essential oil 10ml 6) Final volume 110ml. Store in an amber glass bottle with a lid until ready to use. do.

[0308] Prepare long-acting supported biosilicate / food-grade diatomaceous earth (FGDE). : 1) Pour 500 ml of Dead Sea salt solution into a quart-sized glass bottle with a lid. 2) Wear a mask and protective eyewear to prevent interstitial lung disease caused by improper handling / inhalation. It prevents the inhalation of dry FGDEs that may occur. 3) Add 50g of food-grade diatomaceous earth to the Dead Sea salt solution to hydrate the FGDE and mineral Therefore, nano-sized particles are used to support German chamomile essential oil and Roman chamomile essential oil. Prepare the particles. 4) Use a whisk to create a homogeneous mixture. 5) In a solution of FGDE + Dead Sea salts, add a mixture of German chamomile essential oil + alcohol and rose Add maca chamomile essential oil + alcohol. You will be surprised to see the oil rise to the surface. Ultimately, FGDE will sink to the bottom. 6) Use a whisk to create a homogeneous mixture. 7) Add 15g each of organic pea protein and organic brown rice protein. . 8) A total of 450 mg of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, and L-valine were added. do. 9) Use a whisk to create a homogeneous mixture. 10) Add a total of 700 mg of vitamin B-6. 11) Use a whisk to create a homogeneous mixture. 12) Add a total of 7000 mg of N-acetylcysteine. 13) Use a whisk to create a homogeneous mixture. 14) Add a total of 3500 mg of niacinamide. 15) Use a whisk to create a homogeneous mixture. 16) Add a total of 7000 mg of vitamin C. 17) Use a whisk to create a homogeneous mixture. 18) A total of 10,500 mcg of retinol activity equivalent (RAE) is administered to the vitamin A palmite As palmitate, 49 mcg of RAE is added as beta-carotene. 19) Use a whisk to create a homogeneous mixture. 20) Add a total of 42,000 IU (1050 mcg) of vitamin D. 21) Use a whisk to create a homogeneous mixture. 22) Tighten the cap and leave at room temperature overnight or until a blue oil layer rises to the surface. To exist. 23) Use a whisk to create a homogeneous mixture. 24) Pour the mixture into a glass container large enough to hold at least 4000ml, ensuring it is homogenized. ingredient. 25) Mix with 960ml of emu oil. 26) Using a whisk, create a homogeneous mixture from the traditional Chinese medicine herbal mixture. Pour 480 ml into a glass container containing the main mixture and mix well. 27) Using a whisk, create a homogeneous mixture from the seeds and orange oil mixture. Add 110 ml of the seed and orange oil mixture to the main mixture and mix well. 28) Add 30 ml of holy oil to the main mixture and mix well. Total 2,713 ml I'll do that.

[0309] It contains German and Roman chamomile essential oils, vitamins, minerals, and Because it contains natural biosilicate nanoparticles compounded with amino acids, this is the final preparation This is the long-acting part of the substance. Before use, ensure it is thoroughly mixed until homogeneous.

[0310] Note: Alternatively, diatoms / biosilicates / FDGE each individually carry it. It is possible to create separate batches (for example, silica immersed in Dead Sea saltwater that already carries minerals) Algae are extracted, and each compound is added separately, for example, FDGE carrying vitamins, minerals (to produce FDGE supported by amino acids, FDGE supported by amino acids, etc.), then, 1 aliquot Diatoms carrying each type of support are extracted and combined.

[0311] Prepare a fast-acting alcohol-preserved chamomile mixture: 1) For a final total volume of 480ml, use alcohol-preserved German chamomile essential oil (120 (Total volume in ml) and alcohol-preserved Moroccan chamomile essential oil (total volume in 240 ml) and Combine with Coal Preserved Roman Chamomile Essential Oil (120ml total volume).

[0312] Prepare an anxiolytic and antidepressant compound: 1) Organic jasmine grandiflorum essential oil and organic lemongrass essential oil in a 1:1 ratio. Combine. Store in a dark glass container with a lid until use.

[0313] [Example 5] Pain Preparation 3.1 (PP3.1): PP3.1 was prepared.

[0314] [Table 5]

[0315] [Example 6] PP3.1's anti-aging and anti-wrinkle properties PP3.1 was applied sporadically to the face (3 times over 7 days) for 2 weeks. After 2 applications, the patient: The deep horizontal line across the bridge of the patient's nose, which the patient had had for the past 10 years, suggests that the patient intentionally created wrinkles on their nose. Unless you bring them together, they are no longer visible; and enlarged pores in the T-zone (forehead, nose, chin). You will notice that the particles have become significantly smaller, the skin surface itself has become finer, and it shines brighter. It was added. PP3.1 reduces wrinkles and pore size, and improves skin brightness and texture. I made them go up.

[0316] Components were selected for PP1-PP3.1, and four standard transcription factors Sox2, Oct- Formulated to stimulate 4, c-Myc, and Klf4 (PMID 169041) 74). Sox2, Oct-4, c-Myc, and Klf4 in terminally differentiated cells It has been reported that stimulation can reprogram them back to an undifferentiated stem cell state. (For example, using a viral vector, the transcription factor Sox2, O in mature skin cells) Promoting the expression of ct-4, c-Myc, and Klf4 puts them into a stem cell state. (It was sufficient to restore it.) (See Figure 25 and (PMID 16904174)) This original work by Dr. Shinya Yamanaka (PMID 169) 04174) helped him win the Nobel Prize in Physiology or Medicine. However, the application of his work has largely remained in the laboratory, and its use in human patients is still limited. This has not been translated into clinical context.

[0317] Essentially, the difference between the earlier work and PP3.1 is that the latter uses a viral vector Without the use of artificial substances, natural ingredients are used to deliver a combination of signals into cells, differentiating skin cells. The ability to transform cells back into a "biologically younger" pluripotent stem cell state. It seems so.

[0318] Pluripotency is the ability to produce other cell types in response to signals in the cellular microenvironment. It is a force; therefore, suitable for specific cellular environments, neurons, blood vessels, connective tissue, and multi It is possible to regenerate other cell types such as P When P3.1 is applied to the scalp, it activates hair follicles to produce more hair, and the skin When applied to the skin, it can affect additional connective tissue (such as in wrinkles) or additional skin cells. It stimulates the production of [substance]. Local environmental signals within any given tissue will cause the tissue to regenerate as needed. It will direct the induced pluripotent stem cells to restore the condition. The signals within the facial skin will be more numerous. While this will likely direct the production of facial skin, the signals within the scalp will lead to more hair follicles / It will likely direct hair production. Therefore, there is no concern, for example, about hair growing on the face.

[0319] Increasing the number of stem cells in the skin promotes youthfulness, reduces inflammation, and promotes rapid recovery. It has the potential to promote rapid wound healing and the formation of new skin. Terminally differentiated skin cells Any localized system that can produce inducible stem cells from cells or any other cells to which it is applied. It should be noted that there are endless applications to manufactured products. For example, peripheral neuropathy In patients with palsy, PP3.1 is applied to the underlying tissue of the skin where nucleopathies are present. It may be possible to regenerate the steroid. This requires new blood vessels, connective tissue, and skin cells. In patients with burns, it may be possible to regenerate each of these. This only means that PP3.1 or a future version can be delivered to the injured tissue.

[0320] [Example 7] PP3.1's skin-brightening properties The use of PP3.1 resulted in faster healing and brightening of blemishes. The person's skin was more radiant, healthy, and vibrant. One possible explanation: This is because licorice root extract inhibits melanin formation and inflammation, as well as UBV-induced hyperpigmentation. It has been shown that it contains glabridin (PMID 98705). 47) By coating glabridin with a lipid mixture that imparts skin penetration properties, This was delivered to the tissue, leading to a brightening effect on the skin.

[0321] [Example 8] Hair retention properties of PP3.1 A few drops of PP3.1 were applied sporadically to the central part of the patient's scalp (for approximately 3-7 days). (Applied once per application). Noticed hair retention and the growth of new hair along the affected area.

[0322] [Example 9] Ulcer healing properties of PP3.1 The patient developed a painful spot / ulcer when she accidentally bit the tip of her tongue. Place one drop of PP3.1 on the ulcer, and the pain will instantly subside upon contact; the ulcer will immediately... It began to heal and shrink in size, and by morning the ulcer had disappeared. This is PP1, PP2, and The response is much stronger than in PP3. The floral / bitter flavor is for some. It may be unpleasant, but its effectiveness will probably outweigh that. This preparation treats pain. In addition to this, it promotes rapid healing by stimulating the stem cell response in injured tissue. prompt.

[0323] [Example 10] Verification of the long-term release and lymphatic drainage characteristics of the active compound PP3.1. Following the trauma, the patient had a herniated disc at L3 and L4, as well as a sprained right groin. He has a sprained right gluteal muscle, a sprained right gluteal muscle, and a tear in one of the muscles that stabilize the right pelvis. Due to a problem in the lower back, I was unable to lift my right leg more than one inch off the floor. Apply approximately 10 drops of PP3.1 to the lesion area and use one set of near-infrared lamps for 5 minutes. By utilizing this, we enabled deeper penetration of PP3.1.

[0324] 23 hours after the application of PP3.1, the patient was to receive lymphatic drainage / deep tissue massage. The female masseuse began working on the injured right gluteal muscle / buttock / groin area. It was found that there was no inflammation or swelling. The patient had a surface that would normally cause discomfort. Despite lymphatic drainage massage, pain was only present in the area where PP3.1 was applied. I noticed that the female masseuse was in the same area where PP3.1 was not being applied. When the massage began, the patient experienced the usual discomfort.

[0325] The patient can withstand deeper pressure on the injured side compared to the uninjured side. It should be noted that while the female masseuse worked on the right / injured side, the patient I felt the same light / medium / deep sensation as usual; no numbness was observed. Therefore By reducing inflammation, less lymphatic fluid is trapped in the patient's tissues, and pain is reduced. We hypothesized that pain would also be reduced. In addition, PP3.1 is involved in the insertion of lipids into the cell membrane. By disrupting the multimerization of pain receptors required for pain signaling, pain can be controlled. The threshold for swelling in patients was raised. The long-term fraction (supported biosilicate nanoparticles) showed swelling It has been found to be effective in reducing pain and inflammation. In addition, patients experience pain and inflammation. , or recurrence of swelling (within 4-6 hours after taking traditional nonsteroidal anti-inflammatory drugs) Since it did not experience (what would be expected), this means that FDGE-supported diatom nanoparticles This is evidence that it is effective for the extended release of bioactive compounds. With a single application of PP3.1 , which was sufficient to provide relief.

[0326] [Example 11] Wound healing properties of PP3.1 The patient has idiopathic peripheral neuropathy of both lower extremities, with almost no sensation below the knee. Therefore, he developed a slowly spreading infection due to poor wound healing. He didn't realize what had happened for over a month. About a month after the injury, he went to the emergency room. I went to the doctor and was prescribed an oral antibiotic (cephalexin), which controls skin infections. He failed to do so; then he was given oral Bactrim as a substitute, however However, this also failed to control the cellulitis. Therefore, he was hospitalized and given IV antibiotics ( I received clindamycin overnight, then oral clindamycin and was discharged home. A few days later... When it becomes clear that the wound is persisting without healing, this is oral linezo He was switched to Lido. He stayed on Linezolid for three weeks, and an MRI showed the infection had spread to the bone. Although it was shown that it had not healed, the wound persisted.

[0327] The patient then showed the wound, which had not healed in the past four months, to a family physician. The practicing physician applied three drops of PP3.1 to the wound and completely covered the leg.

[0328] After 24 hours, examination of the wound showed a reduction in edema, however, there was still some mild swelling in the lower part. Some erythema and warmth were observed near the wound site, with fluctuations in degree. Consult with the infectious disease specialist managing the patient's care, and advise against further antibiotic intervention. Observation was deemed appropriate. A faster healing response was desired, and the infection in the wound was not expected to persist. Upon noticing its presence, the family physician applied the antimicrobial compound formulation 1 prepared according to the present invention. did.

[0329] Antimicrobial compound previously prepared by the inventor to prevent colds / influenza 1. Mix AB1 with PP3.1 in a 1:1 ratio and apply to the patient's front right calf. It was applied in a thin layer, then spread thickly over the wound area. Hair I used the hairdryer in a diffusive manner for a few minutes, gradually increasing the circulation.

[0330] Shortly after the application of heat, the wounded skin began to change, becoming mildly erythematous. Several small blisters, 2-3 mm in size and filled with bright yellow serous fluid, formed. The symptoms subsided within a few minutes to a few hours, while the lesions themselves began to adhere to each other. The patient said that fever was helpful. Realizing this, he spent the day sitting outside in the sun, exposing the wound to sunlight. The brawny changes of the incomplete tissue began to dissipate within minutes of application + heat. The changes continued for 6 hours. It was the most noticeable.

[0331] After 6 hours, the edema had subsided, the patient's leg had shrunk by at least 30-40%, and the wound was partially healed. The venous insufficiency, which had been present for decades, closed and the hypertrophic changes were noticeably improved. Each application to the skin Once fully absorbed, the patient applies a thicker layer of a new round of AB1+PP3.1. They would have likely used an adryer or sunlight to improve absorption.

[0332] This wound did not heal within four months, but with the appropriate combination of nutrients and bioactive components... It should be noted that when a combination was provided, the immune system and stem cells responded quickly and appropriately. It was. By the end of 9 hours, the 3+ pitting edema in both lower extremities had completely resolved. Discoloration is minimized to the point where it looks like a sunburn, and the wound has grown to the point of forming a small scab. He further reduced his waist size. His legs felt more comfortable due to the reduced swelling, and he walked better. He noticed a slight improvement in sensation in both his feet and lower limbs. He also noticed an improvement in his balance. He mentioned that he felt more stable when standing on his feet. (Regarding the progression of peripheral neuropathy) Along with the development of the disease, over the past 20 years, patients have been experiencing symptoms that begin at the ankle and progress upward towards the knee. He was gradually losing hair on the front of his shins. After several weeks of daily application of AB1+PP3.1, The patient noticed hair regrowth that began near the knee and progressed downwards towards the ankle.

[0333] The patient's ankles and feet were so tight that he would have trouble fitting his feet into slippers. Because it was so swollen, he was previously able to wear moccasin indoor slippers. I also realized that it was missing. Nine hours after the initial treatment, the patient's ankle was normal in size and shape. As a result, the slippers are actually more spacious, and the large gaps allow the moccasins to slip off your feet. He was dropped, something he had never experienced before.

[0334] Using AB1+PP3.1 in a 1:1 ratio in wound care accelerates the healing of non-healing wounds. It was concluded that it can help close the sphincter, improve edema, and enhance hair regrowth. However, due to the strong odor and concentration of AB1, the mixture may not be applied near the face or mucous membranes. If so, caution will be necessary. Patients may have allergies to the mixture. It is important to note that a patch test must be performed first, and that it will not cause injury. It should not be applied to damaged skin.

[0335] [Example 12] Antimicrobial mixture (AB1) 500ml of organic extra virgin olive oil, 30ml clove essential oil (Eugenia caryophyllus) 30ml of cinnamon essential oil (Cinnamonum cassia) 30ml Rosemary Essential Oil (Rosemary (Rosmarinus officinalis)) 30ml of eucalyptus essential oil (Eucalyptus globulus) 30ml lemon essential oil (Lemon (Citrus limon)) 10ml of Ravintsara essential oil (Cinnamomum camphora) 5ml of cinnamon leaf essential oil (Cinnamonum vera) Add it.

[0336] Mix all ingredients thoroughly. Store in a dark glass bottle, protected from heat and light. Add this 165ml of essential oil to a total volume of 665ml, or dilute it 1:4.

[0337] [Example 13] Pain Preparation 4 (PP4): Pain preparation 4 (PP4) may incorporate the following designs and improvements, among others, if desired. It is incorporated. The main improvement here will be to make it more closely mimic human skin / oil. It's likely that vegetable oil was added in a specific proportion.

[0338] [Table 6-1]

[0339] [Table 6-2]

[0340] For accurate measurement, the mixture should be placed in a 15 ml dark glass (preferably green or blue). This is because these should be mixed in an IV bottle (to make it darker and protect it from light) Please note the following.

[0341] The inventors believe that immediate-acting essential oils are effective, and that 6% or more of them are used as described in various textbooks. In contrast to lower concentrations, it can potentially be safely used at concentrations closer to 20%-30%. I learned this from the above case.

[0342] [Example 14] PP5. Pain preparation 5 PP5 was prepared as follows: 1) Long-acting supported biosilicate / food-grade diatomaceous earth (FGDE): 3m l 2) German chamomile essential oil, Moroccan chamomile essential oil, Roman chamomile essential oil in a 1:1 ratio: 1 mixture: 2.5ml 3) 1:1 mixture of jasmine and lemongrass essential oils: 2.5 ml 4) MNO+CO (Macadamia Nut Oil + Coconut Oil Stock): 2.0ml 5) Mix all of the above ingredients in a 15 ml glass drip bottle until homogeneous. 6) Divide the contents into three 15ml glass drip bottles, and add up to 15ml of emu oil. Add it. 7) Store at room temperature, protected from light and heat.

[0343] [Example 15] PP6. Pain preparation 6

[0344] [Table 7-1]

[0345] [Table 7-2]

[0346] [Example 16] Preparation of Macadamia Nut Oil + Coconut Oil Stock Mixture "MNO+CO" The MNO+CO mixture could be prepared as follows: 1) Gradually heat 60 ml of coconut oil in a 75-degree Celsius water bath until it melts (coconut oil is (It melts above 72°F). 2) Add to 400 ml of macadamia nut oil and mix well until completely homogeneous. 3) Store at room temperature until ready to use; it will remain in liquid form.

[0347] [Example 17] The basic "liquid skin" (an emu / vegetable oil mixture that mimics the fatty acid composition of human sebum) preparation The liquid skin could be prepared as follows: 1) Add 107ml MNO+CO (macadamia nut oil + coconut oil) to 1893ml emu oil. Add the nut oil stock and mix thoroughly until completely homogeneous. 2) Divide equally into glass bottles. Store at room temperature. 3) It can be applied immediately or can be miscible with other bioactive compounds.

[0348] [Example 18] Basic preparation of "vegan liquid skin" Vegan liquid skin could be prepared as follows:

[0349] 1.1893ml of high-oleic sunflower seed oil with 107ml of MNO+CO(Macada) Add the mia nut oil + coconut oil stock and mix thoroughly until completely homogeneous. . 2. Divide equally into glass bottles. Store at room temperature. 3. It can be applied immediately or can be miscible with other bioactive compounds. 4. Basic "liquid skin" or "vegan liquid skin" is not suitable for use with other organisms on the skin. It should be noted that this is sufficient to improve the incorporation and absorption of the active compound. Both of these can be achieved by adding ceramides, phospholipids, and other compounds listed in the chart below. And it can be modified even further.

[0350] [Example 19] Antimicrobial mixture 1 (AB1) AB1 is an antimicrobial compound with antibacterial, antifungal, and antiviral properties. It has the strongest bacterial properties, followed by antiviral properties, and then antifungal properties. AB1 is as follows: It could be prepared as: 1) Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2) For a final volume of 2000ml, add 107ml of MNO+CO2 (macadamia nuts Add oil (stock coconut oil). 3) 120ml each of clove, cinnamon, rosemary, eucalyptus, and lemon essential oils. In addition, 40 ml of ravintsara essential oil and 20 ml of cinnamon leaf essential oil are added. 4) Mix well and store at room temperature. Protect from excessive heat and light.

[0351] [Example 20] antimicrobial mixture 2 oil AB2 is an antimicrobial compound with wound healing, antibacterial, antifungal, and antiviral properties. AB2 could be prepared as follows: 1) Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2) For a final volume of 2000ml, add 107ml of MNO+CO2 (macadamia nuts Add oil (stock coconut oil). 3) 120ml each of clove, cinnamon, rosemary, eucalyptus, and lemon essential oils. Also, 40 ml of ravintsara essential oil, 20 ml of cinnamon leaf essential oil, and 30 ml of fragrant Add cinnamon essential oil. 4) Mix well and store at room temperature. Protect from excessive heat and light.

[0352] [Example 21] Antimicrobial compound 2 Low calorie ABL2 is a diluted version of AB2. By doubling the amount of carrier oil, AB Dilute 2 by 50%. This is for people who are sensitive to strong smells, as well as children. It is more tolerable for the elderly.

[0353] [Example 22] Antimicrobial Mixture 2 Respiratory Formula AB2B is based on AB2 and contains additional components that promote bronchodilation. These are as follows: It can be prepared as follows. 1) Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2) For a final volume of 2000ml, add 107ml of MNO+CO2 (macadamia nuts Add oil (stock coconut oil). 3) 500ml peppermint essential oil, 120ml clove, cinnamon, rosemary, and yu - Potassium and lemon essential oils, as well as 40ml of ravintsara essential oil and 20ml of Cinnamon leaf essential oil, 30ml frankincense essential oil, 90ml spearmint essential oil, Add 30 ml of wintergreen essential oil. 4) Mix well and store at room temperature. For information on the use of wintergreen essential oil, refer to Table 1. I want to be illuminated.

[0354] [Example 23] AB1 triple antimicrobial formulation AB1T is based on AB2 but contains white thyme essential oil. It also has additional antiviral and antifungal properties. For its antibacterial and antifungal benefits, 120 ml of white thyme essential oil is added to the AB2 formulation. Add.

[0355] A 40-year-old woman who has had toenail fungus on all her toenails for the past three years has been taking multiple prescription medications and I have tried various over-the-counter medical treatments, but the fungus persists, leaving me with discolored, brittle, and porous toenails. This resulted in her being unable to have her toenails manicured, because it was This was to worsen the infection. Thirty minutes after she applied AB1T to the lesion area, the nail The area with the fungal infection, including the floor and surrounding skin, was reddened. 24 of the AB1T application After some time, the redness subsided, and the appearance of the toenails returned to normal. After application, the toenails were brittle and porous. The nail grew back and was replaced by a healthy toenail. The toenail fungus has not recurred since the initial application of AB1T. I haven't done that.

[0356] [Example 24] Antimicrobial compound extended release formulation (AB1 ER - FDG for extended release of active compound) (formulated together with E) AB1 ER can be prepared as follows: 1) While wearing a mask properly and in a well-ventilated space, add 60g to 250ml of saturated Dead Sea saltwater. Add FDGE and mix well. 2) Add 250 ml of ABL1 (or, if possible, make it into an extended release). (Any of the formulations) 3) Add 24 ml of emu oil. 4) Add 10 ml of MNO+CO2 (macadamia nut oil + coconut oil stock). . 5) Mix well and label as AB1 ER fraction. 6) Add 3 ml of AB1 ER to a 15 ml glass infusion bottle. 7) Add the remaining AB1 up to a maximum of 15 ml. 8) Before use, shake well and mix thoroughly until homogeneous. 9) Store at room temperature, protected from heat and light.

[0357] [Example 25] Wound healing formulation: (AB1 + PP3 / PP4 / PP5 combined in a 1:1 ratio or subsequent PP formulations) It is applied to the intact skin surrounding the wound to promote rapid healing. As described above, Applying near-infrared light, heat, or sunlight can stimulate stem cells and further promote rapid wound healing. It is possible.

[0358] [Example 26] Antimicrobial hybrid formulation 1 (ABUF1) ABUF1 has high efficacy against bacteria, fungi, and viruses. 1 can be prepared as follows: 1) Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2) For a final volume of 2000ml, add 107ml of MNO+CO2 (macadamia nuts Add oil (stock coconut oil). 3) Add 1000ml of olive oil. 4) 120ml each of clove, cinnamon, rosemary, eucalyptus, and lemon essential oils. Also, 40 ml of ravintsara essential oil, 20 ml of cinnamon leaf essential oil, and 30 ml of frankincense. Sense essential oil, 30ml: White Thyme, Rosalina, Palmarosa, Niaouli, Laurel Add the essential oils of the leaves of the plant and the leaves of the litsea plant. 5) Mix well and store at room temperature. Protect from excessive heat and light.

[0359] The 60-year-old woman continued to experience symptoms despite using a steroid cream prescribed by her dermatologist. Then, for several weeks, localized redness, swelling, and purple spots spread from finger to finger on both hands. She presented with a sudden onset. Due to pain and swelling, she was unable to bend her fingers or use her hand. It could not be used. After ruling out autoimmune and other differential diagnoses, she was diagnosed with COVID-19. Because it meets the clinical criteria for an infectious disease, the biopsy suggests that she has COVID-19. The patient presented with vasculitis of unknown cause. After applying ABUF1 to the hand several times daily, swelling and The pain decreased, and she was able to use her hand again without discomfort. The lesions are spreading. The medication was stopped, and the lesions disappeared within a week.

[0360] F, a 62-year-old who has had a history of Raynaud's phenomenon since his youth, applied ABUF1 to his hand. I noticed a reduction in poor circulation, pain, and swelling in my hands. In contrast, 60-year-old F, who has a history of RA, is given AB1 or ABUF1 as standard prescription medication. I noticed improvement in the painful joints within minutes of applying it to my shoulders and knees.

[0361] [Example 27] Antimicrobial Mixture 2 (ABF2) ABUF2 exhibits high efficacy against bacteria, fungi, viruses, and trypanosomes. It possesses. ABF2 could be prepared as follows: 1) Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2) For a final volume of 2000ml, add 107ml of MNO+CO2 (macadamia nuts Add oil (stock coconut oil). 3) Add 1000ml of olive oil. 4) 120ml of clove, cinnamon, rosemary, eucalyptus, lemon, shan mao, and huang Thyme and lemongrass (Cymbopogon citratus) Add each of the essential oils. 5) Add 40ml each of ravintsara, frankincense, and myrrh essential oils. do. 6) 30 ml of Rosalina, Palmarosa, Niaouli, Bay Leaf, and Litsea Leaf Add each of the essential oils. 7) Add 20 ml of cinnamon leaf essential oil. 8) Mix well and store at room temperature. Protect from heat and light.

[0362] [Example 28] Lymphedema formula (AB1LY) AB1LY can be prepared as follows: 1) Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2) For a final volume of 2000ml, add 107ml of MNO+CO2 (macadamia nuts Add oil (stock coconut oil). 3) Add 150 ml of lemon, rosemary, and cinnamon essential oils. 4) 120ml each of clove, eucalyptus, frankincense, and myrrh essential oils Add this. 5) Add 40 ml of ravintsara essential oil. 6) 30ml grapefruit, fennel, cypress, geranium, juniper Add each of the Lee essential oils. 7) Add 20 ml of cinnamon leaf essential oil. 8) Mix well and store at room temperature. Protect from excessive heat and light.

[0363] Local application of AB1LY was able to reduce swelling.

[0364] [Example 29] Hypertension formula (HYPF1) HYPF1 can be prepared as follows: 1) Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2) For a final volume of 2000ml, add 107ml of MNO+CO2 (macadamia nuts Add oil (stock coconut oil). 3) 120ml frankincense, myrrh, galangal, shan mao, melissa (lemon) Add each of the essential oils (from the balm). 4) 30ml of lavender, bergamot, clary sage, rose, and sweet marjoram Add coriander, celery seed, wintergreen, and neroli essential oils. . 5) Add 5 drops each of jasmine and ylang-ylang essential oil. 6) Mix well and store at room temperature. Protect from excessive heat and light.

[0365] HYPF1 is applied topically, and while waiting for the antihypertensive drug to take effect, the symptoms associated with hypertension are... It was able to treat headaches and other symptoms. For information on the use of wintergreen essential oil, see Table 1. Please pay attention to the recommendations listed.

[0366] [Example 30] Headache formulation (HDF1) HDF1 could be prepared as follows: 1) Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2) For a final volume of 2000ml, add 107ml of MNO+CO2 (macadamia nuts Add oil (stock coconut oil). 3) Add 240 ml each of peppermint and galangal essential oils. 4) 120ml of frankincense, myrrh, shan mao, and melissa (lemon balm) Add each of the essential oils. 5) Add 60 ml each of wintergreen and neroli essential oils. 6) Add 5 drops each of jasmine and ylang-ylang essential oil. 7) Mix well and store at room temperature. Protect from excessive heat and light.

[0367] Topical application of HDF1 was able to treat the headache. Regarding the use of wintergreen essential oil. Please take note of the recommendations listed in Table 1.

[0368] [Example 31] Relaxant / sleep-inducing formula Relaxant / sleep formulations could be prepared as follows: 1. Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2. For a final volume of 2000ml, add 107ml of MNO+CO2 (Macadamia Nut Add oil (stock coconut oil). 3.60ml each of orange and frankincense essential oils, and 30ml of blue tangerine Each of the following: 1 ml each of liquor and ginger seed essential oils, and 1 ml each of licorice and ginger extracts. Along with this, add 300 ml of peppermint essential oil and 120 ml of geranium essential oil. Add 4.5 drops each of jasmine and ylang-ylang essential oil. 5. Mix well. Divide into two 2L glass bottles with lids, 1000ml per bottle. Along with high-oleic sunflower seed oil, 30ml of MNO+CO (macadamia nut oil + Add 473 ml of emu oil to the coconut oil stock. 6. Mix well and store at room temperature. Protect from excessive heat and light. The relaxation / sleep formulation could be applied topically to the face, back of the neck, and throat before bedtime.

[0369] [Example 32] hair growth Topical formulations that stimulate hair growth could be prepared as follows: 1. Put 1 / 2 gallon of high-oleic sunflower seed oil into a 2L glass bottle with a lid = 189 Pour in 3ml. 2. For a final volume of 2000ml, add 107ml of MNO+CO2 (Macadamia Nut Add oil (stock coconut oil). Add 3.1000 ml of emu oil. Add 4.2000g of lecithin and mix at high speed until completely dissolved and homogeneous. Add 5,240 ml each of rosemary and pine needle essential oil. 6.120ml of clove, cinnamon, rosemary leaf, eucalyptus, lemon, and frankincense. Add the essential oils of lance and myrrh, respectively. Add 7.40 ml of ravintsara essential oil and 20 ml of cinnamon leaf essential oil. 8.30ml of lavender, peppermint essential oils, carrot seed oil, geranium, and Each of the ginger essential oils is added. This is the fast-acting portion of the topical hair growth formulation. be. 9. Mix well and store at room temperature. Protect from excessive heat and light. 10. Using FDGE, create a long-acting portion for a hair growth topical agent. To do: In a separate 500ml glass container, add 350ml of saturated FDGE to 200g of FDGE. Mix Dead Sea saltwater (wear an N95 mask properly, work in a well-ventilated area, and dry with FDG (Be careful not to inhale E). Mix well and take 750 mg of essential amino acids. (L-histidine, L-isoleucine, L-leucine in a 1:1:1:1:1:1 ratio) (L-lysine, L-methionine, L-phenylalanine, L-threonine, L-valine) Add each of the following. Mix well until completely dissolved. Then add 50,000 mg Add biotin and mix well until completely dissolved. 10,000 mg of vitamin Add C and mix well until completely dissolved. Add 4g zinc and mix until completely dissolved. Mix well until combined. 4g of vitamin B complex (approximately 100ng of thiamine, 100ng of thiamine) g of riboflavin, 200 ng of niacin, 160 ng of vitamin B6, 800 mcg Folic acid, 1000mcg vitamin B12, 400mcg biotin, 100mg of bacon Tothenic acid, 100 mg PABA, 77 mg phosphatidylcholine, 42 mg wild boar Add 200 mcg of alpha-lipoic acid (Thor) and mix well until completely dissolved. Next, add 100 ml of the fast-acting portion of the previously prepared topical hair growth formulation. Mix well. Add 10 drops of 1,500 mcg RAE / drop, and each to 1 volume of liquid. Add 125mcg / 500mcg of vitamin D3 and K2. Dissolve completely. Mix well until it becomes liquid. 50g of yubey has been heated in a 46°C water bath until it becomes liquid. Add quinol and mix well. This is the long-acting component for hair growth. 11. Add 3 ml of the long-acting portion for hair growth to each 15 ml bottle. Add 2 ml of the hair growth topical formulation (fast-acting portion). 12. Store at room temperature. Protect from excessive heat and light. Apply to the scalp daily before going to bed. Mix well. For best results, apply twice a day.

[0370] [Example 33] Gastrointestinal tract healing preparations Formulations for oral administration to treat gastrointestinal tract conditions could be prepared as follows: 1. Pour 1 / 2 gallon (1893 ml) of emu oil into a 2L glass bottle with a lid. 2. For a final volume of 2000ml, add 107ml of MNO+CO2 (Macadamia Nut Add oil (stock coconut oil). 3. 100ml of German chamomile / Roman chamomile pre-mixed in a 3.1:1:1 ratio. Add chamomile / Moroccan chamomile essential oil. Add 4,100 ml each of ginger and galangal essential oils. Add 5.1300g of lecithin granules and mix at high speed until completely homogeneous. 6. Create 1000 mg gel capsules from this mixture. Target various parts of the digestive tract. Capsules are available in rapid dissolution, intermediate dissolution, delayed dissolution, and extended delayed dissolution properties. Four types of gel formulations are used for the urinary tract, such as the stomach. For example, the rapidly dissolving capsule is used for the stomach and other gastrointestinal tract. It would be most useful for healing peptic ulcers in the most proximal part; intermediate release is for duodenal ulcers. Delayed release is best for healing ulcers, and is best for healing jejunal or ileal lesions. Furthermore, prolonged and delayed release may cure diseases of the colon and rectum, such as ulcerative colitis. It would be best to do so. Crohn's disease affects any part of the GI duct, all four types. Treatment using this type of gel capsule will be necessary. Prepare a suppository of this formulation, It can treat internal hemorrhoids and can be applied topically to external hemorrhoids. This preparation promotes the regeneration of the mucosal lining. It should help stimulate it. 7. Case report: A patient underwent advanced treatment with mesalamine, biopharmaceuticals, and steroids. Despite treatment, ulcerative colitis persists due to severe abdominal pain and diarrhea up to 15 times a day. He had been bedridden for 20 years. He could only get up to use the toilet. This was possible. The family medicine practitioner instructed him to continue until the symptoms subsided or he experienced side effects. At that point, he should return to the dosage that did not cause side effects, 1g of Emi per day. The patient was advised to take oil and increase the amount by 1 gram per week. After taking emu oil, abdominal pain decreased within a week, and diarrhea frequency dropped to only 1-2 times a day. His health has declined, and he now participates in daily activities such as driving, shopping, and running errands. He reported that it was possible to add it. He increased it to a maximum of 2g per day and stopped taking prescription medication. This led to the patient eventually stopping taking emu oil capsules. 8. Phosphatidylcholine (PC) is an important component of the mucosa of the GI duct, and within the mucosa It acts as a surfactant, creating a barrier that prevents erosion and microbial invasion. PC is, It is definitively reduced in patients with inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. (Parian et al. Inflammatory Bowel Disease, Integrative Medicine Fourth Edition) (tion, 2018). For this reason, lecithin was incorporated into the formulation to improve PC in this patient population. They replenished it. The chamomile mixture combined with emu oil reduced inflammation while crushing Further stimulate mucosal stem cells to regenerate and repair ulcerated and inflamed tissue. It should be so, and macadamia and coconut oils provide essential components of cell membranes, and new It will likely repair the intestinal lining.

[0371] The preparation can be taken orally.

[0372] [Example 34] Insomnia Nasal Spray (INS1) INS1 is a medication used to treat insomnia and anxiety, and it improves fat metabolism. S1 could be prepared as follows: 1. In a 2.5L glass bottle with a lid, 660ml emu oil and 132ml In MNO+CO (Macadamia Nut Oil + Coconut Oil Stock), 3mg / 1 67ml ml of melatonin (providing a final concentration of 100mcg / ml or 100mcg / spray) (and) add 1155 ml of high-oleic sunflower seed oil. 300 mcg The dosage of melatonin restored melatonin levels to levels characteristic of healthy young patients. It showed the best tolerance, improved sleep, did not lead to daytime drowsiness, and melatonin Since it has been shown to be sufficient to avoid desensitization of nin receptors, this spray - Up to 4 sprays can be administered intranasally per night (Wurtman et al. Low Doses of M elatonin Promote sleep Onset and Maintenance in Older People - An Update US Neur ology, 2014;10(2):117-9). 4. Sprays allow for spray loss due to dripping. ru. 2. Add 32 tablespoons of lecithin as an emulsifier and antioxidant, and continue until completely homogenized. It mixes at high speed. 3. To reduce anxiety and improve metabolism and fat utilization / lipolysis, for adults 24 International Units (IU) per 1 ml spray, or 1 ml spray for children For a final dose of 12 IU, sterile filtered stabilized oxytocin (PMID 29) is used. 898580, PMID 24067301, PMID 24297883, PMID 24352377), as well as 4 ml of organic Moroccan cambogia for additional anti-anxiety benefits. Add Tanacetum annuum essential oil. Mix until completely homogeneous. Mix thoroughly at high speed until smooth, then dispense 1 ml per spray into a dark glass nasal spray bottle. Divide equally into two portions. Mix well before each dose.

[0373] [Example 35] eczema preparations Approximately 15% to 50% linoleic acid by volume; and various types of chamomile essential oil ( Regarding chamomile (German / Moroccan), approximately 0.05% to approximately 50% by volume; and An eczema preparation containing approximately 0% to 5% orange oil can be prepared. The preparation can be made from 0.05% to 60% by volume. Contains hyaluronic acid at a concentration of % by volume. C16:1Δ6 fatty acids are present in 5% to 40% by volume of the formulation. The formulation contains a 3:1:1:1 ratio of active ingredients required to rebuild the skin barrier. It may contain sufficient components of tetraol and phospholipids.

[0374] For a 15 ml bottle, 1 to 3 ml of the long-acting preparation may be added.

[0375] [Example 36] Psoriasis / Eczema / Wrinkles / Anti-aging / Formula (PEWAF1) Formulations for the treatment of eczema and psoriasis may be prepared as follows: Add 10 ml of AB1 to 1.6 x 15 ml of PP4 (total 90 ml). 2. Mix well. Add 3,960,000 IU of vitamin D. Add 4.6 ml of hyaluronic acid. Add 5.6 ml of vitamin E (1200 mg of d-alpha-tocopherol). 6.30 drops of Vitamin A (1507 mcg RAE / drop) are added. Add 7.6 ml of vegetable glycerin. Add 2 drops of 45mcg of vit K2(MK7) to 8.6ml (1ml = 20 drops) (Please note this.) 9. Add 12 ml of the previously described FDGE mixture. 10. Add 400 mg of ubiquinol, which has been heated to 46°C, to melt it. do. 11. Mix thoroughly until homogeneous, then dispense into 15 ml glass drip bottles. (Approximately 9 bottles) It should become a torrent. It protects from heat and light.

[0376] The above formulation was tested, and after two applications applied 24 hours apart, an adult woman in her 30s... The newly developed eczema was resolved (the lesions had appeared in the past two weeks). The woman was The product was reported to reduce itching immediately upon contact.

[0377] Both were men in their late 30s and early 40s who reported a history of eczema for several years. The formulation was tested in both patients; after three applications applied 24 hours apart, the eczema did not resolve. I reported the disappearance.

[0378] The formulation was also tested in a man in his 60s, and it treated his persistent eczema, which had been present for three years. The condition was resolved after five applications of the formulation, each applied approximately 24 hours apart. A one-year follow-up study was conducted. At that point, he reported zero recurrences after resolution following the fifth application.

[0379] The formulation was also tested in two children, one 1.5 years old (female) and one 4 years old (male). Both pediatric patients reported immediate pain relief upon application. Perioral eczema improved within 9 hours of application. Within that timeframe, it was observed that the condition had completely resolved in both children, and at the time of the one-year follow-up. A recurrence of zero symptoms after resolution was reported.

[0380] The formulation is for patients with a history of severe eczema since childhood, appearing on all skin surfaces, including the genitals. The study was conducted on a female patient in her early 30s who had high-potency steroids, including She reported that she had tried various over-the-counter prescription and over-the-counter eczema formulations, Many of these topical medications cause allergic reactions, and topical steroid medications are They reported that the efficacy eventually decreased over time. Dupilumab twice a week Despite receiving injections, she still suffered from a severe eczema outbreak covering large areas of skin. The patient still reported 5 PEWAF2 levels after 24 hours of isolation. After completing the application cycle, the author's work was limited to the areas where PEWAF2 was applied, but only in the areas where she applied it. She noticed a significant improvement. The lesion areas where she did not apply PEWAF2 had lesions. It remained unchanged. No allergic reactions were observed. Improvement was seen in open wounds and minor bleeding. This included a reduction in occlusion, pain, itching, and erythema.

[0381] [Example 37] Psoriasis / Eczema / Wrinkles / Anti-aging compound 2 (PEWAF2) PEWAF2 can be prepared as follows: 1) Add 1.5 ml of AB1 to 12 ml of PP4. 2) Mix well. 3) Add 50,000 IU of vitamin D. 4) Add 2 ml of hyaluronic acid. 5) Add 2 ml of vitamin E. 6) Add 60 drops of Vitamin A (1507 mcg RAE / drop). 7) Add 1 ml of vegetable glycerin. 8) Add 2 drops of vit K2(MK7) 45mcg to 2 ml (1 ml = 20 drops) Therefore, please note that the total is 900 mcg. 9) Add 3 ml of FDGE as previously described. 10) Add 600 mg of ubiquinol, which has been heated to 46°C, to melt it. do. 11) Prepare the myrrh + frankincense essential oil stock mixture as follows: 45 ml Add 30 ml of myrrh essential oil to the frankincense essential oil and mix well. Use a dripper. Store in a dark glass bottle. 12) Add 2 drops of myrrh + frankincense essential oil stock mixture. 13) Add 1 ml of saturated dead sea salt solution. 14) 1 ml of 1:1:1 German chamomile + Roman chamomile + Moroccan chamomile Add the essential oil stock mixture. 15) Mix thoroughly until homogeneous, then dispense into 15 ml glass drip bottles. Avoid heat and light. Protects from. Apply to skin lesions.

[0382] PEWAF2 is used to treat psoriasis, eczema, wrinkles, and / or reduce the appearance of aging. It can be used to slow down.

[0383] [Example 38] Psoriasis / eczema / wrinkle / anti-aging compound 3 (PEWAF3) with anti-itch properties PEWAF3 can be prepared as follows: Add 1.5 ml of AB1 to 1.12 ml of PP4. 2. Mix well. Add 3.50,000 IU of vitamin D. Add 4.2 ml of hyaluronic acid. Add 5.2 ml of vitamin E. Add 6.60 drops of Vitamin A (1507 mcg RAE / drop). Add 7.1 ml of vegetable glycerin. Add 2 drops of 45mcg of vit K2(MK7) to 8.2ml (1ml = 20 drops) (Please note that this totals 900 mcg.) 9. Add 3 ml of FDGE as previously described. 10. Add 600 mg of ubiquinol, which has been heated to 46°C, to melt it. do. 11. Prepare a myrrh + frankincense essential oil stock as follows: 45ml frankincense Add 30 ml of myrrh essential oil to the cinnamon essential oil and mix well. Dark colored dripper Store in a glass bottle. Add 12.2 drops of myrrh + frankincense essential oil stock. 13.5 drops of Zanthoxylum coreanum nakai extract Add oil. Add 14.1 ml of saturated Dead Sea salt solution. 15.1ml of 1:1:1 German chamomile + Roman chamomile + Moroccan chamomile Add the essential oil mixture. 16. Mix thoroughly until homogeneous, then dispense into 15 ml glass drip bottles. Avoid heat and light. Protects from. Apply to skin lesions.

[0384] PEWAF2 is used to treat itchy psoriasis, eczema, insect bites, and other itchy rashes. It can be used.

[0385] [Example 39] Eczema Hand Healing Kit The kit includes one or more formulations according to the present invention, a sealing / sealing barrier cream, and Includes 100% organic cotton gloves and a complete set of instructions for use. The instructions cover, for example, the lesion area. Wash the area with lukewarm water, then gently pat the skin with a towel to keep it moist; First, immediately apply the hydrated hyaluronic acid (1:1) mixture mixed with liquid skin. Next, apply the eczema preparation, then the occlusive / occlusive barrier cream, and then just before going to sleep. Patients may be advised to wear gloves.

[0386] [Example 40] conditioner One or more formulations according to the present invention are mixed with a conditioner base in a 3:1 ratio. The conditioner contains 1% to 20% by volume of Roman / German / Moroccan essential oils, It may contain 1% to 10% of a long-acting fraction (FGDE-supported biosilicate). The idea is to use it as a hair mask, lather it up, and then apply it to the scalp. The long-acting fraction is absorbed into the scalp. The conditioner softens the scalp. It can moisturize.

[0387] [Example 41] Face / Scalp Mud Mask The mask contains approximately 5% to 70% of the long-acting fraction (FGDE-supported biosilicate). It contains, but also contains any more FGDE in the range of 5×~30× and more supported This can guarantee the presence of diatoms. The mask can be prepared as follows: 1) As a final step for immediate occurrence, approximately 1% to 20% of volume of Roma / D Add Itz / Moroccan essential oil. 2) Use the eczema preparation and liquid skin in a 1:1 equilibrium ratio.

[0388] The mask can be applied to the face / scalp or other affected areas and left on for 30 minutes to 1 hour. It is best used while at rest under near-infrared light, which increases circulation and penetration (proper maintenance (The use of protective eyewear will likely be required.)

[0389] [Example 42] Facial cleanser: The facial cleanser is a basic composition for a gentle cleanser, and is mixed with liquid skin in a 1:1 ratio. It may contain hyaluronic acid, and the basic composition may constitute 10% to 80% by volume of the final product. Cleansers can help with eczema treatment in the approximate percentages listed above, though not all. It can contain most of the constituent elements of a substance. For example, a facial cleanser does not contain saponins or detergents. This is because they can worsen eczema.

[0390] [Example 43] Mask spray formulation A spray containing one or more formulations of the present invention can be prepared. Surgical face mask (without affecting the integrity of N95 or KN95 masks, N Spray onto the outside of a 95 or KN95 (can be worn over a 95 or KN95) or onto a cloth mask. For example, it may be helpful for nausea in pregnant women, or for improving the experience of wearing a mask. It can be elevated. The spray reduces anxiety, improves mood and attention, and reduces appetite. It may also have the additional benefit of being considered beneficial.

[0391] [Example 44] Sweet Mint (SM1) Spray SM1 can be prepared as follows: 1) In a 200 ml glass container, 100 ml of organic medium-chain triglycerides (MCTs) Mix the oil with 5 ml each of spearmint and peppermint essential oil. Mix well. Divide equally into 5ml glass spray vials. For use with any cloth or any 3-layer surgical device. Spray 1-2 sprays onto the outside of the mask (do not spray on N95 or KN95 masks). (This is because oil reduces the ability of the filter to filter things.)

[0392] SM1 has a sweet, refreshing, and relaxing fragrance.

[0393] A 25-year-old pregnant healthcare worker in the first trimester of pregnancy experiencing morning sickness during an 8+ hour workday. She had difficulty tolerating wearing a mask. She repeatedly put the mask on to vomit. She removed it. After spraying 1-2 times SM1 onto the outside of the 3-layer surgical mask, she felt Her condition improved, and with a decrease in nausea, she was able to wear her mask without interruption for the rest of her shift. It was able to withstand use.

[0394] [Example 45] Fresh Mint (FM1) Spray FM1 can be prepared as follows:

[0395] In a 200ml glass container, add 100ml of organic medium-chain triglyceride (MCT) oil. Mix with 5 ml of spearmint and 10 ml of peppermint essential oil. Mix well. Divide equally into 5ml glass spray vials.

[0396] FM1 has a sharp yet mellow and refreshing fragrance, and as described above, it can be used on any fabric. Alternatively, a spray vial, mechanical pump, or aerosol can be placed on the outside of a 3-layer surgical mask. It can be sprayed using a spray pump (e.g., 1-2 sprays). The spray is N95 Alternatively, it should not be sprayed on a KN95 mask because oil can get into the filter. This is to reduce those abilities.

[0397] [Example 46] Lemonwood Spice (LWS1) Spray LWS1 has a clean, forest-like scent along with the aroma of citrus fruits. 1 can be prepared as follows:

[0398] In a 500ml glass container, 400ml of organic medium-chain triglyceride (MCT) oil And 5ml of organic black pepper (Piper nigrum), 30ml of lemongrass, Mix 15ml of Cedarwood Atlas and 15ml of Cypress (Spain) essential oil. Combine. Mix well and divide equally into 5 ml glass spray vials.

[0399] LWS1 is a spray vial that can be applied to the outside of any cloth or 3-layer surgical mask, and is mechanically operated. It can be sprayed using a conventional pump or an aerosolizing pump (e.g., 1-2 sprays). ). The spray should not be sprayed on N95 or KN95 masks. The oil reduces the ability of the filter to filter things.

[0400] [Example 47] Sedative Concentrated (CFS1) Spray CFS1 has a clean scent, light citrus, mint, spice, and sweet green. It has a laurel aroma. CFS1 can be prepared as follows:

[0401] In a 500ml glass container, 100ml of organic medium-chain triglyceride (MCT) oil And 5ml each of bergamot mint and gingergrass essential oils, and 1ml Mix with 1 bergamot essential oil. Mix well and pour into a 5 ml glass spray vial. To divide.

[0402] CFS1 is a spray vial that can be applied to the outside of any cloth or 3-layer surgical mask, or by machine. It can be sprayed using a conventional pump or an aerosolizing pump (e.g., 1-2 sprays). ). The spray should not be sprayed on N95 or KN95 masks. The oil reduces the ability of the filter to filter things.

[0403] [Example 48] Fast-acting sunscreen spray (ISS1): ISS1 is a vibrant, uplifting, minty scent that provides immediate satisfaction. It has a fresh citrus aroma and can be prepared as follows:

[0404] In a 500ml glass container, 100ml of organic medium-chain triglyceride (MCT) oil And 14 ml bergamot, 5 ml spearmint, 9 ml tangerine, and 2 Mix with ml of cardamom essential oil. Mix well and pour into a 5 ml glass spray vial. To divide.

[0405] ISS1 is a spray vial, machine, applied to the outside of any cloth or 3-layer surgical mask. It can be sprayed using a conventional pump or an aerosolizing pump (e.g., 1-2 sprays). ). The spray should not be sprayed on N95 or KN95 masks. The oil reduces the ability of the filter to filter things.

[0406] [Example 49] Pest / insect control spray A pest / insect control spray can be prepared using the formulation of the present invention. The spray can be, for example, It may contain plant-based essential oils. Essential oils have a pleasant scent and instantly disinfect upon contact. and selected to have antimicrobial (e.g., antifungal, antiviral, and antibacterial) properties. The formulation is nontoxic to mammals and has beneficial properties as listed in Table 1, but spinal movement Due to significant differences in the physiology and anatomy of animals and invertebrates, it is toxic to invertebrates. In a particular embodiment, the formulation is, for example, by sterilizing the air. ...

Claims

1. (i) A basic composition containing lipids including fatty acids, and (ii) One or more additional components dispersed in the basic composition, wherein phospholipids Ceramides, cholesterol, fatty acids, oils, vitamins, minerals, therapeutic agents, bioactive ingredients, Select from a group consisting of exosomes or any combination of two or more of the aforementioned. Additional components Includes, The fatty acids in the basic composition are such that the fatty acid composition of the basic composition is such that it is the molecular structure of mammalian cells. Substantially identical to the fatty acid composition of spore membranes, cell organelles, sebum, or exosomes. It is a type and quantity that brings a state to a certain point. The aforementioned basic composition constitutes approximately 30% to approximately 99% by volume of the formulation. formulation.

2. (i) A basic composition containing lipids including fatty acids, and (ii) One or more additional components dispersed in the basic composition, wherein phospholipids Ceramides, cholesterol, fatty acids, oils, vitamins, minerals, therapeutic agents, bioactive ingredients, Select from a group consisting of exosomes or any combination of two or more of the aforementioned. The additional components that are added, (iii) Biosilicate Includes, The lipid is a mixture containing coconut oil and macadamia nut oil, and the basic composition This constitutes approximately 30% to 99% of the formulation by volume. formulation.

3. The aforementioned fatty acids are myristic acid (C14:0), lauric acid (C12:0), and palmitic acid. Acid (C16:0), arachidonic acid (C20:4 n-6), stearic acid (C18:0) , oleic acid (C18:1 n-9), linoleic acid (C18:1 n-9), linoleic acid (C18-3 n-9), crotonic acid (C ４ H ６ O ２ ), myristoleic acid, palmitole C16:1 acid, sapenoic acid (C16:1 n-10), oleic acid (C18:1 n-9), elaidic acid or trans-oleic acid (C18:1 n-9), Ceconic acid (C18:1 n-7), gadoleic acid (C20:1 n-11), eicosene Acid (C20:1 n-9), erucic acid (C22:1 n-9), nervonic acid (C24:1 Select from a group consisting of two or more combinations of the above (n-9) The formulation according to claim 1 or 2.

4. The fatty acid composition of the basic composition is substantially the same as the fatty acid composition of the cell membrane. The formulation according to claim 1, wherein the mammalian cells are human cells.

5. The formulation according to claim 2, further comprising emu oil in the mixture.

6. The formulation according to claim 2, wherein the mixture further comprises high-oleic sunflower seed oil.

7. The formulation according to claim 2, further comprising olive oil in the mixture.

8. The formulation according to claim 1 or 2, comprising one or more additional components.

9. Contains a mixture of essential oils from German chamomile, Roman chamomile, and Moroccan chamomile. Furthermore, the mixture constitutes approximately 5% to approximately 30% by volume of the formulation, as described in claim 8. formulation.

10. The lipid further comprises high-oleic sunflower oil, and the one or more additional components are , clove, cinnamon, rosemary, eucalyptus, lemon, love dispersed in the basic composition It is a mixture containing the essential oils of tinsara and cinnamon. Clove essential oil constitutes approximately 0.1% to 30% by volume of the aforementioned preparation; Cinnamon essential oil constitutes approximately 0.1% to 30% by volume of the aforementioned preparation; Rosemary essential oil constitutes approximately 0.1% to 30% by volume of the aforementioned preparation; Eucalyptus essential oil constitutes approximately 0.1% to 30% by volume of the aforementioned preparation; Lemon essential oil constitutes approximately 0.1% to 30% by volume of the aforementioned preparation; Ravintsara essential oil constitutes approximately 0.1% to 20% by volume of the aforementioned preparation; The essential oil of cinnamon leaves constitutes approximately 0.05% to approximately 20% by volume of the aforementioned preparation; The basic composition constitutes approximately 50% to approximately 99% by volume of the formulation. The formulation according to claim 2.

11. Approximately 0.05% to approximately 20% by volume of frankincense essential oil and / or approximately 1% by volume The formulation according to claim 10, further comprising approximately 30% by volume of thyme essential oil.

12. Approximately 1% to 30% biosilicate, approximately 0.04% to 20% German chamomile extract Oil, approximately 1% to 20% Moroccan chamomile essential oil, approximately 0.04% to 20% Roman chamomile Meal essential oil, approximately 0.04% to 10% jasmine essential oil, approximately 0.04% to 10% lemon Grass essential oil, approximately 1% to 10% coconut oil, approximately 5% to 4% macadamia oil, approximately 10 The formulation according to claim 11, further comprising % to approximately 80% emu oil in volume percentage.

13. Vitamin D, hyaluronic acid, vitamin E, vitamin A, glycerin, ubiquinol, Rabini myrrh, frankincense, German chamomile, Roman chamomile, and Moroccan chamomile. The formulation according to claim 12, further comprising chamomile essential oil.

14. Approximately 0.01% to 7% ubiquinol, approximately 0.01% to 4% vitamin A, approximately 0.0 1% to approximately 10% vitamin D, approximately 0.01% to approximately 10% vitamin E, approximately 0.01% to approximately 10% Vitamin K2 MK7, approximately 0.01% to approximately 25% Vitamin C, approximately 0.01% to Approximately 4% alpha-arbutin, approximately 0.01% to 3% gallic acid, approximately 0.01% to 10% % frankincense essential oil, approximately 0.01% to approximately 10% myrrh essential oil, approximately 0.01% to approximately 5 % kojic acid, approximately 0.01% to approximately 10% licorice root extract, approximately 0.01% to approximately 12% nayl Asinamide, approximately 0.01% to approximately 6% essential oil of turmeric (Kaempferia galanga), approximately 0 0.01% to approximately 5% niaouli essential oil, approximately 0.01% to approximately 3% glutathione, approximately 0.01% ~Approximately 12% hyaluronic acid, approximately 0.01% to 3% rosemary essential oil, approximately 0.01%~ Approximately 3% palmarosa essential oil, approximately 0.01% to approximately 5% macadamia nut oil, approximately 0.01% Approximately 3% coconut oil, approximately 2% to 9% lecithin, and approximately 1% to 9% vegetable glycerin. The formulation according to claim 10, and comprising approximately 35% to approximately 90% emu oil in volume percentage. 。

15. The aforementioned one or more components include German chamomile, Moroccan chamomile, and Roman chamomile. Flavors: Frankincense, Myrrh, Jasmine, Lemongrass, Sweet Orange, Beef Essential oils of tah orange, rosemary, galangal, shan mao, palmarosa, and neroli. The mixture comprises licorice extract, lecithin, and coconut oil; the mixture is in the basic composition. Distributed to, The lipids include a mixture containing emu oil, coconut oil, and macadamia nut oil. The basic composition constitutes approximately 50% to approximately 99% by volume of the formulation. The formulation according to claim 8.

16. Approximately 0.01% to 3% German chamomile essential oil, approximately 0.01% to 3% Moroccan chamomile Meal essential oil, approximately 0.01% to 3% Roman chamomile, approximately 0.01% to 10% flax Incense essential oil, approximately 0.01% to 10% myrrh essential oil, approximately 0.01% to 2% jasmine Sumin essential oil, approximately 0.01% to 2% lemongrass essential oil, approximately 0.01% to 3% swirl Orange essential oil, approximately 0.01% to approximately 3%; Bitter orange essential oil, approximately 0.01% to approximately 3% Rosemary essential oil, approximately 0.01% to 3% galangal essential oil, approximately 0.01% to 3% Shanmao essential oil, approximately 0.01% to 3% palmarosa essential oil, approximately 0.01% to 3% ne Loli essential oil, approximately 0.01% to 5% licorice extract, approximately 2% to 9% lecithin, approximately 0.01 % to approximately 2% coconut oil, approximately 0.01% to approximately 5% macadamia nut oil, approximately 35% to approximately 9% The formulation according to claim 15, comprising 0% emu oil in volume percentage.

17. The lipid is coconut oil, and the one or more additional components are from the group consisting of essential oils. Selected from the above, the basic composition constitutes approximately 70% to approximately 99% by volume of the formulation. The preparation described in item 1.

18. The formulation according to claim 17, wherein the fatty acid is a medium-chain triglyceride.

19. Damage, injury, or dysfunction of cell membranes, exosomes, or organelles in mammals. A formulation according to claim 1 for treating diseases related to the whole.

20. Damage, injury, or dysfunction of cell membranes, exosomes, or organelles in mammals. A formulation according to claim 1 for treating diseases related to the whole.

21. The formulation according to claim 1 or 2, wherein the additional component is an exosome.

Images